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Abstract 
This thesis aimed to examine the roles of growth differentiation factor 5 (GDF5), a 
secreted member of the TGF-β superfamily of ligands with a well characterised role in 
limb morphogenesis, in the developing hippocampus and sympathetic nervous system.  
Previous studies have demonstrated that GDF5 promotes the growth and elaboration 
of dendrites from developing mouse hippocampal neurons in vitro and in vivo. As a 
first step to investigating whether GDF5 plays additional roles in the development of 
the mouse hippocampus, brains of P10 and adult Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice 
were analysed by anatomical MRI. The gross morphology and total volume of 
hippocampi were not significantly different between the three genotypes at either 
age, making it unlikely that GDF5 plays a significant role in modulating other aspects of 
hippocampal development in addition to promoting the growth and elaboration of 
dendrites. For this reason, no further time was spent on investigating whether GDF5 
plays novel roles in regulating hippocampal development.  
Developing sympathetic neurons of the mouse superior cervical ganglion (SCG) require 
nerve growth factor (NGF) to promote their survival and target field innervation in 
vivo. Data in this thesis has revealed that GDF5 modulates NGF promoted survival and 
enhances NGF promoted process outgrowth in cultures of P0 SCG neurons. In addition, 
GDF5 promotes process outgrowth and branching from cultured perinatal SCG neurons 
in the absence of NGF. P10 Gdf5bp/bp mice, that lack functional GDF5 expression, 
display a marked deficit in sympathetic innervation of the iris, but not the 
submandibular gland, compared to P10 Gdf5+/+ mice.  Whole-mount analysis of 
sympathetic innervation in P10 Gdf5bp/bp and Gdf5+/+ mice has revealed that GDF5 is 
required for correct innervation of the trachea and heart, but not the pineal gland. 
Further in vitro and in vivo investigations have suggested that the neurotrophic effects 
of GDF5 on developing SCG neurons are mediated by a receptor complex that includes 
the type 1 receptor, BMPR1A. These findings highlight a role for GDF5 in promoting the 
sympathetic innervation of selective target fields in vivo.  
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1.1 An overview of the organisation and development of 
the peripheral nervous system (PNS) 
The work contained in this thesis focuses on the roles of growth differentiation factor-
5 (GDF5) in neuronal development. GDF5 is a widely expressed member of the bone 
morphogenetic protein/growth differentiation factor family that constitutes a 
collection of closely related proteins within the TGF-β superfamily1. Whilst the roles 
that GDF5 plays in the development of both central nervous system (CNS) and 
peripheral nervous system (PNS) neuronal populations have been investigated, this 
thesis particularly focusses on whether GDF5 is able to promote the survival of, and 
target field innervation by, developing sympathetic neurons of the superior cervical 
ganglion (SCG). The vertebrate nervous system has evolved a plethora of intrinsic 
mechanisms, both temporal and spatial, which allow neurons to make precise 
connections with their most distant target organs. This enables the nervous system to 
establish and maintain the cognitive, sensory and motor functions that are so vital to 
life. During development of the nervous system, neurons are born, differentiate and 
migrate to their final location, whilst also extending processes towards targets and 
forming appropriate numbers of functional synapses. The following introduction will 
provide a frame work on which to describe the work conducted in this thesis. Initially, I 
will lay out the structure and function of the PNS. Next, I will give a detailed account of 
the mechanisms that regulate neuronal process outgrowth and neuron survival in the 
specific population of neurons investigated in this study. Finally, I will describe the 
transforming growth factor β (TGF-β) family of secreted proteins, of which GDF5 is a 
member, with specific focus on GDF5 and its role in regulating neuronal process 
outgrowth and neuron survival 
The PNS is divided into 2 broad divisions; the somatic and autonomic nervous systems. 
The somatic branch comprises the sensory neuronal populations of the dorsal root 
ganglion (DRG) and cranial sensory ganglia, and is responsible for conveying sensory 
information from; skin, viscera, joints, bone and muscle, as well as information 
concerning; taste, balance, hearing and blood pressure/gas compositon2. The 
autonomic nervous system (ANS) consists of the sympathetic, parasympathetic and 
enteric nervous systems, and mediates exocrine responses and visceral reflexes2. PNS 
neurons are a good model system for investigating the morphological and molecular 
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aspects of embryonic and postnatal neuron development. PNS neurons are well 
characterised, both in terms of their trophic requirements and the molecular markers 
they express at different stages of development3.  
1.1.1 Organisation of the autonomic nervous system 
The ANS contributes to body homeostasis, a process whereby internal systems of the 
body are maintained at equilibrium despite variations in external conditions. Fibres of 
the ANS provide visceral motor innervation to: smooth muscles of the digestive system 
and blood vessels; cardiac muscle; endocrine and exocrine glands4. The ANS is not 
under conscious control and is therefore involuntary; however, it can work in parallel 
with the somatic nervous system, which is under conscious control. The ANS is 
composed of 3 subdivisions: the sympathetic, parasympathetic, and enteric nervous 
systems. The sympathetic and parasympathetic systems are often considered to be 
opposing sides of the same coin. Traditionally the sympathetic nervous system was 
thought to be the excitatory branch of the ANS that initiated ‘fight or flight’ responses. 
The parasympathetic system on the other hand was thought to be inhibitory and 
regulated ‘rest and digest’ responses. This model is now considered outdated as there 
are multiple exceptions to definitions of both branches5. 
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Figure 1.01: Diagram of the ANS. A) Sympathetic division, B) and parasympathetic division 
connections from the CNS to targets of the body (Bill Blessing and Ian Gibbins (2008))5.  
The intermediolateral (lateral grey) column of the spinal cord, between axial levels T1-
L2, contains the soma of preganglionic sympathetic neurons. Preganglionic neurons of 
the sympathetic nervous systems are cholinergic, using ACh as a neurotransmitter2, 4, 5. 
The axons of preganglionic sympathetic neurons are generally short, as most project to 
ganglia within the paravertebral sympathetic chain2(figure 1.01). The lightly 
myelinated axons of preganglionic sympathetic neurons leave the spinal cord through 
the ventral roots and run for a short distance within the mixed spinal nerves, before 
diverting into the white rami that connect the spinal nerves with the paravertebral 
sympathetic chain. Once they enter the sympathetic chain, preganglionic fibres can 
either: synapse with a postganglionic sympathetic neuron in a ganglion at the same 
axial level; travel a short distance up or down the sympathetic chain to synapse with a 
postganglionic neuron within more rostral or caudal sympathetic chain ganglia; pass 
through the sympathetic chain and extend to prevertebral sympathetic ganglia to 
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make a synaptic connection with a postganglionic neuron2. The ganglia of the 
paravertebral sympathetic chain are found from the cervical region of the spinal cord 
to the sacral levels of the spinal cord. The SCG, middle cervical ganglion and stellate 
ganglion are found at the cervical region. There are 11 sympathetic ganglia at the 
thoracic level, 4 lumbar ganglia and 4-5 sacral ganglia. Unmyelinated postganglionic 
neurons of the sympathetic chain project their axons through the grey rami to join 
spinal nerves that will carry the axons to their targets4. Postganglionic fibres tend to be 
significantly longer than preganglionic sympathetic fibres. Postganglionic fibres of the 
SCG run adjacent to blood vessels in the head and neck to innervate targets that 
include; iris, submandibular gland, nasal mucosa and lacrimal glands. Postganglionic 
sympathetic fibres innervate multiple targets of the body such as: sweat glands, 
piloerector smooth muscles, cardiac muscle and blood vessels. The result of 
sympathetic activity can result in varied responses that include; pupil dilation, 
increased heart rate and contractility, bronchodilation, contraction of erector pili 
muscles, vasoconstriction of mesenteric vessels and vasodilation of skeletal muscle 
arterioles. Whilst the preganglionic/postganglionic synapses of sympathetic neurons 
are cholinergic, the postganglionic synapses with targets are adrenergic3-5. 
Parasympathetic preganglionic soma reside in midbrain and hindbrain nuclei 
associated with cranial nerves III (oculomotor), VII (facial), IX (glossopharyngeal) and X 
(vagus). Preganglionic parasympathetic neurons are also found in the lateral grey 
column at sacral levels 1-3 4, 6. The outflow of fibres extending from these 2 sources is 
referred to as cranial-sacral outflow, and both preganglionic and postganglionic 
parasympathetic neurons are cholinergic. Postganglionic parasympathetic neurons are 
found either in ganglia close to their targets, or in nerve plexi embedded within their 
targets. Therefore preganglionic parasympathetic fibres tend to be long, whereas 
postganglionic fibres are short3, 4. Preganglionic parasympathetic fibres associated with 
cranial nerves III arise from the Edinger-Wesphal nucleus and project to postganglionic 
neurons within the ciliary ganglion. Postganglionic fibres from the ciliary ganglion 
project to the pupillary sphincter and ciliary muscles of the eye to regulate pupil 
diameter and lens curvature. Preganglionic neurons associated with parasympathetic 
outflow in cranial VII reside in the superior salivatory nucleus of the pons and project 
fibres to the pterygopalatine and submandibular ganglia. Postganglionic fibres from 
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the pterygopalatine ganglion project to the lacrimal glands and nasal mucosa, whereas 
postganglionic fibres from the submandibular ganglion project to the submandibular 
and sublingual salivary glands and oral mucosa3, 4.  The inferior salivatory nucleus of 
the Pons contains preganglionic neurons associated with cranial nerve IX. 
Preganglionic fibres innervate the otic ganglion and postganglionic otic ganglion 
neurons project to the parotid salivary gland. The dorsal motor nucleus of the vagus 
(X) within the medulla contains preganglionic parasympathetic neurons associated 
with the vagus nerve. These project long axons that innervate nerve plexi containing 
postganglionic neurons that are adjacent to, or embedded within: the heart; smooth 
muscles and arteries of the airways, stomach, upper intestine and ureter; secretory 
tissue of the pancreas3, 4.  Sacral preganglionic parasympathetic neurons project via 
the pelvic nerve to synapse with postganglionic neurons in various pelvic plexi. 
Postganglionic parasympathetic neurons innervate the distal colon, rectum, bladder 
and genitalia. The activation of the parasympathetic nervous system results in reduced 
blood pressure and heart rate, and normal digestive activity3, 4, 7. 
The enteric nervous system (ENS) controls the functions of the gastrointestinal system. 
ENS neurons are found in the submucosal (Meissner’s) and myenteric (Auerbach’s) 
plexi. These plexi contain sensory neurons that can detect the chemical composition of 
the gut lumen and the degree of stretch of the gut walls. They also contain visceral 
motor neurons that innervate both smooth muscle, to regulate peristaltic movement 
and gastrointestinal blood supply, and exocrine glands, to regulate the secretion of 
mucous and digestive enzymes. Sensory neurons and motor neurons within enteric 
plexi are connected by interneurons. Whilst the ENS functions largely independently of 
external signals, it is modulated to some extent by the other two branches of the ANS2, 
4, 5.  
1.1.2 Development of the Peripheral nervou s system. 
NCCs are a multipotent transient cell population that occupy the lateral margins of the 
neural plate, adjacent to the presumptive epidermis, during the early stages of 
neurulation. As the neural tube closes, NCCs, which are by now located at the roof of 
the neural tube, undergo an epithelial to mesenchymal transition and migrate away 
from the neural tube to form a large variety of different cell types that include: 
neurons and glia of the PNS, melanocytes, craniofacial skeleton, cranial connective 
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tissues and smooth muscles of major arteries (figure 1.02)8. In chicken embryos, neural 
crest specification begins during early gastrulation, prior to neural plate formation, and 
requires expression of the Pax7 transcription factor 9.  In Xenopus, FGF and Wnt, 
secreted from the underlying mesoderm, induce the initial development of NCCs at the 
neural plate/ectoderm borders in the presence of intermediate levels of BMPs10. NCC 
progenitor induction in the lateral neural plate is accompanied by the onset of Pax3, 
Pax7 and Zic1 transcription factor expression. In the presence of continued Wnt 
signalling, these transcription factors induce the expression of the transcription 
factors: Snail1, Snail2, FoxD3, Sox9, Sox10, Id, c-Myc and AP-2 in developing dorsal 
neural folds, thereby specifying multipotent NCCs10. The importance of Wnt signalling 
in NCC specification is reflected by the observation that neural specific deletion of β-
catenin, a component of the canonical Wnt signalling pathway, in mouse embryos 
results in the loss of neural crest-derived cranial skeletal structures and abnormalities 
in cranial sensory and dorsal root ganglia11.  
The epithelial to mesenchymal transition of newly specified NCCs is regulated by a 
number of processes including; changes in the composition of extracellular matrix 
molecules, changes in the expression of cell adhesion molecules expressed by NCCs, 
secretion of members of the FGF and TGF-β families10. The fate of migrating NCCs is 
determined by the environment they are exposed to as they migrate, i.e. their route of 
migration, and their final location10. There are 2 predominant migration routes utilized 
by trunk NCCs; the dorsolateral pathway and the ventral pathway (figure 1.02). NCCs 
that migrate via the dorsolateral pathway primarily gives rise to melanocytes in the 
epidermis. Alternatively, melanocytes can be generated from peripheral nerve–
associated Schwann cell precursors that fail to express the Hmx1 transcription factor, a 
neural specification gene12, 13.  
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Figure 1.02: Diagram showing the location of neural crest and NCC migration. NCCs migrate 
and differentiate into a variety of cell types. Cranial NCCs give rise to neurons and glia of the 
cranial sensory ganglia, postganglionic parasympathetic neurons, cartilage, bone and  
connective tissue of the head. Trunk NCCs migrating in the ventral pathway generate neurons 
and glia of sympathetic and dorsal root ganglia and sympatho-adrenal cells. Trunk NCCs 
migrating in the dorso-lateral pathway generate melanocytes (diagram adapted from Knech, 
A.K. and Bronner-Fraser, M., 200214 and P. Ernfors., 201013).  
In the trunk, NCCs that migrate through the ventral pathway develop into neurons and 
glia of dorsal root and sympathetic ganglia and chromaffin cells of the adrenal medulla. 
In the cranial region, migrating NCCs develop into proximal neurons and glia of cranial 
sensory ganglia, postganglionic parasympathetic neurons, cells of the craniofacial 
skeleton and cranial connective tissues. In addition, some NCCs form the midbrain 
trigeminal mesencephalic nucleus containing proprioceptive trigeminal sensory 
neurons2. Enteric neurons develop from vagal and lumbosacral NCCs and lumbosacral 
NCCs also give rise to pelvic postganglionic parasympathetic neurons3, 8, 10, 15. 
In the mouse, neural crest cells migrate ventrally to form the anlage of the sympathetic 
chain along the dorsolateral aspect of the dorsal aorta between E10 and E10.5. The 
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anlage extends rostrally as far as the Xth cranial ganglia16.  Whilst most of the anlage is 
derived from trunk NCCs, the most rostral region that will become the SCG is derived 
from vagal neural crest cells16, 17. Neural crest cells migrate from the sympathetic 
anlage to form the SCG at around E12 and the earliest SCG neurons are generated 
from proliferating neuroblasts at E137, 18. Canonical Wnt signalling and  BMP2/4/7 
signalling play a role in directing the migration of NCCs to the dorsal aorta and the 
specification of NCCs down the sympathetic lineage 11, 17, 19. 
Not all cranial sensory neurons are derived from NCCs; some are formed from 
neurogenic placodes20, 21. Placodes are transient ectodermal thickenings that develop 
next to the anterior neural tube and generate a large variety of different cell types 
including; lens fibres, cells of the inner ear, sensory neurons, hair follicles and teeth. 
Neurogenic placodes are placodes that have the potential to give rise to neurons that 
are either associated with the special senses, such as the olfactory epithelium and 
spiral ganglion, or within cranial sensory ganglia. In mammals, distal regions of all 
cranial sensory ganglia contain neurons derived from neurogenic placodes; however, 
all glia in cranial sensory ganglia are derived from NCCs. Dorsolateral neurogenic 
placodes develop into the vestibular ganglia and the ventrolateral trigeminal ganglia. 
The epibranchial placodes give rise to neurons of the nodose, petrosal and geniculate 
ganglia20, 21. 
1.2 Axon growth and Guidance  
The formation of functional neuronal circuits requires individual neurons to extend 
axons to connect with appropriate target neurons, as well as receiving multiple correct 
inputs themselves. Establishing this precise network of connections requires not only 
axon growth, but also accurate axon guidance, a process that is achieved by the 
integration of multiple axon guidance cues22-26.  
Extending axons have a growth cone at their tip. The growth cone, a dynamic structure 
that detects guidance cues to control the direction of the axon, comprises 3 distinct 
regions; the peripheral domain (P domain), the transitional zone (T zone) and the 
central domain (C domain) (figure 1.03)26. The P domain comprises finger like, 
cylindrical filopodia that contain long F-actin filament bundles to provide structure and 
mesh-like branched F-actin networks, which give structure to lamellipodia-like veils. In 
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addition, the P domain contains dynamic individual microtubules (MTs) that run along 
F-actin bundles and “probe” the P domain. The C domain contains bundles of stable 
MTs that enter the growth cone from the axon shaft, as well as numerous organelles, 
vesicles and central actin bundles. The T zone lies between the P and C domains and 
contains F-actin bundles with perpendicular actin/myosin-II contractile structures 
called actin arcs (figure 1.03)26. 
 
Figure 1.03: Schematic representation of a growth cone. Filopodia within the P domain 
contain the adhesive molecule receptors and surface adhesion molecules that are necessary 
for initiating growth cone progression, and hence axon extension. Filopodia also contain 
individual, dynamic microtubules (MTs). F-actin filaments within filopodia provide the 
propulsive power for growth cone movement, whereas dynamic microtubules assist with 
growth cone steering. Lamellipodia within the P domain contain mesh-like, branched F-actin 
networks. Within the C domain there are stable MT bundles. The T zone contains F-actin 
bundles with perpendicular actin/myosin-II contractile structures called actin arcs that regulate 
both the retrograde F-actin flow at rest and the exploratory movement of dynamic MTs during 
growth cones advance (taken from Lowrey, L.A., and Van Vactor, D., 2009)26. 
Axon growth takes place in 4 stages. In the first stage, growth cones encounter an 
adhesive substrate. Next, filopodia and lamellipodia move forward to extend the 
leading edge of the growth cone, a process known as protrusion. In the third stage, 
known as engorgement, F-actin arcs of the T zone move forward away from the C 
domain towards the site of new growth and are replaced by C domain MTs, guided 
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into place by C domain actin bundles. The result of engorgement is an advance of the C 
domain towards the new growth cone leading edge. Finally, consolidation of the 
advanced C domain occurs as the proximal part of the growth cone compacts at the 
growth cone neck to form a new segment of axon shaft26, 27. 
Growth cone movement is driven by actin dynamics. Actin filaments (F-actin) are 
polarised polymers that are composed of globular actin monomers (G-actin). Within 
the growth cone, the assembly, stabilisation and degradation of F-actin is tightly 
regulated. The addition of actin monomers to F-actin is dependent on the monomers 
being associated with ATP. Within the growth cone, ATP-actin is normally added to 
actin filaments at the plus end, the end that faces the leading edge of the growth cone. 
After ATP-actin addition to the plus end, ATP is hydrolysed to ADP and ADP-actin 
disassociates from the actin filament at the minus end facing the transition zone. 
Following disassociation, actin monomers are transported back to the plus end to 
support further growth. By this process, called treadmilling, actin filaments extend in a 
direction towards the leading edge of the growth cone, thereby driving growth cone 
motility. In quiescent growth cones, treadmilling is balanced by a retrograde flow of F-
actin from the leading edge towards the centre of the growth cone, a process that 
appears to be due to combination of myosin-II contractility in the T zone and the 
severing of actin filaments by members of the cofilin family of proteins26. In addition to 
myosin-II and cofilin family proteins, actin filaments are associated with other proteins 
that have a number of roles including: initiating new actin filament plus ends; capping 
filaments to block either actin growth or disassembly; inhibiting the capping of actin 
filaments; anchoring filaments to the growth cone membrane; stabilising F-actin to 
produce higher order actin structures, like bundles and networks26. In actively moving 
growth cones, transmembrane receptors at the leading edge of the growth cone 
interact with an adhesive molecule in the extracellular matrix, leading to the formation 
of an adhesive molecule-receptor-F-actin complex that prevents the retrograde flow of 
F-actin. Candidates for the adhesive receptor and adhesive extracellular substrate 
include N-cadherin and catenins, respectively26. Filopodia appear to be the site of 
growth cone adhesive interactions with extracellular substrates28. Data from 
experiments in which F-actin polymerisation is specifically blocked in filopodia suggest 
that filopodia are necessary for normal growth cone motility, supporting the notion 
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that adhesive interaction between the growth cone and extracellular substrate take 
place in filopodia29. 
Whilst F-actin dynamics provide the propulsive force for growth cone forward 
movement, MTs are important for growth cone steering26. MTs are also polarized 
structures that are composed of α- and β-tubulin dimers assembled into linear arrays. 
A linear array of alternating α- and β-tubulin subunits forms a protofilament, 11–15 of 
which connect in a circular array to form the wall of the tubular MT. The plus end of 
MTs, facing the leading edge of the growth cone, has β-tubulin subunits exposed that 
bind GTP-tubulin dimers, whilst GDP-tubulin dimers are released from the minus end 
of MTs. The plus ends of MTs are dynamic and unstable in growth cones, cycling 
through periods of growth, retraction and pausing. MTs are associated with numerous 
other proteins that have a number of roles including: stabilising MTs (e.g. microtubule 
associated protein 1B (MAP1B)); acting as microtubule motors (e.g. dynein and 
kinesin); linking MT plus ends with actin and membrane associated proteins to stabilise 
them (e.g. adenomatous polyposis coli (APC))26. In quiescent growth cones, individual 
MTs explore the P domains of growth cones by virtue of the inherent dynamic 
instability mentioned above. Localised adhesive interactions between filopodia and the 
extracellular substrate increases the number of exploratory MTs in the vicinity of the 
adhesive interaction, raising the possibility that these MTs might act as guidance 
sensors26. In accordance with this, the dynamic nature of MTs leads to the 
accumulation of signalling molecules involved with growth cone steering at the site of 
the adhesion, such as activated members of the Src kinase family30. During the 
engorgement stage of the axon growth cycle, stable MTs move into the advancing C 
domain, thereby fixing the new direction of axon growth. The importance of MTs in 
the process of growth cone steering is demonstrated by the observation that inhibition 
of MT dynamics prevents growth cone steering in response to adhesive cues, whereas 
locally stabilising MTs promotes turning31. Growth cone turning requires coordinated 
interactions between MTs and actin. During the protrusion phase of axon growth, 
exploratory MT movements in the P domain are regulated by the interactions of MTs 
with F-actin bundles, whereby interaction with F-actin inhibits MT exploratory 
behaviour and uncoupling interactions with F-actin increases exploratory behaviour. In 
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addition to the regulation of MT exploratory behaviour by F-actin bundles, F-actin arcs 
regulate the engorgement and consolidation activities of C domain MTs26. 
Growth cone pathfinding does not consist solely of moving forward. Rather, it is a 
dynamic process in which the growth cone progresses, pauses, turns and retracts as it 
encounters either positive (chemoattractive) axon guidance cues that increase 
protrusion towards the side of new growth, or negative (chemorepulsive) guidance 
cues that decrease protrusion away from the side of new growth25. Guidance cues can 
either act locally at their source or they can diffuse over larger distances from where 
they were synthesised22-25. There are 4 main families of guidance molecules which are 
collectively referred to as canonical guidance cues23. The netrins are one such family, 
of which netrin-1 and netrin-3 are found in mammals. Netrins are bifunctional, being 
able to repel some axons whilst attracting others, and are capable of acting as 
diffusible factors over relatively large distances, around the order of several cell 
diameters or broadly 10µm32, 33. The Deleted in Colorectal Carcinomas (DCC) family of 
receptors mediates the chemoattractive effects of Netrins, whilst the UNC5 family of 
proteins mediates the chemorepulsive actions of Netrins23. The Slit family of proteins 
comprises three secreted glycoproteins which can both repel axons and enhance 
branching of axons and dendrites. The actions of Slit family members are mediated via 
the four members of the Robo family of receptors23, 34. The third family of canonical 
guidance cues are the semaphorins, which can act as both diffusible and membrane 
bound guidance cues. Sema3a was the first member of the family identified in 
vertebrates and disruption of Sema3a function in mice results in severe axon guidance 
defects35. The biological actions of semaphorins are predominantly mediated by the 
Plexin family of receptors, although they can form complexes with other co-receptors 
such as Neuorpilin-1/-2. The ability of semaphorins to bind to multiple receptor 
combinations enables them to have both chemorepulsive and chemoattractive effects 
on axons23. Ephrins, the fourth family of canonical guidance cues, are membrane 
bound ligands for Eph tyrosine kinase receptors. Ephrins are divided into two 
subfamilies: Ephrin-As which are anchored to the membrane by a GPI linkage and do 
not have an intracellular domain; Ephrin-Bs which are attached to the membrane by a 
single transmembrane domain and have a short cytoplasmic domain with a PDZ-
binding motif22-24. Eph receptors are specific for either Ephrin-As (EphA receptors) or 
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Ephrin-Bs (EphB receptors). In mammals there are five Ephrin-A ligands that can 
interact with any of the nine EphA receptors and three Ephrin-B ligands that can bind 
to five EphB receptors.  Axons and non-neuronal cells can express both Ephrins and 
Eph receptors. As with other canonical guidance cues, Ephrin/Eph interactions can 
both repel axon growth cones or promote growth cone extension, depending on the 
physiological context and the identity of the axon22-25. In addition to the canonical 
guidance cues, other classes of molecules have also been identified as axon guidance 
cues, including; cell-adhesion molecules (CAMs), immunoglobulins (Ig) and cadherin 
superfamily members23. Guidance cues direct axon growth by signalling through 
receptors located at growth cones to modulate actin/microtubule dynamics 22, 23.  
Axonal branching occurs throughout development and can be divided into three broad 
categories: arborisation, whereby axon terminals in target fields branch extensively to 
form tree like networks; bifurcation, in which axons split at axons terminals into two 
daughter branches; interstitial (collateral) branching that occurs when axons branch 
off from the trunk of an existing axon, often far from its terminal, so that multiple 
targets can be innervated36. Therefore, new branches are produced from either 
splitting of the growth cone (as in the case of arborisation and bifurcation) or from 
new branches emerging from an existing axon trunk (interstitial branching). Neurons of 
the developing dorsal root ganglion (DRG) have been used as a model for investigating 
axon branching both in vitro and in vivo. The dorsal root entry zone (DREZ) is first 
innervated by centrally projecting axons of mouse DRG sensory neurons at E10 36-38. 
During this early period of innervation, the growth cone of DRG axons bifurcates into 
two daughter branches that subsequently extend in a perpendicular direction to the 
parent axon in both directions along the anterior-posterior (AP) axis of the spinal cord 
white matter. Two days later, interstitial branching from the longitudinally orientated 
DRG neuron axons forms collaterals that extend into the grey matter of the spinal cord 
39, 40. Collaterals of proprioceptive neurons project into the ventral horn, whilst 
mechanoreceptive collaterals terminate in the deep dorsal horn and nociceptive 
neuron collaterals terminate in the superficial dorsal horn36-38. The analysis of spinal 
cord innervation by developing DRG neurons in transgenic mouse models has 
suggested that the bifurcation of centrally projecting DRG axons at the DREZ and the 
subsequent extension of daughter branches along the AP axis is a three-step process36-
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38, 41, 42. Initially, Slit/Robo-mediated repulsion blocks the growth of the centrally 
projecting axon as it reaches the DREZ, steering the growth cone along the longitudinal 
axis in either the anterior of posterior direction in a randomly selected manner. Next, 
locally secreted C-type natriuretic peptide (CNP), acting through its receptor, 
natriuretic peptide receptor 2 (NRP2), stimulates the formation of an axon branch at 
the growth cone turning point and subsequently promotes the growth of this branch 
36-38, 42. Finally, Slit/Robo interactions direct the growth of the new branch along the AP 
axis36-38, 41.  The formation of collateral branches from longitudinally orientated DRG 
neuron axons within the spinal cord white matter is regulated by locally produced 
signalling molecules43-46. These signalling molecules include;  NGF45 (discussed in more 
detail in sections 1.4.3.1 and 1.5, below), Notch144 and  Slits43, 46. 
1.3 PCD and survival of neurons in the developing PNS  
1.3.1 Apoptosis  
Apoptosis, the most common form of PCD in the developing PNS, is an essential 
process that removes excess and inappropriately connected neurons to ensure that 
innervation is matched to the functional requirements of peripheral target fields 47-49. 
In the PNS, the main period of PCD occurs as neurons begin to establish synaptic 
connections with cells within their targets. Apoptosis is regulated by a cascade of 
cysteine proteases called caspases. These proteases are activated by 2 distinct 
pathways: the intrinsic pathway and the extrinsic pathway50-53 (Figure 1.04). Pro-
apoptotic members of the B-cell lymphoma-2 (Bcl-2) family of proteins are intracellular 
regulators50 that initiate caspase activity as a result of cues arising from either; 
mitochondrial stress, DNA damage, growth factor deprivation or viral infection52. The 
extrinsic pathway, which is less important in PCD within the developing nervous 
system than the intrinsic pathway, is initiated independently of pro-apoptotic Bcl-2 
family members by activation of TNF family receptors with death domains, which 
initiate an intracellular signalling cascade that triggers caspase activation53 54. Bcl-2 
family proteins can be divided into 3 groups: anti-apoptotic, pro-apoptotic and BH3-
only proteins, the latter of which regulate the activity of anti-apoptotic members of 
the Bcl-2 family. Bcl-2, Bcl-XL, Bcl-W, A1A and MCL1 proteins comprise members of the 
anti-apoptotic group52. Bax, Bak, and Bok are pro-apoptotic members of the Bcl-2 
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family and BH3-only protein members include Bad, Bid, Bim, Noxa and Puma52,54, 55. 
Bax and Bak are normally sequestered and kept in an inactive form within the 
cytoplasm by interactions with anti-apoptotic members of the Bcl-2 family, in 
particular Bcl-2 itself and Bcl-XL
53. Following cellular stress, the phosphorylation of 
BH3-only family members leads to the dissociation of anti-apoptotic Bcl-2 family 
members from Bax and Bak, enabling them to form pores within the outer 
mitochondrial membrane53, 56-58. Permeability of the outer mitochondrial membrane 
releases a number of proteins that normally reside in the compartment between the 
inner and outer mitochondrial membranes into the cytoplasm. One such protein, 
cytochrome-c, binds to cytoplasmic apoptotic protease-activating factor-1 (Apaf-1), in 
the presence of dATP/ATP, leading to the formation of the apoptosome 53, 56-58,. This 
protein complex is then able to activate procaspase-9, an initiator caspase of the 
intrinsic pathway57, which leads to activation of the effector, or executioner, caspases 
3, 6 and 7. These effector caspases degrade cytoplasmic proteins and activate other 
proteases, lipases and nucleases to disassemble the cell in an orderly manner, a 
hallmark of apoptosis 30, 53, 56-58. In addition to cytochrome C, permeability of the outer 
mitochondrial membrane also results in the release of OMI, Diablo, Apoptosis Inducing 
Factor (AIF) and endonuclease-G into the cytoplasm59. OMI and Diablo bind to and 
antagonise the activity of Inhibitor of Apoptosis Protein (IAP) family members, a family 
of proteins that inhibit the activation of the executioner caspases. AIF and 
endonuclease-G form a complex that leads to caspase-independent nuclear 
disassembly and degradation of nuclear DNA59. 
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Figure 1.04: Schematic depicting the essential components of the intrinsic and extrinsic 
pathways of apoptosis. In the intrinsic pathway, cellular stress activates BH3-only members of 
the Bcl-2 family, thereby inhibiting the activity of anti-apoptotic members of the Bcl-2 family, 
like Bcl-2 itself. Inhibition of Bcl-2 function releases free Bax and Bak, enabling these pro-
apoptotic Bcl-2 family members to form pores in the outer mitochondrial membrane with the 
concomitant release of intermembrane proteins, including cytochrome-c, into the cytoplasm. 
Cytochrome-c release results in apoptosome formation, cleavage of pro-caspase 9 (not shown) 
and activity of the executioner caspase, caspase 3. In the extrinsic pathway, ligand binding to 
TNF-superfamily receptors, including Fas and TNFR1, leads to cleavage of pro-caspase 8 to give 
active caspase 8. Active caspase 8 in turn activates the effector caspases, including caspase 3, 
to execute apoptosis ( Taken from Youle, R.J., and Strasser, A., 200852). 
1.3.2 The neurotrophic factor hypothesis  
During the course of development, neurons of the PNS are exposed to multiple pro- 
and anti-survival factors48, 60. These extracellular cues ensure that apoptosis is a 
regulated process that is able to establish correct target field innervation and neuronal 
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connectivity60, 61. The neurotrophic factor hypothesis evolved as a model to explain 
how neuronal survival and apoptosis are regulated in the developing peripheral 
nervous system48. According to the neurotrophic factor hypothesis, many more 
neurons are born than are required for functional target field innervation. Superfluous 
neurons are lost during a period of developmental programmed cell death that begins 
shortly after axons reach their target fields. Neuronal survival depends on neurons 
obtaining an adequate supply of neurotrophic factors that are synthesised in limited 
quantities by target field cells48, 62, 63. This model proposes that neurons innervating 
incorrect targets will not obtain adequate neurotrophic factor support and will 
consequently be eliminated. The hypothesis was initially devised through studying the 
actions of the prototypical neurotrophic factor, Nerve Growth Factor (NGF) on 
developing postganglionic sympathetic and peripheral sensory neurons63, 64. The 
isolation and characterisation of additional neurotrophic factors closely related to NGF 
in the early 1990s65 substantially added to the body of evidence supporting the 
neurotrophic factor hypothesis, as did the observation that some developing sensory 
neurons are independent of neurotrophic factor support prior to their axons reaching 
their targets66, 67. This hypothesis has been refined in recent decades; however, as it 
does not completely explain the mechanisms regulating neuronal survival and target 
field innervation68. For example, some populations of peripheral neurons require 
neurotrophic factors to support their survival prior to target field innervation7, 19, 60 
others change their neurotrophic factors survival requirements during development62, 
69 and others respond to more than one target field-derived neurotrophic factor during 
the same period of development70. Moreover, target field-innervation is not only 
regulated by neurotrophic factor promoted survival of neurons, but also by 
neurotrophic factor promoted enhancement of axon growth and branching60. More 
recently, it has been shown that the levels of neurotrophic factors expressed within 
target fields can be modulated to a certain extent by the number of neurons 
innervating the target field71 and that autocrine neurotrophic factor signalling loops 
within some populations of developing neurons can have trophic effects on the 
secreting neurons themselves72.  
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1.3.3 Neurotrophic factors  
1.3.3.1 Neurotrophins  
In the early 1990s, a homology based library screening approach identified 3 
neurotrophic factors that were closely related to NGF: brain-derived neurotrophic 
factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5, later designated 
as NT-4)65. The similarity in sequence and structure between NGF, BDNF, NT-3 and NT-
4 resulted in them being classified as a protein family; the neurotrophin family. 
Neurotrophins are secreted proteins, with low molecular weights (12-13 kDa), that are 
functional as homodimers and exert diverse trophic effects on a wide range of CNS and 
PNS neurons. In the developing nervous system, neurotrophins promote the 
differentiation and survival of neurons and regulate their target field innervation. In 
late stages of development and in the adult, neurotrophins regulate synaptogenesis, 
synaptic plasticity and the functional properties of neurons65. Neurotrophins exert 
their trophic effects by binding to receptor tyrosine kinases of the tropomyosin related 
kinase (Trk) family73 and to the p75 neurotrophin receptor (p75NTR). The binding of 
neurotrophin dimers to Trk receptors leads to receptor dimerization and the 
autophosphorylation of a number of intracellular tyrosine residues, which in turn 
results in the activation of several intracellular signalling pathways74. The Trk receptor 
family has three members; TrkA, TrkB and TrkC, that show ligand specificity. NGF binds 
to TrkA, BDNF and NT-4 to TrkB and NT-3 to TrkC; however, NT-3 can also bind to and 
activate TrkA and TrkB in the absence of the p75NTR 74-76 (figure 1.05). p75NTR is a 
member of the TNF receptor superfamily that contains a cytoplasmic death domain, 
but no intrinsic catalytic activity. Unlike the Trk receptors that show specificity, all 
neurotrophins bind to p75NTR with an equal affinity. The binding of neurotrophins to 
p75NTR results in a diverse array of physiological outcomes that is dependent on cell 
type, developmental stage and whether cognate Trk receptors are expressed74. 
Neurotrophic factor signalling through Trk’s and p75NTR will be discussed in more 
detail, below. 
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Figure 1.05: Neurotrophins bind to Trk receptors as homodimers, resulting in dimerization of 
receptors. Whilst neurotrophins bind to specific Trk receptors, all neurotrophins bind to p75NTR 
with equal affinity. Trk and p75NTR can interact with each other, increasing the affinity of  Trk 
receptors for neurotrophins. The intracellular regions of both Trk and p75NTR activate signal 
transduction pathways76(diagram taken from Chao., 200376).  
Neurotrophin family members are synthesised as long precursor molecules (30-34 
kDA) that have been termed pro-neurotrophins77. Pro-neurotrophins can be cleaved by 
proconvertases and furin in the ER and Golgi to produce c-terminal mature 
neurotrophins that are subsequently secreted by synthesising cells78-81. The pro 
domain of proneurotrophins seems to regulate intracellular trafficking and secretion of 
mature neurotrophins from neurons, glia and target field cells. Non-cleaved 
proneurotrophins can also be secreted and processed extracellularly by matrix 
metalloproteases and plasmin81. It was initially thought that secreted pro-
neurotrophins, or pro-neurotrophins released from cells following trauma induced cell 
damage, had no biological function as they do not activate Trk receptors. However, it is 
now well established that proNGF and proBDNF have a high binding affinity for a 
receptor complex that is composed of p75NTR and the transmembrane protein sortilin. 
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Activation of the p75NTR/sortilin receptor complex by proNGF or proBDNF activates a 
number of intracellular signalling pathways, including the Jun-kinase (JNK) pathway, to 
initiate apoptosis81, 82.  
TrkA, the first member of the Trk family to be characterised, was initially isolated from 
human colon carcinomas and identified as a chimeric oncoptrotein83, 84. TrkA, has an 
extracellular domain that interacts with NGF, a single transmembrane domain and a 
cytoplasmic region that includes a tyrosine kinase catalytic domain that initiates 
intracellular signalling pathways85. TrkB and TrkC were identified and characterised in 
the early 1990s shortly after their cognate ligands were discovered85. All three 
receptors of the Trk family have a short carboxyl-terminal tail of 15 amino acids with a 
conserved Tyr residue85, 86.  
As mentioned above, ligand induced dimerization of Trk receptors induces 
autophosphorylation of tyrosine residues within their intracellular kinase domain. 
Autophosphorylated tyrosine residues phosphorylate additional Trk intracellular 
tyrosine residues, and these recruit and phosphorylate a number of cytoplasmic 
proteins that initiate intracellular signalling pathways74. Recruited proteins include 
numerous phosphotyrosine-binding (PTB) or Src-homology-2 (SH2) domain containing 
adaptor proteins, such as Shc, SH2-B, FRS2, Grb2, and the enzyme phospholipase-C-γ-
1(PLCγ-1)74, 76, 87, 88(Figure 1.06). The phosphorylation of adaptor proteins results in Ras 
mediated activation of the mitogen-activated protein (MAP) kinase (ERK1/2) signalling 
cascade together with phosphatidyl inositol-3 (PI3)-kinase mediated stimulation of Akt 
activity. Activation of ERK1/2 and Akt enhances gene transcriptional activity and 
promotes the differentiation and/or survival of neurons, as well as axon growth, in a 
number of neuron types in vitro89-93. Interestingly, analysis of conditional ERK1/2 
deficient transgenic mouse embryos, that lack ERK1/2 expression only in developing 
sensory neurons, has revealed that ERK1/2 is not necessary for developing sensory 
neuron survival in vivo, but it is required for correct NGF-dependent target field 
innervation94. Akt appears to enhance neuron survival by regulating the function of 
BH-3 only Bcl-2 family members. Akt phosphorylates BAD, thereby preventing it from 
interfering with the function of anti-apoptotic Bcl-2 family members95. Akt also 
phosphorylates and inactivates the transcription factors FOXO1 and p53, leading to a 
reduction in the transcription of BH-3 only proteins: BIM, Puma and Noxa96. The 
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activation of PLCγ-1 following Trk dimerization and autophosphorylation, leads to the 
generation of IP3 and DAG from phosphatidyl inositides. A combination of IP3-induced 
mobilization of Ca2+ from intracellular stores and DAG mediated protein kinase C 
activation modulates synaptic plasticity and local axon growth and branching74, 76. 
 
Figure 1.06: Trk receptors signal by recruiting PLCγ-1 and multiple PTB and SH2 domain 
adaptor proteins, such as Shc, SH2-B, FRS2 and Grb2, to phosphorylated tyrosine residues. 
The recruitment of adaptor proteins initiates the Ras-MEK-ERK1/2 and PI3-kinase-Akt 
signalling cascades that result in enhanced neuron survival and axon growth. PLCγ-1 activation 
promotes local axon growth and branching. The binding of neurotrophins to p75NTR recruits the 
adaptor protein, TRAF6 that can lead to the initiation of NF-κB signalling, thereby promoting 
neuron survival. In contrast, p75NTR ligation can result in activation of JNK and consequent 
apoptosis.  The binding of neurotrophins to p75NTR also modulates the activity of cytoplasmic 
RhoA, thereby regulating axon growth (taken from Chao., 200376). 
p75NTR was the first neurotrophin receptor to be isolated and cloned97. At the time, 
NGF was the only known member of the neurotrophin family and the Trk receptors 
had yet to be identified, with the result that p75NTR became known as the NGF 
receptor. Following the characterization of other members of the neurotrophin family, 
it became evident that p75NTR was a common receptor for all neurotrophin family 
members74.  
Neurotrophin binding to p75NTR results in varied physiological responses ranging from 
promotion of survival, enhanced synaptic plasticity, axon elongation, and induction of 
apoptosis74, 98, 99. The presence of p75NTR enhances the interaction of NGF with TrkA, 
thereby potentiating the trophic abilities of low concentrations of NGF48, 76.  Whilst 
p75NTR does not appear to enhance BDNF/TrkB or NT-3/TrkC signalling, it does increase 
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the specificity of Trk signalling, so that in the presence of p75NTR NT-3 can only signal 
through TrkC, and not TrkA or TrkB65, 74. Although p75NTR does not have any intrinsic 
catalytic activity, its intracellular death domain can bind a number of intracellular 
signalling proteins. For example, neurotrophin binding to p75NTR induces an interaction 
between the signalling adaptor protein, TRAF6, and the intracellular domain of p75NTR 
(p75NTR-ICD). This interaction initiates the formation of a four protein complex 
consisting of: TRAF6, Interleukin-1 receptor-associated kinase (IRAK), atypical protein 
kinase C (aPKC) and aPKC associated protein, p62. Complex formation leads to the 
recruitment and activation of IқB kinase-β (IKK-β). IKK-mediated phosphorylation of 
IқB results in release of the transcription factor NF-қB and NF-қB-promoted neuronal 
survival74, 99. In some neurons, the intracellular domain of p75NTR binds to the small 
Rho GTPase, RhoGDI, in the absence of neurotrophins. Free cytoplasmic RhoA, another 
small Rho GTPase, can inhibit neurite/axon growth and RhoGDI can interact with RhoA 
to inactivate it. Neurotrophin binding to p75NTR releases RhoGDI into the cytoplasm 
where it sequesters RhoA, thereby promoting axon growth74. 
In contrast to the trophic actions of p75NTR signalling described above, neurotrophin 
binding to p75NTR in the absence of cognate Trk expression leads to apoptosis by a 
number of different signalling pathways 74, 99, 100. Whilst the binding of neurotrophins 
still induces interaction of TRAF6 with the p75NTR-ICD in the absence of cognate Trk 
expression, a TRAF6-IRAK-aPKC-p62 complex fails to form. Instead, intracellular 
proteases, such as gamma secretase or tumour necrosis factor-α-converting enzyme 
(TACE), cleave the p75NTR-ICD, thereby releasing a soluble TRAF6/p75NTR-ICD complex 
into the neuronal cytoplasm where it can interact with and activate a number of 
proteins to induce apoptosis. For example, the interaction of TRAF6/p75NTR-ICD with 
JNK results in the activation of JNK, which in turn enhances the activity of the 
transcription factor, p53. p53 promotes the transcription of many pro-apoptotic genes, 
including BAX, to induce apoptosis74, 99. The TRAF6/p75NTR-ICD complex can also form a 
complex with the NRIF transcription factor that results in the ubiquitination and 
subsequent nuclear translocation of NRIF. Like p53, nuclear NRIF promotes the 
transcription of a number of pro-apoptotic genes99. The ligation of p75NTR by 
neurotrophins in the absence of cognate Trk expression can also lead to the activation 
of membrane sphingomyelinase, an enzyme that catalyses the hydrolysis of membrane 
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sphingomyelin into ceramide and phosphorylcholine. The resultant ceramide acts as a 
second messenger and appears to be capable of interfering with the activation of PI3-
kinase by Trk’s, resulting in reduced Akt activity and compromised survival74.  
Compartmentalised neuron cultures allow the microenvironments surrounding the 
soma and processes of neurons to be manipulated independently of each other. 
Campenot chambers are composed of two or more independent culture 
compartments separated by a Teflon barrier with a series of collagen tracts 
underneath the Teflon barrier. This arrangement allows the composition of the culture 
media in each compartment/chamber to be manipulated independently and the axons 
projecting from the neuronal soma seeded into one compartment to extend under the 
barrier, along the collagen tracts, and into the axon compartment101. The processes of 
cultured SCG neurons are entirely comprised of axons in short term cultures as they do 
not express the dendritic marker, MAP2. This type of compartmentalised neuron 
culture experiment has demonstrated that neurotrophins can activate Trk signalling at 
the distal processes of sympathetic neurons to promote distal axon extension and 
arborisation75, as demonstrated by addition of NGF to distal axon chambers and not 
soma chambers. Compartmentalised neuron cultures have also shown that 
neurotrophins can stimulate neuronal survival when they are only applied to distal 
axons, as demonstrated by addition of NGF only to the axon compartment and not 
soma compartment of Campenot chambers102.  Whilst neurotrophin addition to the 
soma of neurons promotes survival and proximal axon elongation, it cannot induce 
distal axon extension and arborisation75. Since neurotrophin promoted survival and 
axon extension requires ERK1/2 and Akt mediated gene transcription, the ability of 
target field-derived neurotrophins to promote neuron survival and functional 
innervation implies that either neurotrophins or Trk signalling moieties must be 
retrogradely transported from axon terminals back to the nucleus.  Through a series of 
studies on sympathetic neurons of the SCG, it has now become well established that 
NGF-TrkA complexes are internalised into the cell by pincher, clathrin or caveolin 
mediated endocytosis at the distal axon and enclosed into signalling endosomes that 
are retrogradely transported to the neuron soma by dynein driven transport along MTs 
(figure 1.07)75, 103-106. Evidence suggests that signalling endosomes not only contain 
neurotrophin-Trk complexes, but also adaptor proteins and components of the Ras-
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ERK1/2 and PI3-kinase-Akt signalling pathways. This suggests that retrogradely 
transported signalling endosomes can initiate intracellular signalling both on their way 
back to the neuron soma and in the soma itself 75,107. The nature of the endocytic 
process that leads to endosome formation is not entirely clear, but there is evidence 
for: clathrin-coated vesicle endocytosis; a dynamin-1, caveolin-1 and lipid-raft 
dependent endocytic process; pincher chaperone protein-mediated micropinocytosis 
which is independent of both clathrin and caveolin. It is possible that all three 
mechanism of endocytosis are employed and that the duration of signalling and 
physiological outcome are dependent on the mode of endocytosis107.  
 
Figure 1.07: Retrograde NGF signalling involves internalisation of NGF-TrkA complexes and 
their enclosure into signalling endosomes. Signalling endosome contain adaptor proteins and 
components of the PI3-kinase/Akt and Ras/ERK signalling pathways. Signalling endosomes are 
transported back to the soma by Dynein driven MT transport. TrkA activation in the soma also 
results in intracellular signalling via PI3-kinase/Akt and Ras-ERK1/2 signalling pathways 
(adapted from Sorkin, A. and von Zastrow, M., 2002108).  
Besides the neurotrophins, there are several other families of secreted proteins that 
have been shown to exert neurotrophic effects on developing and adult neurons.  
These include: members of the glial cell–derived neurotrophic (GDNF) factor family of 
ligands (GFL); neuropoietic cytokines109, 110; hepatocyte growth factor (HGF)111-113 and 
macrophage stimulating protein (MSP)70, 114, 115. As discussed in more detail below, the 
development of mouse SCG neurons is dependent on the sequential actions of 
multiple neurotrophic factors at different developmental stages. In addition to the 
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neurotrophins NGF and NT-3, these factors include; Artemin (a GFL member), HGF and 
TNF superfamily (TNFSF) members. In the proceeding sections I will give a brief 
overview of GFL members and their receptors, HGF/HGF receptor signalling and 
TNFSF/TNFSF-receptor signalling.  
1.3.3.2 GFL and GFL receptors  
Glial cell line-derived neurotrophic factor (GDNF) is the prototypical member of the 
GDNF family ligands (GFLs). GDNF was first isolated and characterised as a 
neurotrophic factor for cultured rat midbrain dopaminergic neurons in the early 1990s 
and was later revealed to have neurotrophic effects on locus coeruleus noradrenergic 
neurons, motor neurons and various peripheral autonomic and sensory neurons172. 
After the discovery of GDNF, three other members of the GFL family were identified. 
Neurturin (NTN) was isolated and cloned by virtue of its ability to promote the survival 
of postnatal rat sympathetic neurons in culture. Subsequently, it was shown to 
enhance the survival of cultured nodose and DRG neurons from embryonic rats116. The 
other two GFL members, artemin (ARTN) and persephin (PSN), were isolated using a 
bioinformatics approach117-119. Artemin supports the survival of neonatal rat DRG, 
nodose, trigeminal and SCG neurons and embryonic ventral midbrain neurons in 
culture117, 119. In contrast PSP does not support the survival of cultured neonatal rat 
peripheral sensory or sympathetic neurons, but can promote the survival of embryonic 
rat ventral midbrain and motor neurons in culture117, 119.  
GFLs are functional as homodimers and their neurotrophic effects are mediated by 
dimerization and activation of the transmembrane tyrosine kinase receptor RET117-120. 
GFL homodimers do not directly bind to RET to activate it, rather they bind to a dimer 
of one of four glycosyl phosphatidylinositol (GPI) linked co-receptors (GFRα1, GFRα2, 
GFRα3 and GFRα4) and the tetrameric GFL/co-receptor complex dimerizes and 
activates RET117. GFRα1 is the preferred co-receptor for GDNF, GFRα2 is the preferred 
co-receptors for NTN, artemin binds to GFRα3 and GFRα4 is the PSP receptor117, 121-125.  
The intracellular signalling pathways initiated by RET activation share similarities with 
neurotrophin/Trk signalling pathways125-127. Dimerization of RET leads to auto 
phosphorylation at multiple intracellular tyrosine residues. Two phosphorylated 
tyrosine residues, pY1015 and pY1062, are essential for initiating signaling that 
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promotes neuron survival and target field innervation125.  Much of RET signalling takes 
place within lipid enriched rafts within the plasma membrane. In lipid rafts, the SH2 
adaptor protein Frs2 binds to pY1062 and forms a complex with Grb2 and SOS that 
activates the Ras-ERK1/2 signalling pathway. Frs2 binding to pY1062 also recruits the 
adaptor proteins Grb2 and Gab2, thereby activating PI3-kinase and the tyrosine 
phosphatase, SHP2, which in turn leads to activation of Akt125. PI3-kinase can also 
regulate the activity of small cytoplasmic GTPases, like Rac and Rho, and these in turn 
modulate the activity of Focal Adhesion Kinase (FAK) to regulate axon growth. pY1015 
recruits and initiates signalling from PLCγ1, leading to the generation of IP3 and DAG 
from phosphatidyl inositides, activation of PKC and local neurite growth/plasticity. 
Outside lipid rafts, the function of Frs2 is replaced by Shc125, 126. An overview of RET 
signalling pathways is shown in figure 1.08. 
 
Figure 1.08: The intracellular pathways activated by GFL/GFRα/RET signalling. Much of RET 
signalling is mediated by phosphotyrosine residue 1062 (pY1062). pY1062 recruits multiple SH2 
domain adaptor proteins, such as Shc, FRS2 and Grb2, which initiate Ras-MEK-ERK1/2 and PI3-
kinase-Akt cascades to promote neuron survival. PI3-kinase induced modulation of small 
GTPase- FAK activity regulates axon growth (Taken from Takahashi, 2001126). 
NCAM can also act as a receptor for GDNF in the absence of RET expression127. GFRα1 
and NCAM can associate with one another in the absence of GDNF, reducing NCAM’s 
cell adhesion properties. The presence of GDNF leads to the formation of 
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GDNF/GFRα1/NCAM complexes in which NCAM is phosphorylated and these 
complexes recruit and phosphorylate the small cytoplasmic kinases, Fyn and FAK. 
Activation of Fyn and FAK initiates the Ras-ERK1/2 signalling cascade that promotes 
axon outgrowth from hippocampal and cortical neurons128. NCAM/GFRα1 and 
GDNF/NCAM/GFRα1 signalling appear to be independent of each other127. 
Interestingly, GDNF/GFRα1 dependent signalling appears to be required for the correct 
differentiation and migration of developing cortical neurons in vivo and this signalling 
is not dependent on the expression of either RET or NCAM, suggesting that additional 
transmembrane GDNF receptors may exist129.  
Co-precipitation of 125I-GDNF and GFRα1 from SCG neurons, following the injection of 
125I-GDNF into the eye, supports the hypothesis that GDNF is able to be signal 
retrogradely130. Additional evidence for retrograde signalling comes from the fact that 
GDNF supports the survival of E15 rat DRG sensory neurons in compartmentalised 
cultures when it is applied to distal processes131. Conversely, retrograde GDNF 
signalling does not support the survival of cultured neonatal rat sympathetic neurons, 
although it can promote the growth and branching of sympathetic neuron axons via 
local signalling when it is applied to axon terminals. The differential efficacy of GDNF 
retrograde signalling in supporting the survival of cultured sympathetic and DRG 
neurons is explained by the rapid, proteasome mediated, degradation of activated 
Ret/GDNF signalling complexes in the axons of sympathetic neurons, but not DRG 
neurons131. 
1.4.3.3 HGF/Met signalling  
HGF is initially synthesised and secreted as pro-HGF, which is a biologically inactive 
single chain glycoprotein precursor composed of 728 amino acids132, 133. Extracellular 
proteases cleave Pro-HGF, between residues Arg494 and Val495134, to generate α and 
β chains that are subsequently linked by a disulphide bond to produce the 
heterodimeric  mature HGF protein134. The 494 amino acid α chain contains a signal 
peptide, an N-terminal hairpin loop of around 27 amino acids, which is homologous to 
the pre-activation peptide of plasminogen, and four kringle domains132, 134. The β chain 
is composed of 234 amino acids and structurally resembles a serine protease 132, 134. 
HGF mediates its biological effects through the Met tyrosine kinase receptor that is 
encoded by the c-met proto-oncogene135. Met is synthesised as a single polypeptide of 
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1436 amino acids that is subsequently cleaved into a single membrane pass 
heterodimer of α and β subunits connected by a disulphide bond134, 136. The small α 
subunit of Met is entirely extracellular. The β subunit of Met contains an extracellular 
ligand binding domain, a transmembrane domain and an intracellular kinase domain. 
The extracellular domain comprises a 500 amino acid Sema domain, containing 
homology to semaphorins and plexins, a 50 amino acid PSI domain (conserved in 
plexins, semaphorins and integrins)  and four IPT domains (immunoglobulin-like fold 
shared by plexins and transcription factors) that connect the PSI domain to the 
transmembrane helix132, 134, 136. HGF has two binding sites that interact with the 
extracellular region of Met. The α chain of HGF binds with high affinity to the IPT3 and 
IPT4 domains of the Met β subunit, whereas the HGF β chain interacts with low affinity 
with the sema domain of the Met β subunit136, 137.  
 The juxtamembrane region of the cytoplasmic domain of Met contains a regulatory 
serine at residue 975 that attenuates the tyrosine kinase activity of Met when it is 
phosphorylated. The catalytic region of Met contains two adjacent tyrosine residues, 
Tyr1234 and Tyr1235 within the kinase activation loop that are essential for Met 
activity. The trans-phosphorylation of Tyr1234 and Tyr1235 that follows ligand induced 
Met dimerization promotes phosphorylation of carboxy-terminal tyrosine residues, 
Tyr1349 and Tyr1356, thereby creating a multifunctional docking site for transducer 
and adaptor molecules, such as Gab1, Grb2, Shc and SHP2 132, 134, 136, 137. The docking of 
transducer and adaptor molecules to activated Met leads to the initiation of a number 
of intracellular signalling pathways that include; the Ras/Raf/MEK/ERK, Ras/Rac/JNK 
and NF-κB pathways. In addition, phosphorylated Tyr1356 can also directly interact 
with and activate PI-3 kinase, leading to Akt activation, and directly activate the 
transcription factor, STAT3, thereby promoting its nuclear translocation137. Met is also 
able to bind several protein-tyrosine phosphates (PTPs) which attenuate Met signalling 
by dephosphorylating either the catalytic tyrosine residues, Tyr1234 and Tyr1235 or 
the docking tyrosine residues, Tyr1349 and Tyr1356136. PTPs that target the catalytic 
residues include PTP1B and T cell PTP (TCPTP), whilst density-enhanced phosphatase 1 
(DEP1) targets the docking residues of Met. Met also interacts with a variety of other 
signal modifiers, such as; scaffolding proteins, cytoskeletal proteins and a variety of co-
receptors, that modulate the biological effects of HGF/Met signalling136.  
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Whilst it is not yet clear how many of the multiple signalling pathways that lie 
downstream of activated Met actually operate in neurons, inhibition of PI3K in 
cultured adult mouse SCG neurons prevents HGF mediated phosphorylation of Akt and 
abolishes HGF promoted SCG neuron survival111. Furthermore, preventing the 
activation of ERK1/2 by inhibiting the activity of MEK1 and MEK2 reduces HGF 
promoted survival of cultured adult SCG neurons and prevents HGF from enhancing 
NGF promoted process outgrowth from cultured neonatal SCG neurons111, 113.  
1.3.3.4 TNFSF/TNFSF-receptors 
The TNF superfamily of ligands (TNFSF) and receptors (TNFRSF) is made up of 19 
ligands and 30 receptors. TNFSF/TNFRSF members are expressed in many different cell 
types, from those found in the immune system to lymphoid, ectodermal, mammary 
and neuronal tissue138, 139. TNFSF/TNFRSF members have also been associated with 
many disease pathologies including cancers, autoimmune diseases, neuropathologies, 
cardiovascular diseases and metabolic disorders140, 141. Many TNFSF ligands interact 
with multiple receptors, resulting in multiple biological responses to a single ligand 
that depends on cell type and physiological context141. With the exception of LT-α, 
TNF-β and VEGI, all TNFSF ligands are type II transmembrane proteins with an 
intracellular N-terminus and extracellular C-terminus. Some ligands, such as TNF-α, can 
exist as soluble forms that are cleaved from the cell membrane by proteolysis140, 141. 
Proteases that cleave and release soluble TNFSF ligands include; ADAM17 (a 
disintegrin and metalloprotease domain 17) that cleaves TNF-α and RANKL, furin 
proteases which target APRIL, TWEAK, EDA and BAFF and matrilysin which cleaves 
FASL138. Soluble and membrane bound TNFSF ligands are active as non-covalently 
bounded homotrimers. The C-terminal of TNFSF ligands contains a TNF homology 
domain (THD), composed of 150 amino acids, which mediates trimer formation and 
ligand-receptor interactions138-141. 
The majority of the 29 TNFRSF members are type 1 transmembrane receptors; 
however, some, like BCMA, TACI, BAFFR, XEDAR  are type 3 transmembrane proteins, 
whilst others, like DcR3 and OPG, are soluble proteins142. The extracellular domain of 
the transmembrane TNFRSF members share a characteristic cysteine-rich domain 
motif (CRD) with the canonical sequence CXXCXXC138. The number of CRD motifs in the 
extracellular domain varies between TNFRSF members141. TNFRSF members can be 
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divided into three functional groups:  1) those with an intracellular death domain, a 
conserved region of around 80 amino acids that is involved in apoptotic signalling; 2) 
receptors lacking a death domain, but containing TNF-receptor associated factor 
(TRAF) interacting motifs (TIMS) in their intracellular domain; 3) decoy receptors that 
have no intracellular signalling capability, but regulate TNFSF/TNFRSF signalling by 
sequestering TNFSF ligands138-143. Like TNFSF ligands, TNFRSF members are functional 
as homotrimers that are preassembled prior to ligand binding. Accordingly, TNFRSF 
members have extracellular pre-ligand assembly domains (PLADs) that facilitate 
trimerisation of individual receptor subunits144-146. TNFRSF members with an 
intracellular death domain recruit intracellular adaptor proteins such as Fas associated 
death domain (FADD) and TNFR associated death domain (TRADD). Recruited TRADD 
and FADD in turn recruit pro-caspase 8 to form the Death Inducing Signalling Complex 
(DISC), leading to pro-caspase 8 cleavage, the release of catalytically active caspase 8 
and caspase 8 mediated activation of the executioner caspases 3, 6 and 7147.  
Alternatively, TRADD can recruit TRAF adaptor proteins148 which can induce the 
activation and nuclear translocation of transcription factors, for example JNK and NF-
κB, that promote cell survival, differentiation and the initiation of inflammatory 
responses147. TNFRSF members with TIMS motifs are able to directly recruit TRAFs, 
which can initiate intracellular signalling pathways that lead to the activation of ERK, 
PI3K, p38 MAPK, JNK and NF-κB147-150.  
Members of the TNF ligand and receptor superfamilies are capable of reverse 
signalling, whereby soluble or membrane bound TNF receptors can induce intracellular 
signalling from their cognate membrane bound TNFSF ligands151. Although reverse 
signalling has primarily been investigated in the immune system151, 152, examples have 
been demonstrated in the developing nervous system. For example, TNFR1/TNF-α153 
and CD40/CD40L72 reverse signalling promote target field innervation by developing 
mouse SCG neurons in vivo.  
1.4 Neurotrophic factor requirements of developing SCG 
neurons 
The SCG contains postganglionic neurons of the sympathetic nervous system and is 
located at the rostral end of the sympathetic chain 60. SCG neurons innervate a variety 
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of targets in the head including; submandibular and parotid salivary glands, lacrimal 
glands, iris, nasal and oral mucosa, pineal gland and blood vessels2. In the mouse, the 
SCG coalesces from migrating neural crest cells at around E12, and the earliest SCG 
neurons are generated from proliferating neuroblasts at E13 7, 18, 60. The period of 
neuroblast differentiation takes place between approximately E13 to E15 and is 
followed by a period of proximal axon growth (E13-E16), as newly born SCG neurons 
extend axons towards their targets60. The first axons reach their peripheral targets 
around E15 and target field innervation proceeds to approximately E18. Like all 
developing peripheral neuron populations, and many developing CNS neuron 
populations, SCG neurons are subject to a period of apoptotic cell death shortly after 
the onset of target field innervation, a process that acts to match neuron numbers to 
target field requirements48. In the developing mouse SCG, PCD begins in the perinatal 
period and persists until the beginning of the second postnatal week154. In parallel with 
PCD, axons that have reached peripheral target fields begin to branch and ramify 
extensively within their targets, a process termed arborization60. After target field 
arborisation, sympathetic neurons undergo a period of maturation during the first 
postnatal weeks, acquiring the expression of a full repertoire of functionally important 
proteins and establishing functional synaptic connections. The multiple stages of 
mouse SCG development are dependent on the coordinated sequential actions of 
many neurotrophic factors signalling via many different receptors (figure 1.09). 
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Figure 1.09: A diagram showing several of the key ligand and receptor interactions that 
promote SCG development. A) NGF homodimers bind to TrkA and p75NTR homodimers. NT-3 
normally signals via TrkC; however, in the SCG catalytic TrkC is expressed at very low levels 155, 
and evidence suggests that NT-3 signals via TrkA193. B) HGF heterodimers signal through Met 
heterodimers (Simi and Ibanex, 2010. C) ARTN homodimers bind to homodimeric complexes of 
GFRα3, these complexes then recruit and dimerize RET to initialise intracellular signalling 
pathways. D) Like all TNFSF members, TNFα functions as a homotrimer. TNFRSF members are 
also functional as homotrimers. The functional receptor/binding partner for TNFα is in the 
developing SCG is Tnfr1a. Conventional TNFα/Tnfr1a forward signalling and (E) Tnfr1a/TNFα 
reverse signalling appear to regulate different aspects of SCG development. CD40/CD40L 
reverse signalling (F) enhances target field innervation in the developing as, does GITRL/GITR 
forward signalling (G)72, 153, 156-159.  
Newly born SCG neurons are initially independent of neurotrophic support for survival 
in vitro. By E15, however, the majority of SCG neurons require NGF for survival in 
culture, and this NGF dependence is maintained throughout late embryonic and early 
postnatal development18, 60. Target field-derived NGF is crucial for supporting the 
survival of developing SCG neurons in vivo, as demonstrated by a dramatic loss of SCG 
neurons in neonatal NGF and TrkA null mice154, 160, 161. NT-3 null mutant mice also 
display a significant reduction in the number of neurons in the late embryonic and 
early postnatal SCG compared to wild type mice, suggesting that NT-3 is required, in 
Chapter 1  Introduction 
54 
 
combination with NGF, to support the survival of SCG neurons in vivo after they have 
reached their target fields19, 155, 162. However, the analysis of embryonic and neonatal 
NT-3/Bax double null mutant mice, in which the loss of SCG neurons in the absence of 
NT-3 expression is completely abrogated, has revealed that NT-3 is required for correct 
target field innervation by developing sympathetic neurons 104, 163, 164. This, together 
with the observations that; (1) NT-3 can promote local axon growth when applied to 
the distal axons of SCG neurons in compartmentalised cultures, (2) NT-3 cannot 
retrogradely signal to promote the survival of SCG neurons, (3) NT-3 is expressed along 
the routes that SCG axons take to reach their peripheral target fields, has led to the 
conclusion that NT-3 is not a survival factor for developing SCG neurons104. The current 
model is that NT-3 is required for proximal growth of axons on route to their targets, 
and that the loss of SCG neurons observed in the NT-3 null mouse is due to the failure 
of their axons to reach their peripheral targets and obtain sufficient quantities of NGF 
for survival104. Interestingly, a null mutation of the cognate NT-3 receptor, TrkC, does 
not compromise SCG neuron survival in vivo154. Since the levels of p75NTR expressed by 
SCG neurons is low during the period of proximal axon growth77, thereby excluding the 
possibility that NT-3 signals though p75NTR to promote the early stages of target field 
innervation, NT-3 must signal though TrkA to exert its neurotrophic effects in the 
developing SCG154.  
The analysis of NGF-/-/BAX-/- double transgenic embryos and neonates has revealed a 
crucial role for NGF in regulating target field innervation by developing sympathetic 
neurons164. Tyrosine hydroxylase- (TH)-positive sympathetic innervation of some 
targets is either completely absent (submandibular (SMG) and parotid salivary glands 
and eye) or dramatically reduced (heart, thymus and lungs) in NGF-/-/BAX-/- neonates 
compared to wild type animals. Other organs, including the stomach, kidneys small 
intestine and bladder, have less severe reductions in their sympathetic innervation in 
the absence of Bax and NGF expression. In contrast, sympathetic innervation of the 
trachea is normal in NGF-/-/BAX-/- embryos and neonates164. Therefore it appears that, 
although NGF is clearly important for regulating target field innervation by sympathetic 
neurons, the requirement for NGF is heterogeneous, suggesting that other 
neurotrophic factors may play important roles in promoting the sympathetic 
innervation of some target fields. In addition to data from NGF-/-/BAX-/- double 
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transgenic mice, an analysis of transgenic mice over expressing NGF from a skin-
specific, keratin14 promotor has also highlighted the ability of NGF to direct 
sympathetic target field innervation165. The overexpression of NGF in skin significantly 
increases the TH-positive innervation of blood vessels and hair-shaft erector pili 
muscles within the dermis of adult transgenic mice compared to wild type mice 165. 
Whilst NGF and NT-3 are clearly vitally important for regulating target field innervation 
and preventing PCD in the developing sympathetic nervous system, other neurotrophic 
factors play vital roles during other stages of sympathetic neuron development. For 
example, HGF/MET signalling regulates the differentiation of sympathetic neuroblasts 
into neurons in the early stages of SCG development7 and promotes the survival of and 
process outgrowth from maturing SCG neurons111. HGF and MET are both expressed in 
the early SCG and the addition of anti-HGF antibodies, which block HGF/MET 
signalling, to cultures established from E12.5 to E14.5 SCG reduces the number of SCG 
neuroblasts that differentiate into neurons7. Since the addition of exogenous HGF to 
early SCG cultures does not enhance neuroblast differentiation, it appears as if an 
autocrine HGF/MET signalling loop operates in early SCG cultures to promote the 
differentiation of neuroblasts. Further in vitro analysis revealed that HGF/MET 
signalling does not regulate the proliferation of neuroblasts, but an autocrine 
HGF/MET signalling loop does promote neuroblast survival in an NGF-independent 
manner. In accordance with this, a comparison of wild type embryos and transgenic 
embryos containing a mutation in MET that disables MET signalling (METd/d embryos) 
revealed that the SCG of E14.5 METd/d embryos contain significantly more pyknotic 
nuclei and significantly fewer neurons than the SCG of their wild type litter mates7. In 
addition to enhancing neuroblast survival and differentiation independently of NGF, 
HGF/MET signalling also enhances NGF-promoted process outgrowth from newly 
differentiated SCG and paravertebral chain sympathetic neurons in culture7.  
HGF is able to promote the survival of mature SCG neuron in culture as effectively as 
NGF111. At P40, only 35% of SCG neurons survive for 48hrs in culture in the absence of 
neurotrophic factor support. The addition of saturating levels of NGF or HGF both 
increase 48hr survival to approximately 70%, whereas the addition of anti-HGF 
blocking antibody to cultures does not alter survival compared to control cultures, 
thereby ruling out a potential postnatal HGF/MET autocrine signalling loop that 
Chapter 1  Introduction 
56 
 
promotes neuron survival. Since the addition of both NGF and HGF to cultures does 
not increase survival compared to either factor alone, the population of P40 SCG 
neurons that respond to each factor are completely overlapping. HGF can also 
significantly enhance the extent of NGF-promoted process outgrowth from cultured 
SCG neurons from P1 to P20111.  The addition of HGF to maturing SCG neurons induces 
Akt and ERK1/2 phosphorylation and blocking phosphorylation of either Akt or ERK1/2, 
using specific pharmacological inhibitors, significantly reduces the ability  of HGF to 
promote the survival of P40 SCG neurons. ERK1/2 activation also appears to be an 
essential component of the signalling pathways that mediate HGF promoted process 
outgrowth in the neonatal period111.  
Like HGF, the GFL member ARTN, exerts multiple neurotrophic effects on developing 
SCG neurons during both early and late stages of development166-168. An analysis of 
embryos containing a null mutation in either ARTN or GFRα3 has revealed that, in the 
absence of ARTN/GFRα3 signalling, SCG progenitors fail to migrate properly and the 
SCG is located more caudally than in wild type embryos167, 168. Cohort studies in SCG 
cultures established from E12 and E13.5 SCG have shown that the addition of ARTN to 
cultures promotes the generation of post-mitotic SCG neurons from dividing 
neuroblasts166. This, together with the observations that early SCG from GFRα3 null 
mutant embryos contain significantly fewer dividing cells and less post mitotic neurons 
than SCG from their wild type littermates, suggests that ARTN plays an important role 
in regulating the proliferation of sympathetic neuroblasts166.  The addition of ARTN to 
SCG cultures established from postnatal mice increases the survival of neurons 
compared to control from P12 to P60. Indeed, from P20 onwards, ARTN is as effective 
as NGF in promoting the survival of cultured SCG neurons. ARTN is also able to 
promote the growth of processes in cultures of maturing SCG neurons166. A 
comprehensive analysis of neuron number in the SCG of embryonic and postnatal 
GFRα3 null mutant mice and their wild type litter mates has revealed that SCG from 
GFRα3 null mice have significantly fewer neurons from E14.5 onwards167. In fact, by 
P60 the SCG has all but disappeared in GFRα3 null mice. Whilst this undoubtedly 
reflects some dependence of SCG neurons on ARTN/GFRα3 signalling for survival, the 
observations that ARTN is expressed along the routes that the axons of newly born 
SCG neurons take to their peripheral target fields and target field innervation is 
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compromised in ARTN null mutant mice, suggests that some of the neuron loss 
observed in the SCG of GFRα3 null mutants is secondary to a deficit in target field 
innervation and the inability of SCG neurons to derive sufficient target field-derived 
NGF168. 
Several members of the TNFSF have been shown to modulate the extent of NGF-
promoted target field arborisation in the perinatal period without affecting NGF-
promoted survival.  For example, Glucocorticoid-Induced TNFR-Related Protein (GITR) 
and GITR Ligand (GITRL) signalling is able to enhance NGF promoted process 
outgrowth and branching from cultured neonatal mouse SCG neurons during a narrow 
developmental window that extends from P1 to P3169. GITRL and GITR are both 
expressed in a similar temporal pattern in the developing SCG, and blocking 
GITRL/GITR signalling, by either siRNA mediated knockdown of GITR expression or the 
addition of soluble GITR-IgG to culture media, reduces the efficacy of NGF in 
promoting process growth in culture, suggesting that an endogenous GITR/GITRL 
paracrine or autocrine loop normally acts to enhance NGF-promoted process growth. 
An analysis of intracellular signalling downstream of GITR, has revealed that activated 
GITR signals though the ERK1/2 pathway to enhance SCG neuron process growth. The 
physiological relevance of these in vitro observations is reflected by the fact that P1 
GITR-/- mice show a significant deficit in SCG target field innervation compared to wild 
type mice 169.  
Another TNFSF member, Receptor Activator of NF-κB Ligand (RANKL), reduces the 
extent of NGF-promoted process growth from cultured mouse SCG neurons over a 
broad period of postnatal development170. The RANK receptor is expressed by 
developing SCG neurons and RANKL is expressed in their targets. Compartmentalised 
cultures have shown that RANKL acts locally on processes to inhibit the growth 
promoting effects of NGF, suggesting that target field-derived RANKL may regulate 
sympathetic target field innervation in vivo.  RANKL/RANK signalling inhibits SCG 
neuron process outgrowth by IKKβ mediated phosphorylation of the p65 subunit of 
NF-κB at serine 536170. 
As mentioned in section 1.4.3.4, TNFSF members and their TNFRSF partners can signal 
by two modalities: (1) conventional forward signalling where either soluble or 
membrane bound TNFSF ligands engage their transmembrane receptors to induce a 
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receptor-derived signalling cascade and a biological outcome; (2) reverse signalling, 
whereby membrane bound TNFSF ligands are engaged by either soluble or membrane 
bound TNFSF receptors to induce a ligand-derived intracellular signalling cascade and a 
biological outcome151.  TNFα is expressed in the soma and processes of neonatal 
mouse SCG neurons, whereas its receptor, Tnfr1a, is only expressed in neuron soma153. 
However, Tnfr1a is expressed at high levels in the targets of SCG neurons in the vicinity 
of innervating fibres, raising the possibility that target field Tnfr1a may interact with 
TNFα expressed on innervating axons to induce TNFα reverse signalling within 
neurons. In support of this, the addition of either soluble Tnfr1a or a Tnfr1a-Fc chimera 
to cultures of P0 SCG neurons enhances NGF promoted process outgrowth and 
branching, but does not modulate NGF promoted survival153. The ability of Tnfr1a-Fc to 
enhance process outgrowth and branching from SCG neurons cultured with NGF is 
restricted to a developmental window from P0 to P5. In accordance with a reverse 
signalling paradigm, the addition of Tnfr1a-Fc chimera to the axon compartment of P0 
SCG compartmentalised cultures enhances NGF promoted axon growth, whereas 
Tnfr1a-Fc addition to the soma compartment has no effect on the extent of process 
outgrowth and branching in the presence of NGF. The observation that TNFα-/- and 
Tnfr1a-/- postnatal mice exhibit deficient innervation of many SCG targets fields 
compared to their wild type litter mates, has demonstrated the physiological 
importance of TNFα/Tnfr1a reverse signalling in establishing correct target field 
innervation by developing SCG neurons153. Interestingly, the addition of soluble TNFα 
to mouse SCG cultures reduces the extent of NGF-promoted process outgrowth and 
branching during a narrow developmental window from E18 to P1, presumably by a 
forward signalling mechanism171. However, the physiological relevance of this is 
unclear given that the expression of Tnfr1a is restricted to the soma of SCG neurons153. 
Recently, the TNSF family member, CD40 ligand (CD40L), and its cognate receptor, 
CD40, have been shown to regulate the innervation of SCG target fields expressing low 
levels of NGF by a mechanism that involves both an autocrine signalling loop and 
reverse signalling72. Preventing endogenous CD40L/CD40 autocrine signalling in 
cultures of neonatal SCG neurons, by the addition of either anti-CD40 or anti-CD40L 
blocking antibodies, reduces the extent of NGF promoted process outgrowth and 
branching over a narrow developmental window from P0 to P3. In line with this, SCG 
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cultures established from P3 CD40 null mutant mice are less responsive to the process 
growth enhancing effects of NGF than cultures established from their wild type 
littermates72. Importantly, the efficacy of NGF in promoting process outgrowth from 
CD40-/- SCG neurons can be restored to that seen with wild type neurons by the 
addition of a CD40-Fc chimera to cultures, demonstrating that CD40/CD40L autocrine 
signalling enhances NGF promoted process growth by a reverse signalling mechanism. 
NGF negatively regulates the expression of both CD40 and CD40L in developing SCG 
neurons in a dose dependent manner. In accordance with this, detailed dose response 
analysis has revealed that cultured P3 CD40-/- neurons only show a deficit in NGF-
promoted process outgrowth and branching compared to wild type neurons at low 
concentrations of NGF. A comparison of SCG target field innervation between       
CD40-/- embryonic and postnatal mice and their wild type litter mates has shown that 
targets expressing high levels of NGF, like SMG and nasal mucosa, are innervated 
normally in the absence of CD40 expression. In contrast, SCG target fields expressing 
low levels of NGF, such as the thymus and periorbital tissue, show a significant deficit 
in sympathetic innervation in the absence of CD40 compared with the corresponding 
target fields from wild type animals72.   
In addition to HGF, ARTN and several TNFSF members, Wnt5a is another secreted 
protein not belonging to the neurotrophin family that regulates the extent of target 
field innervation by developing sympathetic neurons of the mouse SCG172.  Wnt5a is 
expressed in developing mouse SCG neurons during the period of target field 
innervation and NGF upregulates its expression in neonatal SCG cultures. The addition 
of fibroblast conditioned containing secreted Wnt5a to cultures of neonatal 
sympathetic neurons increases the number of branch points displayed by neuronal 
processes in the absence of NGF, but does not enhance either process length or 
neuronal survival172. The induction of branching by Wnt5a is rapid, occurring within 30 
minutes of Wnt5a addition, and does not require de novo transcriptional activity.  The 
use of compartmentalised cultures has shown that exogenous Wnt5a is able to act 
locally on processes to increase branching. In addition, adding an anti-Wnt5a blocking 
antibody to the axon compartment of compartmentalised cultures significantly inhibits 
NGF promoted branching, suggesting that NGF promoted synthesis and release of 
Wnt5a from processes enhances branching in the absence of exogenous Wnt5a172. 
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Cultured SCG neurons from neonatal Wnt5a-/- mice show a deficiency in NGF 
promoted branching compared to wild type neurons, but show no reduction in NGF-
promoted survival. In accordance with the in vitro data, Wnt5a-/- embryos display 
reduced sympathetic innervation of a number of target fields compared to wild type 
embryos. Postnatal Wnt5a-/- mice have reduced numbers of SCG neurons compared to 
wild type mice, suggesting that the target field innervation deficit seen at embryonic 
stages in transgenic mice reduces the availability of target field-derived survival factors 
at postnatal ages172. Wnt5a does not signal though the canonical β-catenin-dependent 
pathway to enhance the branching of SCG neuron processes. Rather, Wnt5a binds to a 
Ror family receptor and Ror activation recruits and phosphorylates an adaptor protein 
from the dishevelled family, leading to phosphorylation and activation of PKC and PKC-
mediated branching172, 173. 
1.5 Transforming growth factor β (TGFβ) superfamily  
TGF-β1, the prototypical member of the TGF-β superfamily, was initially isolated from 
virally or chemically transformed cells in the early 1980s based on its ability to 
transform, or induce anchorage-independent growth of, rat kidney fibroblasts in the 
presence of epidermal growth factor174, 175. TGF-β1 was soon purified to homogeneity, 
from both transformed and non-transformed cells, and characterised as a 25 kDa 
protein composed of 2 subunits that are held together by disulphide bonds176, 177.  In 
addition to its ability to transform cells, it quickly became evident that TGF-β1 had 
other functional properties, including an ability to promote wound healing and prevent 
proliferation. Research over the next decade or so revealed that TGF-β1 was involved 
in modulating a wide range of biological processes, including regulating; the cell cycle, 
early morphogenetic events during development, differentiation, extracellular matrix 
formation, angiogenesis, haematopoiesis, chemotaxis and immune functions178-183. 
Following the isolation and characterisation of TGF-β1, many closely and more 
distantly related proteins have been identified, characterised and grouped together 
into the TGF-β superfamily.  
1.5.1 TGF-β superfamily ligands  
The TGF-β superfamily of ligands are a diverse family divided into multiple subfamilies 
(figure 1.10). Thus far, over 30 secreted factors have been identified184, all with some 
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degree of sequence/structural homology. TGF-β family members have been found to 
regulate diverse cellular functions in many organisms from insects and nematodes to 
mammals183, 185-188. For example, Drosophila melanogaster contains a gene at the 
decapentaplegic (Dpp) locus that encodes a protein with significant sequence 
homology to the vertebrate TGF-β superfamily members189. This conservation of TGF-β 
like proteins across not just species, but also phylum, indicates that TGF-β superfamily 
members play vital roles in the development and homeostasis of all metazoans185. 
 
Figure 1.10: The TGF-β superfamily. Members are traditionally subdivided into 4 main 
subfamilies that comprise: the TGF-β subfamily; the activins/inhibins subgroup; the DVR or 
bone morphogenetic proteins (BMPs)/growth and differentiation factors (GDFs) subfamily; the 
most distantly related subgroup comprising GDNF family ligands (GDNFs). Designation of TGF-β 
family members into the 4 subfamilies is based upon amino acid sequence homology within 
the subfamilies (taken from Weiskirchen, 2009190). 
Based on sequence and structural homology, the TGF-β superfamily is divided into a 
number of divisions: the TGF-βs (TGF-βs 1, 2, and 3); the activins/inhibins subgroup; 
the decapentaplegic (Dpp) and vegetal-1 (Vg1)-related (DVR) subdivision (which is also 
known as the bone morphogenetic proteins (BMPs) and growth and differentiation 
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factors (GDFs) subgroup); the glial cell line-derived neurotrophic factors (GDNFs) 
division (figure 1.10) 185, 190. The GDNF division is the most distantly related subfamily 
to the ancestral TGF-βs. In addition to these four subfamilies, even more distantly 
related members exist, such as inhibin α-chain and Mullerian inhibiting substance 
(MIS) 185, 190.  
TGF-β superfamily members are translated as larger precursor pro-proteins that have 
an amino-terminal pro-domain, which includes a signal peptide, and a carboxyl-
terminal that gives rise to the mature protein that typically comprises between 110 
and 140 amino acids 191-193. Whilst mature TGF-β proteins are monomers, TGF-β 
superfamily members are predominantly functional as homodimers. It is thought that 
the pro-domain is important for protein trafficking within the cell, correct monomer 
folding and subsequent dimerization of monomers into functional proteins. Cleavage 
of the pro-domain, by proteases of the subtilisin-like proprotein convertases (SPC) 
family, occurs at a dibasic cleavage (RXXR) site. For example, TGF-β1 is processed by 
SPC family member, furin, whereas BMP4 can be processed by either furin or the SPC 
protein, PACE4193, 194. Dimerization of the mature proteins occurs within the cells in the 
presence of the pro-domain. The dimeric structures of the TGF-β family proteins have 
a central 3-1/2 turns of one monomer helix that packs against the surface of the β-
strand of the second monomer191, 195. This arrangement, which is stabilised by di-
sulphide bonds, is often described as curved hands, where the palm of one hand rests 
in the heel of the other195. The structural and sequence homology of the TGF-β 
members is conserved exclusively between the monomer subunits and not the pro-
domains, which are poorly conserved191, 196. The association between mature TGF-β 
proteins and their pro-domains does not end after cleavage of the latter. The pro-
domain and the mature cytokine retain a high affinity for each other and are secreted 
by synthesising cells in association with each other192, 193. The complex of the pro-
domain and mature TGF-β, which can be covalently bonded together, is referred to as 
large latent complex (LCC). The LCC causes the suppression of the biological activity of 
the mature TGF-β family protein196, 197. Dissociation of the pro-domain (latency 
associated peptide198) results in the mature TGF-β family member being able to exert 
biological activity. In some cases, the LCC exerts biological actions on its own. For 
example, the nodal latency associated peptide binds to and activates activin receptors, 
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resulting in enhanced expression of furin, PACE4 and BMP4199, and GDF11 forms a LCC 
that is believed to be important in modulating neuronal differentiation197, 200, 201. 
For the majority of TGF-β family members, the carboxyl-terminal peptide that 
constitutes the monomer subunit of the mature protein has a characteristic 7 cysteine 
knot motif192, 202. This motif is observed in NGF and also platelet-derived growth factor 
(PDGF)202, suggesting a common ancestry of these molecules or, at the very least, 
convergent evolution of these proteins 203, 204. Lefty A, Lefty B, BMP-15, GDF-9 and 
GDF-3 are all TGF-β family members with 6 cysteine knot motifs, rather than the 
characteristic 7 cysteine knot motif 192, 205. Whilst most TGF-β family members are 
functional as homodimers, functional heterodimers can occur. For example, Nodal and 
BMPs can create heterodimeric ligands which interfere with BMP signalling206.  
1.5.2 TGF-β superfamily receptors  
Most TGF-β superfamily ligands signal via heterotetrameric receptor complexes 
composed of homodimers of both type 1 and type 2 receptors184, 207. A third type of 
receptor, type 3 receptors, also exists. Type 3 receptors, which will be discussed in 
more detail below, are comprised of are glycoproteins that have no intrinsic catalytic 
activity. Whilst they cannot initiate signal transduction, type 3 receptors can modulate 
signalling by type 1 and 2 receptors 207, 208. Type 1 and 2 receptors are ostensibly 
transmembrane serine/threonine kinases, although they can also potentially 
phosphorylate on tyrosine, as inferred by the structural similarities they share with 
tyrosine kinases receptors 192, 207. As discussed above, the GFL subfamily of TGF-β 
ligands do not signal though a complex of type I and type 2 serine/threonine kinase 
receptors like other TGF-β superfamily members. Rather, they predominantly signal 
through a receptor complex consisting of the RET tyrosine kinase receptor together 
with a GPI-linked, GFRα receptor 127,209.  
Type 1 and type 2 receptors are both polypeptides of approximately 500 amino acids, 
with type 1 receptors ranging in size from 65 kDa to 75 kDa and type 2 receptors being 
between 85 kDa to 110 kDa in size184, 207. Both type 1 and type 2 receptors have a short 
N-terminal, cysteine-rich, extracellular ligand binding domain, a single transmembrane 
domain and a highly conserved intracellular C-terminal serine/threonine kinase 
domain207, 210. The receptor types are categorized on the basis of whether or not they 
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contain an intracellular glycine-serine rich sequence (GS region) upstream of the kinase 
domain. The GS region is found on type 1 receptors and is phosphorylated by type 2 
receptors to confer catalytic activity upon type 1 receptors192 (figure 1.11). Whilst most 
TGF-β superfamily ligands are able to bind to homodimers of either type 1 or 2 
receptors, the initiation of intracellular signalling requires an interaction between both 
receptor classes 197, 211, 212. It appears as if homodimers of type 1 and type 2 receptors 
come together to form a loosely associated heterotetrameric active receptor complex. 
Ligand binding to one member of this complex induces a conformational change that 
brings both receptor types closer together, but not into direct physical contact, 
enabling the phosphorylation of the GS domain of the type 1 receptor by the  
constitutively active kinase domain of the type 2 receptors, a process that results in 
type 1 receptor activation and intracellular signal transduction. Ligand-receptor 
interactions appear to occur in two different ways. TGF-β and activin subfamilies have 
a very high affinity for their cognate type 2 receptor homodimers and fail to interact 
significantly with type 1 receptor homodimers. Therefore, TGF-βs and activins initially 
bind to homodimers of type 2 receptors213 and the type 2 receptor-ligand complex 
recruits nearby type 1 receptor homodimers into a closer heterotetrameric complex to 
initiate signalling 214, 215. Whilst, BMP ligands also preferentially bind to their cognate 
type 2 receptors in the absence of appropriate type 1 receptors, they can also bind to 
BMP-associated type 1 receptors with relatively high affinity184, 215. BMP subfamily 
ligands bind with highest affinity to heterotetrameric complexes of appropriate type 1 
and type 2 receptors and signalling by ligands of this subfamily appears to be 
transduced by binding to pre-formed heterotetrameric receptors216, 217.  
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Figure 1.11: Structure and function TGF-β receptors and ligand/receptor interactions. A) 
Shows the functional interaction between homodimers of type 1 and type 2 receptors.  Ligand 
binding results; aggregation of type 1 and type 2 receptor homodimers, phosphorylation of the 
GS region of type 1 receptors by type 2 receptors and intracellular signalling. B) Schematic 
showing the interactions between TGF-β superfamily type 1 and 2 receptors. Left hand side 
depicts type 2 receptors, Those shown in light orange box and green boxes are type 1 
receptors for TGF-β and activin/inhibin (TGF-β-like) ligands and BMP/GDF (BMP-like) ligands, 
respectively (taken from Wrana, J., et al., 2008192). 
There are over 30 reported TGF-β superfamily ligands, but only 5 members of the type 
2 family of receptors and 7 members of the type 1 family of receptors184, 192, 195.  The 
vast array of biological activities exerted by TGF-β superfamily members must 
therefore rely to a certain extent on  ligand/receptor promiscuity 192. Type 1 receptors 
are divided into 2 broad categories: TGF-β/activin/inhibin (TGF-β-like) receptors and 
BMP/GDF (BMP–like) receptors184, 192(figure 1.11b). TGF-β and activin/inhibin 
subfamily ligands only signal via TGF-β-like type 1 receptors and BMP/GDF subfamily 
Chapter 1  Introduction 
66 
 
ligands only signal via BMP-like type 1 receptors (figure 1.11). Some individual type 2 
receptors are able to interact with TGF-β-like ligands and their corresponding type 1 
receptors, as well as with BMP-like ligands and their corresponding type 1 receptors, 
with the result that there are a large number of potential ligand-type1/type2 receptor 
combinations (figure 1.11)213, 215, 216, 218-220. These combinatorial interactions are 
illustrated by the type 2 receptors ActRII and ActRIIB (ACVR2A and ACVR2B, 
respectively in current nomenclature), which can both associate with  either ActRIB or 
ALK7, members of the TGF-β-like type 1 receptor group, to mediate the activities of a 
number of activin/inhibin ligands. Alternatively, interaction of ACVR2A or ACVR2B with 
either ALK3 (BMPR1A) or ALK6 (BMPR1B)221 can form functional receptors that 
mediate the diverse biological effects of a number of members of the BMP/GDF 
subfamily of TGF-β superfamily ligands217, 222-224. This ligand/receptor complexity is 
further increased by the existence of heterodimeric TGF-β superfamily ligands, as 
opposed to the classically described homodimers. For example, TGF-β1.2 is a 
heterodimer composed of monomers that normally constitute TGF-β1 and TGF-β2, 
respectively225. TβR1 is able to bind TGF-β1, TGF-β1.2 or TGF-β2 with a relative order 
of affinity of 16:5:1, whereas the order of affinity for these ligands in the case of TβRII 
is 12:3:1. Moreover, as mentioned above, Nodal can inhibit BMP signalling by forming 
heterodimers with BMPs206. 
As alluded to above, the type 3 glycoprotein receptors, betaglycan and endoglin also 
modulate the signalling of some TGF-β superfamily members. Type 3 receptors have a 
large extracellular domain, a transmembrane domain and a short intracellular domain. 
Whilst the intracellular domains of both type 3 receptors have no inherent catalytic 
activity, they can be serine/threonine phosphorylated by type 1 and type 2 TGF-β 
receptors, and phosphorylation regulates the interaction of their intracellular domains 
with other cytoplasmic proteins, such as β-Arrestin2 184, 192, 226-228. Betaglycan and 
endoglin primarily exist as homodimers, although heterodimers containing both 
proteins have been observed in some tissues228. Betaglycan has two extracellular 
regions capable of binding TGF-β ligands and it is likely that these ligand binding 
domains initiate signalling with different functional outcomes227, 229. Betaglycan binds 
to TGF-βs 1, 2 and 3 and increases their affinity for type 2 receptors 208. Betaglycan 
plays a particularly important role in facilitating TGF-β2 signalling, since TGF-β2 cannot 
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directly bind to type 2 receptors in the absence of  betaglycan208. Betaglycan also binds 
to Activin-A, BMP2, BM-4, BMP7, and GDF5228. Endoglin, does not appear to bind to 
TGF-β ligands directly, but can bind TGF-β1, TGF-β3, Activin-A and BMPs 2, 7, 9 and 10 
when they are within TGF-β receptor complexes 228, 230. Endoglin can also interact with 
both type 1 and type 2 receptors within functional ligand/receptor complexes, and can 
either potentiate or antagonise TGF-β superfamily/TGF-β receptor signalling in a 
manner that depends on both the identity of the components of the ligand/receptor 
complex and the cellular context228, 231. The mechanisms that endoglin uses to 
modulate TGF-β/TGF-β receptor signalling are not entirely clear, but do not appear to 
include increasing the affinity of ligand/receptor interactions. Potential mechanisms 
may include: altering the phosphorylation status of type 2 receptors, altering the 
stability of ligand/receptor complexes, altering the nature of signalling pathways 
downstream of type 1 receptor activation228, 231.    
1.5.3 TGF-β signalling  
There are, broadly speaking, two types of intracellular signalling pathways activated in 
response to ligand induced activation of TGF-β superfamily receptor complexes; the 
canonical pathway  and the non-canonical pathways. The canonical pathway is unique 
to TGF-β superfamily members and is mediated by members of the Smad-protein 
family. Responses to TGF-β family ligands are transduced by non-Smad proteins in non-
canonical signalling pathways, such as; ERK, JNK and p38 MAP kinase 184, 192, 207, 217, 232 
that play roles in mediating intracellular signalling induced by many other extracellular 
cues.   
1.5.3.1 Smads and the canonical pathway  
The Smad family of proteins were first identified in Drosophila and Caenorhabtidis 
elegans as a result of genetic screening looking for regulators of Dpp signalling233. The 
downstream signalling molecules, mothers against Dpp (Mad) and Medea, and the 
Sma family of proteins234 were uncovered in Drosophila and Caenorhabtidis elegans, 
respectively. Vertebrate homologs of these proteins were named after their 
Drosophila and Caenorhabtidis elegans counterparts, and thus termed Smads184, 192. 
Smads appear to be highly conserved across species. Whilst there are 4 Smads and 6 
Smads in Drosophila and Caenorhabtidis elegans, respectively, most vertebrates 
express 8 Smads184. Smad1 to Smad8 can be divided into three different functional 
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classes: receptor mediated Smads (R-Smads) that comprise Smad1, Smad2, Smad3, 
Smad5 and Smad8207; the common mediator Smad (Co-Smad), Smad4; inhibitory 
Smads (I-Smads), Smad6 and Smad7 181, 192.  
The structure of Smads is shown in figure 1.13. R-Smads and the Co-Smad, Smad4, 
have a conserved Mad-homology-1 (MH1) domain and a C-terminal MH2 domain. The 
MH1 domain promotes transcription via a β-hairpin structure that facilitates DNA 
binding184, 207. The MH1 domain and MH2 domains are bridged by a linker domain, 
which is less well conserved between R-Smads and Smad4 than the MH1 and MH2 
domains, and in the R-Smads contains a number of proline and serine residues (PY 
motif) that can be phosphorylated to modulate interactions between Smads and 
regulatory proteins, such as ubiquitin ligases184, 207, 217, 235. In Smad4, the linker region 
contains a Smad activation domain (SAD) that is essential for transcriptional activity.  
The I-Smads do not possess a conserved, DNA-interacting β-hairpin region in their MH1 
domain, but do possess the linker region, PY motif and the highly conserved MH2 
domain region (NES) that mediates oligomerization of Smads and the specificity of 
individual Smads for either TGF-β-like or BMP-like type 1 receptors 184.  
Chapter 1  Introduction 
69 
 
 
Figure 1.12: Structural schematic of different classes of Smads. The MH1 (closed), linker 
(open) and MH2 (hatched) domains of Smads are displayed. Structural characteristics: Nuclear 
localization signal (NLS) (hatched) and NES sequence (light grey) sequences; the DNA binding β 
hairpin loops; SAD domain and PY motifs are all displayed. PP donates the SSXS motif that is 
phosphorylated by type 1 TGF-β receptors to activate R-Smads. Sites for post-translational 
modifications such as phosphorylation (P), ubiquitination (Ub), acetylation (Ac) and 
sumoylation (Sumo) are indicated. The kinases involved in the phosphorylation of the MH1 and 
linker regions of R-Smads  are also listed (diagram taken from Heldin, 2008235). 
Smad2 and Smad3 are activated by the carboxy-terminal of the TGF-β-like type 1 
receptors236, whereas Smad1, Smad5 and Smad8 are activated by the carboxy-terminal 
of the BMP-like type 1 receptors 184, 192, 207. Both categories of R-Smads become 
activated by type 1 receptors as a result of phosphorylation on a consensus C-terminus 
SSXS motif237. Phosphorylation of the SSXS motif enables R-Smads to form heteromeric 
complexes with Smad4 236, 238, 239. The R-Smad/Smad4 complex translocates to the 
nucleus where it regulates transcription to initiate cellular responses to TGF-β 
superfamily ligands 240. Although R-Smads can form oligomers that translocate to the 
nucleus to regulate transcription of target genes in the absence of Smad4, Smad2 has 
no effective DNA binding domain due to a small insert in the β-hairpin region of its 
MH1 domain 211, and the transcriptional regulatory activity of complexes containing 
other R-Smads is reduced in the absence of Smad4240. The I-Smads, Smad6 and Smad7, 
negatively regulate the canonical TGF-β signalling pathway in 3 ways: competing with 
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R-Smads for binding to type 1 receptors; binding directly to active R-Smads to inhibit 
their activity; inducing the degradation of TGF-β type 1 receptors. In the latter case, 
Smad 7 has been shown to form complexes with the HECT type E3 ubiquitin ligases, 
Smurf 1 and 2, resulting in type 1 receptor ubiquitination and degradation207, 217, 241. 
Figure 1.13 shows more clearly the Smad mediated signalling pathways activated by 
TGF-β superfamily members. 
 
Figure 1.13: The Smad signalling pathways activated by TGF-β superfamily members. TGF-β-
like type 1 receptor mediated pathways (Smad2 and Smad3) and BMP-like type 1 receptor 
mediated pathways (Smad1, Smad5 and Smad8) are both shown. Phosphorylated R-Smads 
form complexes with Smad4 that are translocated to the nucleus to regulate gene expression. 
The inhibitory Smads, Smad6 and Smad7, act as negative regulators  of canonical Smad 
signalling (taken from Villapol, S., et al., 2013242). 
This translocation of R-Smad/Smad4 complexes to the nucleus is mediated by a 
nuclear localisation sequence (NLS) and facilitated by importin-β 184, 207. There is 
evidence that in the absence of importin-β, Smads can interact directly with 
nucleoporins to facilitate nuclear translocation, particularly in the case of R-
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Smad/Smad4 complexes containing Smad2, which has been shown to directly interact 
with nucleoporins Can/Nup214243, 244. Once translocated to the nucleus, R-
Smad/Smad4 complexes interact with particular DNA sequences, known as Smad-
binding elements (SBEs), which contain a consensus AGAC sequence at their core245. 
Smad complexes can both enhance and repress the transcription of target genes 
depending on which co-activator or co-repressor transcription factors they recruit to 
the complex207. The recruitment of co-activators and co-repressors to R-Smad/Smad4 
complexes is cell type and developmental stage dependent, partially accounting for 
the huge variation in biological responses to TGF-β superfamily ligands207. 
The canonical Smad pathway can be regulated by the activity of other signalling 
pathways as well as the I-Smads188. For example, HGF and EGF, signalling via their 
cognate RTK receptors, can induce ERK mediated phosphorylation and modulation of 
Smad activity. Such HGF/EGF signalling can inhibit the activity of Smad2 and enhance 
the activity of Smad1, thereby regulating signalling by TGF-β superfamily ligands246. In 
mammary gland and lung epithelial cells, Ras activity can induce ERK mediated 
phosphorylation of Smad2 and Smad3, thus preventing their translocation to the 
nucleus247. In addition to ERK mediated inhibition of Smad2, Ca2+-calmodulin-
dependent protein kinase II (Cam kinase II) phosphorylates Smad2 and inhibits its 
activity by preventing it from forming complexes with other R-Smads and Smad4. In an 
interesting example of cross-talk between growth factor mediated intracellular 
signalling cascades, PDGF/PDGF receptor signalling leads to ERK mediated activation of 
Cam kinase II and the subsequent phosphorylation and inhibition of Smad2 to 
antagonise TGF-β signalling 248, 249. Protein kinase C (PKC) can also inhibit the ability of 
R-Smads to initiate transcriptional responses by phosphorylating them in a manner 
that reduces their DNA binding ability250.  
In contrast to the negative regulation of canonical TGF-β signalling discussed above, 
the ligand induced activation of TGF-β receptors can lead to the activation of JNK via 
non-canonical signalling pathways (discussed in more detail in section 1.6.3.2, below), 
and activated JNK can phosphorylate Smad3 to facilitate its nuclear translocation and 
enhance its activity251. The intracellular domain of the transmembrane receptor, 
Notch, can also potentiate the canonical TGF-β/TGF-β receptor signalling pathway by 
interacting with Smad3 and increasing its DNA binding affinity252. Another example of 
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the convergence of TGF-β/Smad signalling pathways with signalling pathways initiated 
by other ligand/receptor interactions is seen with canonical Wnt signalling. 
Downstream mediators of Wnt signalling, such as lymphoid enhancer binding factor 
1/T cell specific factor (LEF1/TCF) and β-catenin, directly interact with Smad3 to 
cooperatively activate transcription of target genes that include the Xenopus 
homeobox gene, twin (Xtwn)253 
1.5.3.2 Non-canonical TGF-β/TGF-β receptor signalling pathways  
Although Smad dependent TGF-β signalling pathways appear to be active in all cell 
types examined184, the biological actions of TGF-βs can be mediated by non-canonical, 
Smad independent pathways in some cell types under specific circumstances188. The 
activation of non-canonical signalling is predominantly mediated by type 2 TGF-β 
receptors, in particular BMPR2188. Phosphorylated serine/threonine residues in the 
intracellular domain of type 2 receptors act as docking sites for SH2-domain and non-
SH2-domain adaptor proteins that in turn activate a number intracellular pathways 
that ultimately result in the activation of, amongst other things, JNK, p38 MAPK, 
ERK1/2, p160ROCK and S6 kinase (figure 1.14)188, 215, 219, 254, 255. In addition, BMPR2 can 
directly bind and activate LIM kinase 1 (LIMK1) to modulate cytoskelatal structure254. 
In PC-3U human prostate carcinoma cells, TGF-β-induced lamellipodia formation is 
independent of Smad signalling and is facilitated by activation of the small Rho 
GTPases, Cdc42 and RhoA256. Moreover, TGF-β induced epithelial-mesenchymal 
transition is mediated by a PI3K–Akt-mammalian target of rapamycin (mTor) signalling 
pathway in the absence of Smad signalling, suggesting this pathway may make a good 
target for the development of cancer treatments257. Not all non-canonical TGF-β 
signalling is mediated by type 2 TGF-β receptors, since it appears that TGF-β type 1 
receptor mediated activation of p38 MAPK induces apoptosis in mouse mammary 
epithelial cells independently of Smad activation258. In addition, TGF-β1 induces the G1 
cell cycle arrest of EpH4 epithelial cells by ALK-5 mediated activation of protein 
phosphatase-2A (PP2A) which subsequently dephosphorylates and inactivates S6 
kinase259. 
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Figure 1.14: TGF-β superfamily ligands can signal by both canonical and non-canonical 
pathways. TGF-β type 1 receptors can interact with Smads as shown to initiate canonical 
signalling. In addition, phosphorylated intracellular residues of TGF-β type 2 receptors can 
interact with a number of adaptor proteins leading to the activation of JNK, p38 MAPK, 
ERK1/2, p160ROCK and S6 kinase  (taken from Derynck, R., and Zhang Y.E., 2003217). 
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1.5.4 Bone morphogenetic proteins (BMPs) and growth 
differentiation factors (GDFs)  
1.5.4.1 Ligand structure  
The BMPs and GDFs are a single family of proteins, only differentiated from each other 
by historical nomenclature, that comprise over 20 highly related cytokines1. From an 
evolutionary perspective, BMP/GDF family proteins are amongst the oldest members 
of the TGF-β superfamily260, and were initially identified based upon their ability to 
induce bone and cartilage formation260. BMPs fall into 4 subfamilies based upon their 
amino acid homology: BMP2/BMP4 subfamily, BMP5-BMP8 subfamily, GDF5-GDF7 
subfamily and BMP3/BMP3B (GDF10) subfamily261-263. Within each subfamily, 
members share 74%-92% amino acid sequence homology within the C-terminal 
regions that encode mature functional proteins. The structural homology between the 
4 BMP/GDF subfamilies is 40%-60% shared amino acid similarity262. BMP1 is not a 
member of the BMP/GDF family but is a member of the astacin family of 
metalloproteinases that are involved in extracellular matrix formation264. The 7 
cysteine knot configuration of TGF-βs/activin/inhibins, a motif that is important for 
ligand/receptor interactions and the formation of covalently bound homodimers, is 
not completely conserved in BMP/GDFs. For example, GDF3, GDF9 and GDF15 all lack 
the conserved cysteine residue thought necessary for establishing disulphide linkages 
in homodimer formation1, 185. Because of this, it is thought that GDF3, GDF9 and GDF15 
form non-covalently bound homodimers265, 266. GDF3, GDF8 and GDF11 contain an 
additional N-terminal cysteine residue upstream of cysteine 1 of the TGF-β cysteine 
knot motif and GDF8 and GDF11 also have a second additional cysteine residue 
immediately after cysteine 11. In common with other TGF-β superfamily members, 
most BMP/GDFs are secreted as mature proteins from the cells that synthesise them 
after intracellular cleavage of their pro-domains. However GDF8, GDF9 and BMP7 are 
secreted from cells whilst they are still associated with their pro-domains and, in the 
case of BMP7, this is despite proteolytic cleavage1. One characteristic that 
differentiates BMP/GDFs from members of the other subdivisions of the TGF-β 
superfamily is that they signal through receptor complexes that recruit R-Smads 1,5,8 
to initiate canonical signalling265-267. 
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The human GDF5 gene codes for a 501 amino acid precursor protein that shows high 
sequence conservation with the 495 amino acid mouse GDF5 precursor261, 262. In 
common with other BMP/GDFs, the GDF5 pro-protein is cleaved to produce a mature 
functional protein at an RXXR recognition site; however, the RRKRRA cleavage 
recognition sequence of both the human and mouse GDF5 precursors contains two 
potential cleavage sites, raising the possibility that secreted mature GDF5 may differ in 
length depending on the identity of the synthesising cells268.  
1.5.4.2 BMP/GDF Receptor structure  
 
Figure 1.15:  Potential receptor complexes that mediate the biological effects of GDF5. 
Experiments using transient transfection of receptor cDNAs into cell lines269 have revealed that 
the most likely functional receptor combination for GDF5 is a heterotetrameric complex 
composed of the type 1 receptor BMPR1B with either of the type 2 receptors, ACVR2A or 
BMPR2.  
BMPs and the closely related GDFs can bind to the type 2 TGF-β receptors: BMPR2, 
ACVR2A and ACVR2B and the type 1 receptors: ALK2 , BMPR1A, and BMPR1B (also 
known as ACVR1, ALK3 and ALK6, respectively)270. Whilst the three type 2 receptors 
that are utilised by BMPs/GDFs are similar in structure, BMPR2 has a long C terminal 
tail after the serine/threonine kinase domain that can interact with cytoskeleton 
associated signalling molecules to modulate cytoskeletal dynamics. The type 1 
receptors BMPR1A and BMPR1B share close structural similarity, whereas ALK2 has a 
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somewhat different structure 270. BMP2 and BMP4 bind with a similar affinity to both 
BMPR1A and BMPR1B type 1 receptors; however, GDF5 binds significantly more 
strongly to BMPR1B than it does to BMPR1A269. In ROB-C26 cells, a cell line that 
responds to GDF5 by increasing alkaline phosphatase expression, iodinated GDF5 (I-
GDF5) binds to a receptor complex comprising BMPR1B and BMPR2, but does not bind 
to receptor complexes containing BMPR1A269. Transient transfection of COS cells with 
type 1 and 2 BMP receptors has revealed that  GDF5 binds to BMPR1B, but not 
BMPR1A, in the absence of type 2 receptor expression. In contrast, GDF5 appears to 
bind all three type 2 receptors: BMPR2, ACVR2A and ACVR2B in the absence of type 1 
receptor expression with an equal affinity269. When BMPR2 is co-expressed; GDF5 
binds with a high affinity to BMPR1B but fails to interact with BMPR1A. However, 
when ACVR2A is co-expressed, GDF5 binds with a low affinity to BMPR1A, although it 
binds with a much higher affinity to a receptor complex comprising ACVR2A and 
BMPR1B. Importantly, transient transfection of Mv1Lu cells  (R mutant, clone 4-2, cell 
line derived from trypsinization of foetal Aleutian mink lungs) with a combination of 
type 1 and 2 receptor constructs together with a luciferase reporter, has demonstrated 
that receptor complexes comprising; ACVR2A/BMPR1B, ACVR2A/BMPR1A and 
BMPR2/BMPR1B, but not BMPR2/BMPR1A, can initiate intracellular signal 
transduction by binding GDF5269. Affinity binding studies using a bio-sensor, rather 
than radio-labelled ligand binding, has revealed that GDF5 has a 12-fold higher affinity 
for BMPR1B than BMPR1A and mutation of a single amino acid in GDF5, Arg57, 
removes the preference for BMPR1B binding over BMPR1A binding271. 
1.5.4.3 Physiological roles of BMPs and GDFs  
The crucial roles that members of the BMP/GDF branch of the TGF-β superfamily of 
ligands play in embryonic development is reflected by the severe phenotypes that 
transgenic mice containing null mutations in BMPs/GDFs or their receptors display272. 
Many of these knockout mice strains are embryonic lethal, encouraging the generation 
of conditional knockout mouse models. In addition to transgenic mouse models, the 
biological roles of BMPs/GDFs have also been explored in primary cell cultures and cell 
lines272. 
Homozygous BMP4 null mutant mice die before birth273. Most Bmp4-/- embryos do not 
develop beyond the egg cylinder stage, dying around E7, and show very little 
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mesodermal differentiation. Homozygous BMPR2 null mutant mouse development is 
also arrested at the egg cylinder stage274. Like Bmp4-/- mice, BMPR2 null mutants fail to 
undergo mesodermal differentiation. In addition, Bmpr2-/- embryos display abnormal 
epiblast differentiation. The phenotype of Bmpr1a-/- embryos is remarkably similar to 
those of Bmp4-/- and Bmpr2-/- embryos275, demonstrating the crucial role that BMP4, 
signalling through a receptor complex containing BMPR1A and BMPR2, plays during 
gastrulation.  
In addition to regulating gastrulation, BMPs also appear to play an important role in 
cardiovascular development. Homozygous BMP2 null mutant mice are embryonic 
lethal, with embryos showing multiple deficits that include a failure of proamniotic 
canal closure, with consequent malformation of the amnion/chorion, and abnormal 
cardiac development276. Heterozygous Bmpr2+/- mice are viable, but display 
characteristics of familial primary pulmonary hypertension, a condition that is 
associated with excessive proliferation of endothelial and smooth muscle cells within 
the pulmonary arteries277, 278. Transgenic mice that express an isoform of the BMPR2 
that lacks half of the extracellular ligand binding domain show normal gastrulation, but 
die mid-gestation displaying significant abnormalities in cardiac development, as well 
as skeletal abnormalities279. These extracellular domain modified BMPR2 mutant mice 
have malformations of the heart that are comparable to a condition found in humans 
called persistent truncus arteriosus (type A4)279. BMPR1A conditional knockout mice, 
with a cardiac myocyte specific deletion of functional BMPR1A, display aberrant 
cardiac development, with abnormal: trabeculae, compact myocardium, 
interventricular septum, and endocardial cushion being evident after mid-gestation280.  
A transgenic approach has revealed that GDF11 plays an important role in 
anterior/posterior patterning of the axial skeleton281. Gdf11+/- and Gdf11-/- mice have 
homeotic transformations of vertebral segments compared to wild type mice, whereby 
individual vertebrae display characteristics of more anterior segments. In particular, 
vertebrae with thoracic characteristics are increased in number in homozygous and 
heterozygous mutant mice, resulting in multiple additional pairs of ribs being formed. 
In addition, Gdf11+/- and Gdf11-/- mice have additional lumbar vertebrae and 
malformed vertebrae in the sacral and caudal regions that results in posterior 
displacement of the hind limbs. It appears that GDF11 has a dose dependent effect on 
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axial skeleton development, as the phenotype of Gdf11+/- is less severe than the 
phenotype of Gdf11-/- mice281. Transgenic mouse models have also revealed that 
BMP8b, BMP2 and GDF9, play important roles in regulating the development of 
primordial germ cells and modulating sexual differentiation197. 
BMP/GDF members of the TGF-β superfamily play a plethora of roles in the developing 
nervous system and have also have been shown to be protective against the 
progression of neurological diseases. For example, BMP4 and BMP7 are produced by 
the dorsal aorta and induce neural precursor cells to develop along the sympathetic 
neuron lineage282. Whilst BMPR1A is expressed in neural precursors from the earliest 
stages of neural development, BMPR1B expression is first seen at E9 and is restricted 
to the dorsal neural tube. It appears that BMPR1A activation by BMPs is required to 
promote the proliferation of dorsal neural tube precursor cells as well as induce them 
to express BMPR1B and genes associated with dorsal identity. Once BMPR1B is 
expressed, BMP promoted activation of this receptor terminates precursor 
proliferation, eventually leading to neuronal differentiation283. An analysis of the 
developing spinal cords of Gdf7-/- and Bmp7-/- embryos, together with several in vitro 
assays using both cell lines and spinal cord tissues from wild type, Gdf7-/- and Bmp7-/- 
embryos, has revealed that heterodimers of GDF7 and BMP7 act as a repellent for 
commissural axon growth cones, directing commissural axons to follow their correct 
ventral trajectories284. BMP7 has been found to promote the growth of cortical285, 
hippocampal286 and sympathetic102 neuron dendrites in vitro. An analysis of BMP7 
promoted dendrite growth from cultured E16.5 mouse cortical neurons has identified 
that the C-terminal tail of BMPR2 is essential for dendrite growth in response to 
BMP7287. BMP7/BMPR2 promoted dendrite growth is mediated by a Smad 
independent signalling pathway that entails activation of BMPR2 associated LIM kinase 
1 (LIMK1) by the Rho GTPAse, Cdc42 and subsequent LIMK1 mediated phosphorylation 
and inactivation of cofilin, an actin associated molecule that promotes actin 
depolymerisation and severing287. In addition to promoting dendrite growth, BMP7 
also has neuroprotective actions on cortical and striatal neurons following cerebral 
ischemic injury in the adult rat288, 289. BMP7 expression is significantly upregulated in 
cortical and striatal neurons in vivo following ischaemia and increased BMP7 
expression mirrors an increase in activated-caspase-3 positive neurons, a marker of 
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cells undergoing apoptosis. BMP7 can reduce the expression of activated-caspase-3 in 
neonatal rat cortical and striatal neurons cultured under hypoxic conditions, 
suggesting that it exerts its neuroprotective effects following ischemia by blocking the 
induction of casapase-3 mediated apoptosis289.  
1.5.4.4 Physiological roles  and expression of GDF5 
Strain Allele Type Inheritance Type of 
mutation 
Organs and systems with 
abnormal phenotypes  
Gdf5
bp
 Spontaneous Recessive Intragenic 
deletion, 
Inversion 
limbs/digits/tail, 
growth/size/body, 
skeleton 
Gdf5
bp-J
 Spontaneous Recessive Insertion  limbs/digits/tail and 
skeleton 
Gdf5
bp-3J
 Spontaneous Recessive Intragenic 
deletion 
limbs/digits/tail and 
skeleton 
Gdf5
bp-4J
 Spontaneous Recessive Undefined limbs/digits/tail, 
growth/size/body, 
reproductive system and 
skeleton 
Gdf5
bp-5J
 Spontaneous Dominant Single point 
mutation 
limbs/digits/tail and 
skeleton 
Gdf5
bp-6J
 Spontaneous Recessive Insertion limbs/digits/tail 
Gdf5
brp
 Spontaneous Recessive Insertion limbs/digits/tail, 
growth/size/body, 
reproductive system and 
skeleton 
Gdf5
bp-H
 Spontaneous Recessive Undefined limbs/digits/tail and 
skeleton 
Gdf5
Gt(OST425122)Lex
 Gene trapped Not reported Insertion of 
gene trap 
vector  
Not reported 
Gdf5
png
 Chemically 
induced 
Recessive Single point 
mutation 
Skeleton 
Gdf5
Rgsc451
 Chemically 
induced 
Semi-dominant Single point 
mutation 
limbs/digits/tail and 
skeleton 
Gdf5
tm1a(EUCOMM)Hmgu
 Targeted N/A Insertion Not reported 
Gdf5
tm1e(EUCOMM)Hmgu
 Targeted N/A Insertion Not reported 
Tg(Gdf5-cre-
ALPP)1Kng 
Transgene N/A Insertion Behavioural/neurological, 
craniofacial, 
growth/size/body, 
hearing vestibular/ear, 
immune system, 
limbs/digits/tail and 
skeleton 
Table 1.01: List of commercially available GDF5 strains of mice, displaying the type and nature 
of the mutation and the associated systems with an abnormal phenotype (phenotype data 
were retrieved from the Mouse Genome Database (MGD), World Wide Web (URL: 
http://www.informatics.jax.org). [December, 2015])290.  
GDF5 was first identified as being an important regulator in the development of the 
appendicular skeleton (lower and upper limbs)262. Brachypod mice display numerous 
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abnormalities of their appendicular skeleton that include: shortening of limbs and feet, 
reduction of the number of bones in digits, abnormal joint formation within the limbs 
and sternum; however, their axial skeleton is unaffected. The cause of these skeletal 
defects was identified as a spontaneous frameshift mutation in the GDF5 gene that 
places an aberrant translational stop codon in the pro-domain of the primary GDF5 
transcript, resulting in its translation into a severely truncated non-functional 
protein262. The mutated GDF5 allele that induced the brachypod phenotype was 
referred to as Gdf5bp. Multiple mouse strains containing mutations of GDF5 that 
induce a similar phenotype are commercially available and are listed in table 1.01. The 
phenotype of brachypod mice is reflected in several human pathologies. Mutations in 
the human homologue of GDF5, cartilage-derived morphogenetic protein (CDMP1), 
give rise to Brachydactyly type C, an autosomal dominant disorder causing shortening 
or even absence of bones in the hands and feet291. Chondrodysplasia Grebe type (CGT) 
is an autosomal recessive disorder caused by a homozygous point mutations in the 
Cdmp1 gene that converts a tyrosine residue into a cysteine residue, resulting in 
patients having a short stature, severely shortened limbs and malformation and 
shortening of the digits 292. Hunters Thompson type disorder patients express a 
truncated CDMP1 protein as a result of a frameshift mutation in Cdmp1 and have 
appendicular skeleton abnormalities that resemble those of mice homozygous for the 
Gdf5bp allele (Gdf5bp/bp) mice293. A mutation in Cdmp1 that converts residue 441 from 
leucine to a proline (L441P) cause Brachydactyly type A2, a condition that is 
characterised by shortening of the index finger due to hypoplasia/aplasia of the middle 
phalanx294. The L441P mutation reduces the affinity of GDF5 for BMPR1B and BMPR1A. 
In contrast, a mutation in Cdmp1 that converts amino acid residue 438 from arginine 
to leucine increases the binding affinity of GDF5 for BMPR1A and results in 
symphalangism, a pathology of the digits whereby the phalanges are fused294. Mice 
with mutations in the BMPR1B receptor have a similar phenotype to Gdf5bp/bp mice. 
Bmpr1b-/- mice display a marked reduction in the proliferation of prechondrogenic cell 
type and reduced chondrocyte differentiation that results in deficits of the 
appendicular skeleton295. Human skeletal pathologies can also result from mutations in 
the BMPR1B gene. For example, autosomal dominant mutations in BMPR1B that 
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interfere with its transphosphorylation by type 2 GDF5 receptors cause Brachydactyly 
type A2296.  
The mechanism by which GDF5 functions to regulate the correct development of the 
appendicular skeleton has been studied in some detail. GDF5 is expressed in a pattern 
of transverse stripes within skeletal precursors of the developing limb297. The sites of 
GDF5 expression normally demarcate the position where synovial joints will form, with 
the result that the formation of synovial joints in the limb is disrupted in Gdf5bp/bp mice 
leading to the fusion of bones. In addition to regulating joint formation, GDF5 
regulates chondrocyte differentiation in a dose dependent manner, explaining why 
shortened limbs occur in Gdf5bp/bp mice297. Moreover, virus-mediated over-expression 
of GDF5 in chick limbs, results in an increase in the length of skeletal elements298. 
BMPR1A and BMPR1B have been found to be important in early chondrogenesis. 
Whilst Bmpr1a-/- and Bmpr1b-/- mice are able to form ostensibly normal cartilaginous 
elements, Bmpr1a-/-/Bmpr1b-/- double knockout mice display severe chondrodysplasia 
and the majority of skeletal elements that form through endochondral ossification are 
either absent or very rudimentary. These observations suggest that there is an 
element of redundancy in GDF5 type 1 receptor usage299. GDF5 induced 
chondrogenesis appears to be mediated by a combination of BMPR1B induced 
Smad1/5/8 signalling and the actions of the Ror2 tyrosine kinase300. Ror2 and BMPR1B 
co-localise in C2C12 cells and appear to form a ligand-independent heterodimeric 
complex. BMPR1B trans-phosphorylates Ror2 and, following GDF5 binding, activated 
Ror2 attenuates BMPR1B mediated Smad signalling, whilst promoting Smad-
independent signalling. Smad-dependent and -independent signalling pathways are 
both needed for effective chondrocyte differentiation. Ror2-/- mice have a short 
humerus, similar to Gdf5bp/bp mice; however, the phalanges and metacarpals of Ror2-/- 
mice are significantly less affected than those of Gdf5bp/bp mice. Double homozygous 
GDF5bb-J-/-/Ror2-/- mice have a much more severe appendicular skeleton phenotype 
than either individual null mutant. Double null mutants have very short limbs with an 
almost complete absence of metacarpals/phalanges. In addition, the humerus/femur 
of double mutants lack differentiated chondrocytes and are not ossified300.  
In accordance with the requirement for functional type 1 and 2 BMP receptors for 
correct development of the cardiovascular system described above, GDF5 is expressed 
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in the developing heart301 and has pro-apoptotic effects on cardiomyocytes that are 
mediated by Smad4 activity302, 303. In addition, in vitro investigation has suggested that 
GDF5 is pro-angiogenic and may contribute to the vascularization of developing 
bone302, 304.  
GDF5 and its receptors are expressed widely in the developing and adult nervous 
system. Western blotting has revealed that GDF5 protein is expressed in the 
developing and adult rat brain305. GDF5 is first detected in whole brain lysates at E12 
and expression levels increase from E12 to reach a peak at E14. After E14, the levels of 
GDF5 protein in whole brain lysates gradually decrease, so that GDF5 is barely 
expressed by birth. Postnatally, GDF5 protein levels in the brain increase with age to 
reach a peak at P22, a level that is similar to that seen at E14 and maintained through 
to adult. GDF5 is expressed within the developing ventral midbrain (VM) of the rat with 
a distinct temporal profile that mirrors that seen within whole brain lysates305. Within 
the adult brain, comparable levels of GDF5 are seen within the striatum, midbrain, 
cortex and cerebellum305. In situ hybridization has been used to determine the 
temporal and spatial expression patterns of type 2 BMP receptor mRNAs within the 
nervous system of developing and adult rats306. Bmpr2 mRNA is the most widely 
expressed type 2 BMP receptor mRNA in the developing and adult rat. Bmpr2 mRNA is 
expressed as early as E11 in the neuroepithelium of the newly formed neural tube and 
by E15 it is strongly expressed within the spinal cord, DRG and spinal nerves, with 
lower levels of expression in paravertebral sympathetic ganglia. Perinatally, Bmpr2 
mRNA expression decreases in the spinal cord but high level expression is found within 
DRG and sympathetic ganglia. Postnatally, Bmpr2 mRNA is expressed throughout the 
P6 and P21 rat cortex, striatum and hippocampus. In the adult rat, Bmpr2 mRNA 
expression is expressed within: motor neurons of the ventral spinal cord, DRG, cortex, 
striatum, hippocampus, olfactory bulb, substantia nigra and purkinje cells of the 
cerebellum306, 307. Acvr2a mRNA is first detected by in situ hybridization in the 
developing rat nervous system at E15, when its expression is restricted to the spinal 
cord. By birth, Acvr2a mRNA is detected in the spinal cord, DRG and sympathetic 
ganglia. Postnatally and in the adult, Acvr2a mRNA expression is detected in: the 
cingulate cortex, layers II and III of the cerebral cortex, the olfactory bulb and the 
hippocampal formation306. Whilst in situ hybridization has detected Bmpr1a and 
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Bmpr1b transcripts in the developing peripheral nervous system, it fails to detect these 
mRNAs in the developing and adult CNS306. In addition to in situ hybridization, 
immunohistochemistry has also been used to examine the expression of BMPR1A, 
BMPR1B and BMPR2 in the adult rat CNS308. All three receptor proteins are found in 
the: olfactory bulb, cerebral cortex, hippocampus, thalamus, hypothalamus, basal 
ganglia, cerebellum, midbrain, hindbrain and spinal cord. Within the adult rat spinal 
cord, immunohistochemistry has revealed that BMPR1A, BMPR1B and BMPR2 are all 
expressed within the soma and the ascending and descending axons of neurons, as 
well as within; astrocytes, oligodendrocytes, ependymal cells and microglia309.  
GDF5 has been shown to exert neurotrophic effects on certain developing and adult 
neurons. For example, GDF5 has been shown to enhance NGF and NT-3 promoted 
survival of cultured E8 chick DRG neurons, although it does not enhance their survival 
on its own310. Moreover, GDF5 acts synergistically with the cell adhesion molecules, L1 
and neurofascin, to promote process outgrowth from cultured E9 chick DRG 
neurons311. In addition, to its synergistic promotion of process elongation with cell 
adhesion molecules, GDF5 can also enhance NGF promoted process outgrowth in vitro 
from E9 chick DRG neurons311. The addition of GDF5 to cultures of E14 rat VM 
increases the survival of dopaminergic neurons and promotes their morphological 
differentiation305. In SH-SH5Y cells, a human neuronal cell line that exhibits some 
characteristics of midbrain dopaminergic neurons, GDF5 enhanced process outgrowth 
is mediated by canonical Smad1/5/8 signalling induced by BMPR1B activation312. 
Canonical, BMPR1B mediated Smad1/5/8 signalling is also required for GDF5 enhanced 
morphological differentiation of cultured rat E14 VM neurons313.  There has been a 
great deal of interest in a potential therapeutic role for GDF5 in the treatment of 
Parkinson’s disease. In a rat model of Parkinson’s disease, injection of GDF5 into the 
striatum or substantia nigra ameliorates the severity of amphetamine induced 
rotations following 6-OHDA treatment and reduces the loss of dopaminergic neurons 
from the substantia nigra314, 315. The reduced loss of dopaminergic neurons following 
the administration of GDF5 was confirmed by several approaches. Positron emission 
tomography revealed that GDF5 preserves that integrity of dopaminergic terminals in 
the striatum. Post-mortem analysis showed that GDF5 ameliorated 6-OHDA-induced 
loss of dopamine in the striatum, as determined by liquid chromatography of striatal 
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lysates, and that GDF5 reduced the number of TH-positive neurons lost in the 
substantia nigra, as determined by immunohistochemistry, following 6-OHDA lesion315.  
A potential treatment for PD is the transplantation of foetal mesencephalic grafts into 
damaged striatum, an approach that has been extensively studied in rat models of PD. 
Grafts of foetal mesencephalon have better survival rates, and are more effective at 
compensating for 6-OHDA induced striatal lesions, when they are pre-treated with 
GDF5314. Moreover, transplantation of (Chinese hamster ovary) (CHO) cells which had 
been stably transfected to over-express human GDF5 has a neuroprotective and 
restorative effect on dopaminergic neurons in rat models of PD316. 
In addition to midbrain dopaminergic neurons, GDF5 also promotes the morphological 
differentiation of other CNS neuron populations. For example, GDF5 enhances the 
differentiation of E14 serotonergic neurons of the rat hindbrain raphe in serum free 
cultures317. As will be discussed in more detail in chapter 3, GDF5 promotes dendrite 
elongation and branching from cultured perinatal mouse hippocampal neurons and 
hippocampal pyramidal neurons in postnatal Gdf5bp/bp mice have significantly less 
elaborate dendrites than those in wild type mice318. 
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1.6 Aims 
The overall aim of this project was to investigate the potential roles of GDF5, a 
member of the TGF-β superfamily, and its corresponding receptors in the developing 
nervous system. Since GDF5 and its receptors are expressed in the developing SCG and 
hippocampus these two neuronal populations were selected for study. In addition, 
anatomical studies of the cerebellum were also conducted, because preliminary data 
suggested a potential change in the morphology and total volume of the cerebellum in 
mice lacking functional GDF5 expression. Gdf5bp-3J mice (see table 1.01) were obtained 
from Jackson laboratories to determine the physiological relevance of in vitro data 
obtained during the course of the investigation into the roles of GDF5 in nervous 
system development. Mice homologous for this non-functional GDF5 allele are 
referred to as Gdf5bp/bp during the rest of this thesis. Wild type mice will be referred to 
as Gdf5+/+mice, whereas mice possessing one non-functional GDF5 allele and one wild 
type GDF5 allele (heterozygous) will be referred to as Gdf5+/bp mice. The specific aims 
of this thesis were: 
1. Based on preliminary data suggesting that neonatal mice lacking functional 
GDF5 expression show hippocampal and cerebellar morphological 
abnormalities, the first aim of the thesis was to use comparative MRI study to 
establish if there is any structural differences between the hippocampus and 
cerebellum of P10 and adult Gdf5bp/bp mice compared to aged matched Gdf5+/+ 
mice (The anatomy and development of the hippocampus and cerebellum and 
the rationale behind this aim will be discussed in the introduction to chapter 3). 
2. Developing SCG neurons require NGF to promote process elongation and 
branching, both in vitro and in vivo. In addition, many additional trophic factors 
have been recently identified that can modulate NGF-promoted neurite 
outgrowth from developing SCG neurons. Since GDF5 can enhance the 
dendritic complexity of cultured hippocampal neurons and promote neurite 
elongation from cultured dopaminergic neurons of the embryonic midbrain, 
the second aim of this thesis was to investigate whether GDF5 could either 
promote neurite outgrowth from cultured perinatal SCG neurons in the 
absence of NGF or enhance NGF-promoted process elongation and branching.  
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3. Since developing SCG neurons are acutely dependent on neurotrophic factors 
to support their survival in vitro, and GDF5 has survival enhancing effects on 
dopaminergic midbrain neurons in rodent models of PD, the third aim of this 
thesis was to determine whether GDF5 could enhance the survival of cultured 
neonatal SCG neurons. 
4. Having established that GDF5 promotes process outgrowth and branching from 
cultured perinatal SCG neurons, the next aim was to determine the identity of 
the type 1 and type 2 BMP/GDF receptors that mediate these growth 
promoting effects at P0. Whilst a complex of BMPR2 and BMPR1B is the most 
effective receptor combination for transducing GDF5 signals in cell lines, and is 
the receptor combination that is used by developing midbrain dopaminergic 
neurons, the expression of the type 1 receptor, BMPR1A and the type 2 
receptor, ACVR2A in developing sympathetic neurons raises the possibility that 
GDF5 exerts its growth promoting effects on these neurons by binding to a 
receptor complex other than BMPR2/BMPR1B.  
5. In a bid to further clarify the identity of the receptor complex that mediates the 
growth promoting effects of GDF5 on neonatal sympathetic neurons, in vitro 
experiments were performed to determine whether GDF5 and/or NGF could 
regulate the expression of any of the GDF5 receptor subunits at the mRNA 
level.  
6. Investigate the physiological relevance of GDF5s ability to promote process 
outgrowth and branching from cultured SCG neurons by determining whether 
postnatal Gdf5+/bp and Gdf5bp/bp  mice have deficits in TH-positive innervation of 
SCG neuron target fields compared to postnatal Gdf5+/+ mice.  
7. Analyse sympathetic innervation of SCG neuron target fields in transgenic mice 
containing null mutations in BMPR1A and BMPR1B in an attempt to clarify the 
identity of the type 1 receptor that mediates the target field innervation 
promoting effects of GDF5 in vivo. 
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2.1 Animal maintenance and husbandry.  
Breeding and supply of animals was regulated by the Animals (Scientific Procedures) 
Act 1986 (ASPA), as amended to encompass EU Directive 2010/63/EU and ethical 
guidelines laid out by Cardiff University. Timed mating of CD1 wild type mice and 
transgenic strains of mice were used to generate embryonic and postnatal mice. The 
presence of a vaginal plug was used to confirm successful breeding. The morning of a 
successful breeding was considered to equate to 0.5 embryonic day (E0.5) and the 
date of birth as postnatal day 0 (P0). Adult CD1 mice and transgenic mice were fed on 
a diet of rodent global diet pellets (Harlan) and water ad libidum. CD1 and transgenic 
mice of both sexes were used in the following experiments.  
Bmpr1b (ALK-6) transgenic mice were obtained from Yuji Mishina295. The type I BMP 
receptor BMPRIB is required for chondrogenesis in the mouse limb. These mice have 
exon 1 of the Bmpr1b coding sequence replaced by a neo cassette and can be 
genotyped by polymerase chain reaction (PCR) (Appendix I). GDF5bp-3J (growth 
differentiation factor 5, brachypodism-Jackson) mice were obtained from Jackson 
laboratories. These mice, which will be referred to as Gdf5bp/bp, are the result of a 
spontaneous mutation whereby a CG dinucleotide is replaced by a single base (T) at 
nucleotide position 876, causing a frame shift and a translational stop at the next 
codon which is in the pro-domain of GDF5. The mice, which were originally in a 
Bl6/BALB/cJ background have subsequently been bred into a C57/Bl6 background. 
Homozygous Gdf5bp (Gdf5bp/bp) mice have shortened limbs and malformed and 
shortened feet and digits compared to wild type (Gdf5+/+) and heterozygous (Gdf5+/bp) 
mice. Because a PCR based genotyping approach cannot be used to genotype GDF5bp 
mice, genotyping was based on phenotype of offspring. Mice were bred by crossing 
Gdf5bp/bp with Gdf5+/bp to insure all offspring were either heterozygous or homozygous 
for the GDF5 brachypodism allele. Gdf5+/+ mice were obtained from breeding C57/B6 
mice and were aged matched to their transgenic counterparts because of the small 
litter sizes, mice of both sexes were used indiscriminately; however, to account for 
potential gender variations, experimental groups were balanced between the sexes as 
best as possible.  
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2.2Cell Culture 
2.2.1 Preparation of culture media.  
Ham’s F12 was used as a washing media: 5 ml of pen-strep (penicillin (60 mg/L) and 
streptomycin (100 mg/L) and 50 ml of heat-inactivated horse serum (Gibco) were 
added to 450 ml of F12 (Gibco). Complete F12 medium was sterile-filtered using a 
bottle top filter (Nalgene) 
Ham’s F14 was used as the culture media: 294 mg of sodium hydrogen bicarbonate 
was mixed with 250 ml of distilled water. 25 ml of this solution was discarded and 
replaced with 25ml of 10 X F14 (JRH Biosciences). Following this, 2.5 ml of 200 mM 
glutamine (Gibco) 5ml of albumax (Gibco) and 5 ml of pen-strep were added to the 
F14. Albumax is a 10% bovine serum albumin (BSA) solution containing: progesterone 
(60μg/ml), putrecine (16 μg/ml), L-thyroxine (400 ng/ml), sodium selenite (38 ng/ml) 
and tri-iodothyronine (340 ng/ml).  Complete F14 culture medium was sterile-filtered 
using a bottle top filter (Nalgene). 
2.2.2 Preparation of tungsten dissection needles.  
Two 3 cm lengths of 0.5 mm diameter tungsten wire were bent at a 90⁰ angle 
approximately 1 cm from one end (depending on the user’s preference). The tungsten 
wires were then connected to the cathode of a variable, low voltage AC power supply. 
The anode of the power supply was immersed in a 1M KOH solution in a glass beaker. 
Next, tungsten needle tips were immersed in the KOH solution and a 3-12 V AC current 
was passed through the solution. The tungsten tips were electrolytically sharpened by 
vertically dipping them in an out of the KOH solution. Once sharpened, tungsten 
needles were placed in nickel plated needle holders and sterilised by flaming after 
dipping in ethanol.  
2.2.3 Preparation of cell culture dishes.  
Three types of culture dished were used: 35mm 4-well dishes containing 4 inner wells 
(Greiner), 35 mm culture dishes (Greiner) and 4-well multidishes (Nunc) where each 
well has a diameter of 10 mm. Greiner culture dishes were initially prepared for 
neuronal culture by the addition of 1ml of poly-ornithine (Sigma), incubation at room 
temperature for 12 hours and washing three times with sterile distilled water. Washed 
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dishes were allowed to air dry in a laminar flow hood. Nunc culture dishes were 
prepared in the same way, with the exception that 500 µl of poly-ornithine was initially 
added to each well. Next, poly-ornithine coated dishes were laminin treated by adding 
100 µl of a solution of 20 µg/ml laminin (Sigma) in HBSS (Gibco), to either the centre of 
35 mm culture dishes or to each well of 4-well dishes, and incubating at 37°C, in 5% 
CO2, for 2 hours. Laminin was aspirated just before the addition of dissociated cell 
suspension to the culture dishes.  
2.2.4 Dissecting SCG.  
All instruments were cleaned with 70% ethanol and tungsten needles were flamed 
after immersing in ethanol before beginning dissections. Dissections were carried out 
in a laminar flow hood, which was cleaned with 70% ethanol before and after use, to 
provide a sterile environment for working.  
For embryonic work, pregnant females were killed by the Schedule 1 method of 
cervical dislocation, according to the guidelines set out in ASPA, and the abdomen was 
cleaned with 70% ethanol. Next, the uterus was removed following laparotomy and 
placed in sterile PBS. Embryos were removed from the uterus and the amniotic sac 
that surrounds them and killed by decapitation, a Schedule 1 method as set out in 
ASPA. Postnatal animals were killed by decapitation under project and personal 
licence.  
Dissections were carried out under a stereomicroscope (Nikon) and fibre-optic light 
source (Schott) using forceps, scissors and tungsten needles. For postnatal animals, the 
skin covering the skull was removed prior to commencing SCG dissection. Scissors 
were used to make a cut through the midline of the parietal bone as far as the coronal 
suture. This cut was used as a guide for cutting the skull and underlying brain along the 
mid-sagittal plane with scissors. Next, the brain was the removed from both 
hemispheres and forceps were used to gently break away and remove the occipital 
bone, thereby exposing the nodose ganglion and SCG at the entrance to the jugular 
foramen in each hemisphere. The SCG, an elongated structure resembling a rugby ball 
that lies above the carotid artery, was removed by using forceps to gently cut the 
preganglionic and postganglionic axons that connect it to the paravertebral 
sympathetic chain and peripheral target fields, respectively. Isolated SCG were 
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cleaned, by using tungsten needles to remove the nerve roots, and placed in a 15 ml 
centrifuge tube containing calcium and magnesium free-Hanks Balanced Salt Solution 
(HBSS without Ca2+- Mg2+ (Life Technologies))  to await dissociation.  
2.2.5 Dissociating ganglia.  
Dissected ganglia were incubated in 1 ml of  HBSS without Ca2+- Mg2+ containing 0.5 
mg/ml trypsin (Worthington) at 37°C, in 5% CO2, for a time period that was determined 
by the developmental age of the ganglia (see table 2.01). 
Age Time of trypsinization (min) 
E17 17 
P0 20 
P3 23 
P10 25 
Table 2.01: Duration of trypsinization for each age where SCG were cultured. 
Following trypsin incubation, the trypsin solution was removed and the ganglia were 
washed three times in F12 medium containing 10% heat inactivated horse serum. 
Washed ganglia were then transferred into 1ml of complete F14 prior to trituration. 
The ganglia were triturated into a single neuron suspension using a fire polished 
siliconised Pasteur pipette. Trituration was performed 10-15 times to ensure that a 
high density dissociated neuron suspension was obtained. 
2.2.6 Plating neurons.  
After trituration, 10-15 μl of the neuronal cell suspension was added to 1 ml of F14 in a 
15ml centrifuge tube and mixed. At this stage, any growth factors or antibodies being 
investigated in individual experiments were added to the diluted cell suspension at the 
appropriate concentration. The exact volume of neuronal cell suspension that was 
added to create the diluted cell suspension for plating was determined after the cell 
density of the freshly triturated neurons had been determined using an inverted phase 
contrast microscope (Nikon) to calculate the initial density of the neurons. For 35 ml 
tissue culture dishes, 1 ml of diluted cell suspension was added to each dish together 
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with 1 ml of cell-free F14. For 4-well dishes, 100 μl of the diluted cell suspension was 
added to each individual well. After plating, cultures were incubated at 37⁰C, in 5% 
CO2, for 2 hours. The relative density of neuronal cultures and the health of neurons 
was then checked under an inverted phase contrast microscope. After a further 14 
hours of incubation, at 37⁰C in 5% CO2, the cultures were again assessed under a 
microscope to ensure that significant neuron death had not occurred over the culture 
period. 
2.3 Quantification of neurite outgrowth and surv ival. 
Neurons were cultured in 4-well dishes for experiments designed to determine the 
effects of exogenous factors on the extent of neurite outgrowth and branching. After 
16hrs incubation, at 37°C in 5% CO2, culture dishes were flooded with 2 ml of F14 
containing 100 ng/ml of Calcein-AM (Invitrogen) and incubated for a further 30 
minutes at 37⁰C in 5% CO2. Calcein-AM is a cell-permeant non-fluorescent dye that is 
metabolised by intracellular esterases within living cells, causing it to become non-cell 
permeant and to fluoresce strongly green, thus enabling neurons and their processes 
to be imaged using a fluorescence microscope (Zeiss). At least 50 individual neurons 
were imaged for each experimental culture condition in every experiment. Images 
were later analysed using a modified Sholl analysis program319 that not only generates 
a Sholl profile for all neurons cultured under each experimental culture condition, but 
also allows the mean total length and mean number of branch points of imaged 
neurons to be calculated for each experimental culture condition.  The modified Sholl 
analysis programme runs on MATLAB and works by generating a series of concentric 
virtual rings around the neuronal cell soma, the number of rings and their distance 
apart are programme operator selected. The operator clicks on the neuron soma and 
then inputs the number of processes emerging directly from the soma (5 for the 
neuron in figure 2.01, below). Next, the operator clicks on the terminals of all 
processes (t on figure 2.01) and the MATLAB software calculates the number of 
bifurcations/branches that the processes have. The operator then clicks on each 
branch point (b on figure 2.01). Data from MATLAB are transferred directly to an Excel 
spreadsheet and includes total neurite length and number of branch points for each 
neuron and the number of processes that crosses each virtual concentric ring for each 
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neuron. From the data, a Sholl profile can be generated for each experimental 
condition which has the average number of intersections that neurites make on the Y-
axis and the distance of the virtual concentric rings from the neuron soma on the X-
axis in µm. The Sholl profile (figure 2.01) is a graphical representation of the 
complexity of neurons cultured under each experimental condition. In its simplest 
interpretation, the larger the area under the curve of the Sholl profile the more 
complex the neurons are.  
 
Figure 2.01:  A schematic of the modified automated Sholl program. The radial distance to the 
bifurcation points (b) and the terminals (t), along with the number of processes emanating 
from the soma (5 in this case) is used to generate the Sholl profile for a population of neurons 
(shown in the top left corner) and calculate the total neurite length and number of branch 
points for each neuron (diagram from Gutierrez and Davies, 2007319). 
For experiments to investigate whether GDF5 regulates SCG neuron survival, 
dissociated neurons were plated in 35 ml culture dishes. To determine survival, culture 
dishes were placed on top of a Petri dish that had a 12 X 12 mm2 grid etched into its 
surface, so that the grid was in the centre of the culture dish. A phase contrast 
microscope was used to count the initial number of neurons within the grid after 4 
hours of culture and the number of surviving neurons within the grid 24hr and 48hr 
after plating. The numbers of surviving neurons at 24hr and 48hr were then expressed 
as percentage of the initial number of neurons counted.  
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2.4 Microfluidic Chambers 
During development, as neurons grow towards and innervate their target tissue, the 
extending axons are exposed to different microenvironments. In particular, target 
fields contain a different combination of secreted proteins, including neurotrophic 
factors, compared to ganglia where the neuron soma reside. Target field-derived 
neurotrophic factors may act locally on distal axons to regulate axonal arborisation, or 
may signal retrogradely to promote neuronal survival and/or axonal arborisation. 
Autocrine and/or paracrine signalling by ganglion-derived neurotrophic factors may 
also regulate neuronal survival and/or target field innervation60. In order to better 
understand the physiological relevance of neurotrophic factor promoted neuronal 
survival and/or neurite outgrowth and branching in vitro, it is useful to apply 
neurotrophic factors specifically to either the neuron soma or to distal axons. 
Microfluidic devices enable the microenvironments surrounding the neuron soma and 
axons to be manipulated independently of each other, thereby allowing neurotrophic 
factors to be applied to either the neuron soma, distal processes or both. The devices 
are composed of two compartments connected by micro channels. If neurons are 
plated in one of the compartments, axons can extend though the micro channels and 
into the other compartment (figure 2.02). A small hydrostatic gradient is established 
between the chambers, so that culture media flow through the channels is only one 
way with the result that if  neurotrophic factors are specifically added to either the 
soma or axon compartment they cannot pass through the micro channels and 
contaminate the other compartment.  
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Figure 2.02: Schematic of microfluidic device (adapted from Kisiswa et al, 2013153). 
Microfluidic chambers (Xona) were placed on polyornithine treated 35 mm culture 
dishes and the right and left chamber and micro channels were coated with laminin by 
adding 100 µl and 80 µl of 10 ug/ml laminin in HBSS to the left and right wells, 
respectively. After 2hrs, the laminin in the left well was aspirated and 10 µl of SCG 
neuron suspension (in F14 containing 10ng/ml NGF) was loaded into the channel 
opening of the top and bottom left wells. After 2 hours, to allow the neurons to adhere 
to the base of the left channel, left and right top and bottom wells were slowly topped 
up with F14 containing the desired combination of neurotrophic factors. For 
experiments designed to investigate the effects of adding GDF5 only to the axon 
compartment, 100 µl of F14 containing 10 ng/ml NGF was added to the left wells and 
90 µl of F14 containing 10ng/ml NGF and 100 ng/ml GDF5 was added to the right wells, 
thereby creating a hydrostatic gradient that prevents GDF5 from leaking into the soma 
compartment.  SCG neurons in the microfluidic chambers were incubated for 24 hours, 
at 37°C, in 5% CO2. After 24 hrs, 1 µl of a 1/10 dilution of calcein AM in F14 was added 
to the top and bottom right hand wells that feed the axonal channel. The microfluidic 
chambers were then covered and then left to incubate at 37°C for 30 minutes. The 
channels of the microfluidic chambers (left and right channels proximal to the 
microfluidic cross channels) were then imaged using a fluorescent inverted microscope 
(Zeiss). Channels were imaged in 7 non-overlapping sections (top to bottom) at 10X 
magnification. Neurite length was determined using NIH-ImageJ. Initially, images were 
converted to grey scale. Following this, a grid of vertical lines 200 μm apart was 
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superimposed on the images and the number of intersections between neurites and 
lines of the grid were manually counted. Next, the number of intersections between 
neurite and grid were normalised against the number of labelled somas in the cell 
body compartment of the microfluidic chamber by dividing the total number of 
intersections by total number of calcein AM labelled soma, thereby giving a value for I.  
Average neurite length per projecting cell body was then calculated using the formula 
L = πDI / 2, where L is the estimated length of neurites per neuron soma. π is used to 
construct the boundary of an arc that intersects with two adjacent parallel lines, thus 
enabling the length of the process to be determine upon the grid. D is the interline 
interval of the grid, in this case 200µm, and I is the average number of intersections 
per projecting cell body that has been calculated as described above. Measurements 
were independently carried out in all fields along the microfluidic barrier. This 
previously described method320 was developed to allow stereological measurements 
to be used to calculate the length of neurites in vitro using conventional cell culture 
conditions. The method has been modified to use fluorescence microscopy and 
microfluidic chambers.  
2.5 Gene Expression analysis by RT-qPCR. 
2.5.1 Theory of Reverse transcription Quantitative 
Polymerase chain reaction (RT -qPCR). 
Polymerase chain reaction (PCR) is a method of amplifying specific sequences of DNA. 
Reverse transcription quantitative PCR (RT-qPCR) uses an RNA template that is reverse 
transcribed to a DNA copy (cDNA) and subsequently amplified by PCR. RT-qPCR 
enables the expression of individual genes from cells and tissues to be analysed 
because reverse transcribed RNA can be amplified by primers that are specific to 
individual cDNAs. During the qPCR reaction different temperature steps are used to 
create the conditions for amplification and detection. Typically, a 95⁰C denaturation 
step, resulting in separation of the double stranded cDNA templates by disrupting the 
hydrogen bonds between the DNA strands, is followed by an annealing step, whereby 
the temperature drops to between 50⁰C and 60⁰C to allow gene specific primers to 
anneal to the single stranded DNA templates. Following annealing, the reaction 
temperature is raised to 72⁰C to enable primer extension in a 5’ to 3’   direction along 
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the single stranded DNA template. This 3 temperature cycle is repeated multiple times 
to amplify the target cDNA sequence in an exponential manner. In the case of the data 
generated in this thesis, a modified Taq polymerase (Agilent) was used that allows a 
rapid 2 step PCR cycling procedure to be employed, whereby denaturation at 95°C is 
followed by a single incubation at 60°C that serves to allow both primer annealing and 
primer extension. Dual-labelled hybridization probes were used to detect the 
exponential increase in PCR products during PCR cycling. These sequence, and hence 
template, specific probes anneal to one of the template strands during the annealing 
step, just 3’ to one of the primers. The 5’ end of the probe is labelled with a FAM 
fluorophore that is prevented from fluorescing by a quencher molecule, Black Hole 
Quencher 1 (BHQ1 (Eurofins)) that is attached to the 3’ end of the probe. BHQ1 
quenches FAM fluorescence by fluorescence resonance energy transfer (FRET), a 
process that relies on the close proximity of FAM and the quencher. As the PCR primer 
that is 5’ to the probe is extended to reach the probe, the inherent 5’ to 3’ exonuclease 
activity of Taq polymerase degrades the probe into single nucleotides releasing the 
FAM fluorophore into solution, where it can no longer be quenched by BHQ1, resulting 
in a fluorescent signal. The amount of free, unquenched FAM increases exponentially 
on a cycle by cycle basis. The use of dual-labelled probes to monitor PCR product 
accumulation significantly increases the specificity of the PCR reaction compared to 
the most commonly used fluorescent qPCR product detection method, Sybr Green 
incorporation.  The amount of amplified products of the qPCR reaction is directly 
proportional to the fluorescence signal detected by the qPCR thermal cycler once the 
fluorescence exceeds the threshold detection level of the thermal cycler. The number 
of qPCR reaction cycles that have been completed when threshold detection has been 
reached (Ct value) is inversely proportional to the amount of initial target cDNA i.e the 
greater the amount of target initial cDNA the lower the Ct value.  
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2.5.2 RT-qPCR procedure.  
Gene Oligo Sequence (5’ to 3’) 
Gdf5  Forward 
Reverse 
Probe 
TAA TGA ACT CTA TGG ACC 
GAT GAA GAG GAT GCT AAT 
FAM-TGA ATC CAC ACC ACC CAC TTG-BHQ1 
Bmpr1a Forward 
Reverse 
Probe 
TAC GCA GGA CAA TAG AAT 
AAC TAT ACA GAC AGC CAT 
FAM-TGA GCA CAA CCA GCC ATC G-BHQ1 
Bmpr1b Forward 
Reverse 
Probe 
AGT GTA ATA AAG ACC TCC A 
AAC TAC AGA CAG TCA CAG 
FAM-CCA CTC TGC CTC CTC TCA AG-BHQ1 
Bmpr2 Forward 
Reverse 
Probe 
ACT AGA GGA CTG GCT TAT 
CCA AAG TCA CTG ATA ACA C 
FAM-CAC AGA ATT ACC ACG AGG AGA-BHQ1 
Acvr2a Forward 
Reverse 
Probe 
CGC CGT CTT TCT TAT CTC 
TGT CGC CGT TTA TCT TTA 
FAM-TGC TCT TCA GGT GCT ATA CTT GGC-BHQ1 
Ngf Forward 
Reverse 
Probe 
AAA CGG AGA CTC CAC TCA CC 
GTC CTG TTG AAA GGG ATT GTA CC 
FAM-TGT TCA GCA CCC AGC CTC CAC CCA-BHQ1 
Gapdh Forward 
Reverse 
Probe 
GAG AAA CCT GCC AAG TAT G 
GGA GTT GCT GTT GAA GTC 
FAM-AGA CAA CCT GGT CCT CAG TGT-BHQ1 
Sdha Forward 
Reverse 
Probe 
GGA ACA CTC CAA AAA CAG 
CCA CAG CAT CAA ATT CAT 
FAM-CCT GCG GCT TTC ACT TCT CT-BHQ1 
Hprt1 Forward 
Reverse 
Probe 
TTA AGC AGT ACA GCC CCA AAA TG 
AAG TCT GGC CTG TAT CCA ACA C 
FAM-TCG AGA GGT CCT TTT CAC CAG CAA G-BHQ1 
Table 2.02: Primer/probe sets used to amplify and detect cDNAs of interest and reference 
cDNAs by qPCR. 
To investigate how NGF and GDF5 influence the expression of type I and type II Bmp 
receptor transcripts in developing SCG neurons, high density 48hr P0 SCG cultures 
were set up using 4-well multidishes (Nunc). Neurons were cultured either in the 
presence of 100 ng/ml GDF5 ( R&D ) plus varying concentrations of NGF ranging from 
0.01 ng/ml to 100 ng/ml (R&D), or a fixed concentration of 0.1 ng/ml NGF plus varying 
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concentrations of GDF5 ranging from 1 ng/ml to 100 ng/ml. 500 µl of F14 containing 
each combination of neurotrophic factors and freshly dissociated SCG neurons was 
added to each well of a 4-well multidish. The central cavity of the culture dishes that 
separates the individual wells was flooded with 2 ml of sterile dH20 after plating, to 
ensure that neuronal survival is not compromised by the evaporation of culture media 
during the 48hr culture period. At the time of plating, a 10 µl sample of concentrated 
dissociated SCG cell suspension was taken and placed in each of four 1.5 ml micro-
centrifuge tubes and lysed with 350 µl of RLT buffer (Qiagen) containing 1% β-
mercaptoethanol (Sigma). These “time 0” samples were stored at 4°C during the 
culture period.  After 48hrs of culture,  F14 was aspirated from culture dishes, neurons 
were lysed by the addition of 350 µl of RLT buffer containing 1% β-mercaptoethanol to 
each well of the multidishes, and lysates were placed into individual 1.5 ml microfuge 
tubes. Lysates were stored at 4°C, for up to 72hrs, before RNA purification. Total RNA 
was purified from culture lysates using the RNeasy Micro extraction kit (Qiagen) 
according to the manufactures instructions.  
To determine the expression profile of Bmpr1a, Bmpr1b, Bmpr2 and Acvr2a transcripts 
in developing SCG neurons, ganglia were dissected from multiple embryonic and 
postnatal ages. Dissected ganglia were initially placed into 1.5ml micro-centrifuge 
tubes containing 300µl of RNAlater (Ambion) to inactivate RNases. Following an 
overnight incubation at 4°C, ganglia in RNAlater were stored at -20°C to await RNA 
extraction and purification. SCG target fields were also dissected at various postnatal 
ages to analyse the relative expression levels of Gdf5 and Ngf mRNAs between target 
fields. Dissected target fields were handled prior to RNA extraction in the same 
manner as SCG. RNA was extracted and purified from SCG and target fields using the 
RNeasy lipid mini kit (Qiagen) according to the manufactures instructions. 
5 μl of RNA was reverse transcribed for 1 hour at 45⁰C using the AffinityScript kit 
(Agilent) in a 20μl reaction according to the manufactures instructions. Reverse 
transcription was primed using random hexamer primers (Fermentas). 2 µl of the 
resulting cDNA was amplified in a 20 µl reaction using Brilliant III ultrafast qPCR master 
mix reagents (Agilent). Dual labelled (FAM/BHQ1) hybridisation probes (Eurofins) 
specific to each of the cDNAs of interest were used to detect PCR products. The 
sequences of primers and probes can been seen in Table 2.02. Forward and reverse 
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primers were used at 225 nM, and dual-labeled probes were used at a concentration 
of 500 nM. Primers and probes were designed using Beacon Designer software 
(Premier Biosoft). PCR was performed using an Mx3000P platform (Agilent). The PCR 
profile used consisted of: 45 cycles of 95⁰C for 12 seconds, 60⁰C for 35 seconds. 
Standard curves were generated for every PCR run with each primer/probe set using 
serial five-fold dilutions of adult mouse brain RT RNA (Zyagen). Bmpr1a, Bmpr1b, 
Bmpr2, Acvr2a, Ngf and Gdf5 mRNAs were expressed relative to the geometric mean 
of the reference mRNAs Gapdh, Sdha and Hprt1. The use of geometric means provides 
an average for multiple internal controls, in this case multiple reference genes321. 
2.6 Immunocytochemistry 
Immunocytochemistry was used to localise the expression of GDF5 receptors in 
cultured SCG neurons. P0 SCG cultures were established in 35ml cell culture dishes and 
incubated, at 37°C in 5% CO2, for 16hrs. At the end of this culture period, the cell 
culture media was diluted 2 fold with 8% paraformaldehyde (PFA) (Sigma) and cultures 
were incubated at room temperature for 5 minutes to partially fix the neurons. 
Following this, the media containing PFA was aspirated and replaced with 1 ml of 4% 
PFA and the partially fixed neurons were incubated for a further 5 minutes at room 
temperature. After fixation, the PFA was removed from the cell culture dishes and the 
neurons were washed 3 times with PBS (Sigma) for 5 minutes each time. Fixed, washed 
neurons were then incubated for 1 hour, at room temperature, in 1 ml of PBS solution 
containing 5% bovine serum albumin (BSA) and 0.1% Triton X-100. This enabled 
simultaneous blocking of non-specific antibody interactions and permeabilization of 
the neurons. Following the blocking/permeabilization step, neurons were washed 3 
times, for 5 minutes each time, with PBS. Primary antibodies were then added to the 
neurons in 1 ml of PBS containing 1% BSA and 0.1% Triton X-100 and incubated 
overnight at 4⁰C. See table 2.03 for primary antibody dilutions.  
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Antibody Species and Type Dilution Company and 
Product number 
GDF5 Rabbit, Polyclonal IgG 1:200 Abcam, ab93855 
BMPR-1a Rabbit, Polyclonal IgG 1:200 Abcam, ab38560 
BMPR-1b Rabbit, Polyclonal IgG 1:200 Abcam, ab175365 
BMPR-2 Rabbit, Polyclonal IgG 1:200 Abcam, 124463 
Activin-receptor 2a Rabbit, Polyclonal IgG 1:200 Abcam, ab96793 
β-III tubulin Chicken, Polyclonal IgY 1:500 Abcam, ab41489 
Tyrosine Hydroxylase Rabbit, Polyclonal IgG 1:200 Merck-Millipore, AB152 
Alexa Fluor 488 anti-rabbit  Goat, Polyconal IgG 1:500 Invitrogen, A-1108 
Alex Fluor 594 anti-Chicken Goat, Polyclonal IgY 1:500 Abcam, ab150172 
Anti-Rabbit (H+L), HRP 
Conjugate 
Donkey, Polyclonal, IgG 1:300 Promega, W4011 
Table 2.03: Primary and Secondary antibodies used for immunocytochemistry and 
immunohistochemistry. 
After the primary antibody incubation, neurons were washed 5 times, for 5 minutes 
each time, in PBS. Next, secondary antibodies were added in 1 ml of PBS containing 1% 
BSA and 0.1% Triton X-100 and incubated, for 1 hour at room temperature, in the dark. 
The dilutions of the secondary antibodies that were used can be seen in table 2.03. At 
the end of the 1hr incubation, the secondary antibody was aspirated, neurons were 
washed (3 X 5 minutes) with PBS and 1 ml of PBS with TOTO-3 (1:10000, Invitrogen) or 
DAPI (1:10000, Invitrogen) was applied for 10 minutes. Next, the PBS containing TOTO-
3/DAPI was removed and the neurons were washed 3 times with PBS for 5 minutes 
each time. Stained neurons were visualised using a LSM 710 confocal microscope 
(Zeiss), running ZEN black software (Zeiss). 
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2.7 Immunohistochemistry 
2.7.1 Preparation and sectioning of tissue sections 
SCG target issues were collected in 10ml plastic tubes and fixed in 4% PFA, overnight, 
at 4⁰C. The tissues were then washed once in PBS prior to being cryo-protected in 30% 
sucrose, at 4⁰C, for up to 48 hours, or until the tissues had sunk in 30% sucrose 
solution. The tissues were then transferred to plastic molds (Polysciences Inc) and 
embedded in OCT (Tissue-Tek). The molds containing tissue and OCT were snap frozen 
in 2-methylbutan/iso-Pentan (Fisher scientific) in a metallic crucible surrounded by dry 
ice. Once frozen, the molds were wrapped in tin foil and stored at -80⁰C. Prior to 
sectioning, the molds were transferred to the cryostat (Leica) for a period of at least 1 
hour to equilibrate to -20°C. After removing the OCT/tissue blocks from the molds, 
they were mounted on cryostat chucks and cut down with a scalpel to remove 
unnecessary OCT. The mounted blocks were then left for a further 1 hour to 
equilibrate before sectioning. SCG target tissues were cut on the cryostat in 15 μm 
serial sections and mounted on Xtra adhesive slides (Leica). Slides were left to dry 
overnight at room temperature before being stored at -80⁰C. 
2.7.2 Staining using fluorescent antibodies  
Slides containing tissue sections were removed from the -80⁰C freezer and left to 
thaw. They were then washed once with PBS to remove excess OCT. 1 ml of a PBS 
blocking solution containing 5% BSA and 0.1% Triton X-100 was added to the slides and 
incubated for 1 hour at room temperature. Following the 1 hour blocking step, slides 
were washed 3 times with PBS before applying 1 ml of primary antibodies, 
appropriately diluted in PBS containing 1% BSA and 0.1% Triton X-100 (see table 2.03 
for antibody dilutions), and covering the slides with parafilm to prevent evaporation. 
Slides containing primary antibodies were incubated at room temperature overnight. 
After the overnight incubation, parafilm was removed from the slides and they were 
washed 3 times with PBS. Next, 1 ml of fluorophore conjugated secondary antibodies,  
diluted in PBS containing 1% BSA and 0.1% Triton X-100,  was applied to the slides and 
the slides were incubated at room temperature for 1 hour. The slides were then 
washed a further 3 times with PBS before VectorShield (Vector labs) hard mount was 
used to cover the stained tissue with a coverslip. Coverslip mounted slides were left to 
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dry overnight, in the dark, at room temperature. Fluorescence images were acquired 
on a LSM 510 confocal laser scanning microscope (Zeiss) running LSM 510 imaging 
software.  
2.7.3 Semi-quantitative analysis of SCG target field 
innervation  
The nasal mucosa, iris and submandibular gland (SMG) were collected from P10 
Gdf5bp/bp, Gdf5+/bp and Gdf5+/+ mice and fixed and processed as described above. The 
tissue was then stained using a primary TH antibody (Merck-Millipore, see table 2.03) 
and a secondary Alexa Flour 488 antibody (Invitrogen, see table 2.03). Images were 
acquired using a LSM 510 confocal microscope (Zeiss), running LSM software. Image 
analysis was conducted using NIH-ImageJ as previously described153, 169, 322. First, target 
images were converted to grey scale using NIH-ImageJ. Conversion of images to 
greyscale enables the intensity of the staining per pixel to be represented from a scale 
of 0 to 255 on an image histogram, where 0 represents a pure black background and 
255 a pure white background. Second, a random sample of 3 to 5 images from each 
condition was selected and a Gaussian Blur correction was applied to each image. In 
addition to blurring the image, Gaussian Blur correction has the effect of reducing 
image noise, helping to remove potential outliers during subsequent steps of image 
analysis. Next, a threshold for each random image was determined by using the image 
histogram to remove pixels below a minimum intensity. The maximum intensity of the 
pixels of each image was left at 255. The minimum intensity is unique to each 
individual image and is set manually by the experimenter using their best judgement to 
ensure the final minimum pixel threshold corresponds as accurately to the staining 
intensity as possible. The values of the Gaussian blur and minimum pixel intensity for 
each random image were then recorded in Microsoft Excel, and the values for all 
random images were averaged, thereby providing an average Gaussian blur value for 
the whole experimental cohort of images, as well as the minimum threshold intensity 
to be applied to all images in the experimental cohort. The advantage of this approach 
is that it removes experimental bias generated by manually manipulating each 
experimental image during the course of the analysis. The area of an image analysed 
was defined by the experimenter. For the SMG, random regions of interest were 
chosen with the caveat that an edge of the tissue had to be visible in the region of the 
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image being analysed. For the iris images, quadrants of each section of iris were 
chosen and analysed. By quantifying only the defined areas it enables the analysis to 
be standardised across animals. An average for TH-positive fibres was then determined 
per section of analysed area and this was then used to calculate the percentage of TH 
positive fibres per animal. The data were tabulated and expressed as a percentage of 
wild type data.  
2.8 Whole mount immunostaining 
Whole mount staining using an anti-TH antibody was used to analyse the sympathetic 
innervation of the pineal gland, heart and trachea in Gdf5+/+, Gdf5+/bp and Gdf5bp/bp. 
Tissues were collected at P10 from Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice. Once 
dissected, tissues were fixed, for 24 hours at 4⁰C, in 4% PFA. The PFA was then 
aspirated and replaced with fresh 4% PFA followed by a 1 hour incubation at room 
temperature. The fixed samples were transferred into 50% methanol (MeOH), for 1 
hour at room temperature, to dehydrate them and then transferred into 80% MeOH 
for a further 1 hour. Next, samples were put into 80% MeOH/20% DMSO/3% H202 and 
incubated overnight, at 4⁰C, to quench the activity of endogenous peroxidases. 
Following the overnight quenching step, samples were rehydrated by a room 
temperature incubation in 50% MeOH for 1 hour followed by a similar incubation in 
30% MeOH. After rehydration, samples were transferred to PBS for 1 hour at room 
temperature before being left overnight, at 4°C, in a blocking solution of PBS 
containing 4% BSA and 1% Triton X-100. Samples were then incubated with anti-TH 
antibody diluted in blocking solution (see table 2.03) for 72 hours, at 4⁰C. After the 
primary antibody incubation, samples were washed 3 times at room temperature in a 
PBS solution containing 1% Triton X-100, with each wash lasting 2 hours. Following a 
fourth overnight wash, at 4°C, with PBS containing 1% Triton X-100, the samples were 
incubated, overnight at 4°C, with an anti-rabbit HRP conjugated secondary antibody 
diluted in blocking solution (see table 2.03). The next day, three 2 hour, room 
temperature washes in PBS containing 1% Triton X-100 were used to remove unbound 
secondary antibody. All the incubation and washing steps were carried out on a 
shaking table.  
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DAB-HRP staining enabled visualisation of TH fibres in the samples. Samples were 
incubated in 1 X DAB (Sigma), for 20 minutes at room temperature, before being 
transferred to DAB containing 0.006% H202. When the staining intensity of anti-TH 
labelled fibres had developed sufficiently (3-5 minutes), the samples were washed 3 
times in PBS before being left overnight, at 4°C, in PBS. BABB (1 part benzyl alcohol 
(Sigma): 2 parts benzyl benzoate (Sigma)) was used to clear the samples. Samples were 
dehydrated, at room temperature, by washing in 50% MeOH for 10 minutes followed 
by a 30 minute wash and two 20 minute washes in 100% MeOH. Samples were then 
transferred to 1 part MeOH: 1 part BABB for 5 minutes, before finally being placed in 
100% BABB (Sigma).  
Samples were imaged using a phase contrast microscope (Nikon). For each sample 
tissue, the area imaged was standardised across the samples by using anatomical 
landmarks. For the pineal gland this was the axon bundle entering the gland. For the 
trachea, the landmark was the lateral axon bundle and for the heart it was axon 
bundles in the left ventricle. To analyse the extent of neuron branching a modified 
line-intercept method was employed. Images were processed in NIH-ImageJ, where 
they were converted into 8-bit grey scale images that allows fibres to be clearly 
differentiated, and thus counted.  Using NIH-ImageJ, a 4*6 grid of side length 158 μm 
was aligned in a standard orientation to analyse innervation of the trachea and heart 
and a 6*6 grid with a side length of 50 μm was used to analyse innervation of the 
pineal gland. The number of fibre bundles intersecting the sides of squares in the grid 
was scored blind for the tissues from each animal. Fibre density was estimated using 
the formula πDI/2, where ‘D’ is the interline interval (158 or 50) and ‘I’ the mean 
number of intersections of fibres along one side of each square in the grid. π is used to 
construct the boundary of an arc that intersects with two adjacent parallel lines, thus 
enabling the length of fibres to be determined upon the grid. This method in a 
variation of the same analysis procedure used to calculate length of neurites in the 
microfluidic chambers (see section 2.4). The data are expressed as a percentage of the 
mean wild type data. 
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2.9 MRI analysis of hippocampus anatomy and 
cerebellum 
In order to determine if there were any anatomical differences between the 
hippocampus and cerebellum of Gdf5bp/bp, Gdf5+/bp and WT C57/B6 (Gdf5+/+) mice of a 
mixed gender, at both P10 and 6 months of age, brains, still within the skull,  were 
imaged using a Bruker Biospin Advance 9.4T (400MHz) MRI system (Ettlingen).  Whilst 
submerging small pieces of tissues in 4% PFA is effective in fixing tissue, with larger 
organs, such as the brain, not all of the tissue is fixed evenly, as the fixative is not able 
to suitably and evenly penetrate the whole tissue. As the brains needed to be fixed and 
kept within the skull, the animals were perfused. Mice were first anaesthetized by 
intraperitoneal injection with either 0.1ml of Euthatal for adult mice or 0.03ml for P10 
mice. Once the mice were fully anaesthetized, as determined by ensuring they were 
completely unresponsive to a toe-pinch, a lateral incision was made through the 
integument and abdominal wall beneath the rib cage. A further cut was made in the 
diaphragm wall, and along the length of one side of the rib cage, in order to expose the 
pleural cavity. Next a cut was made along the rib cage up to the collar bone. This cut 
was then repeated on the contralateral side of the mouse, allowing the rib cage to be 
removed to expose the heart, along with any connective tissue and the thymus. Next, 
an incision was made in the posterior of the left ventricle and a needle was passed into 
the incision, through the ventricle, and into the aorta. A final incision was made into 
the animals right atrium allowing blood and perfusion solutions a channel through 
which to drain. Mice were then perfused for 2 minutes with PBS, followed by 4% PFA 
for 5 minutes. Following this, perfused mice were decapitated and the skin was 
removed around the skull. The brain in the skull was then immersed in 4% PFA for 24 
hours before being transferred to a 25% sucrose solution. 5 days prior to scanning, the 
brain and skulls were washed by immersing in fresh high grade PBS (Sigma-Aldrich), 
which had been filtered by the manufacturer using a 0.2 µm filter to provide sterility 
and high quality consistency across batches, daily for 5 days. The washing step 
removes any loose tissue and other contaminants which could be a source of 
unnecessary background in the MRI images. On the day of scanning, the brains and 
skull were soaked in Fluorinert (Acota), a proton free fluid which acts to reduce 
background signals produced during the MRI scan protocols. The skulls were 
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positioned under a 4 channel phased array receive surface coil within a 72mm 
diameter transmit-receive coil, set to transmit only. The 4 channels refers to the 
receivers/detectors used to detect the radio frequency (RF) generated by the MRI 
scan, the more channels a system has the quicker the acquisition time of the MRI scan. 
An MRI coil is essentially a loop of wire that is placed over the region being 
investigated in order to create the magnetic field. A phased array coil is able to focus 
its magnetic field depending on the sample being scanned, as opposed to a fixed coil 
which cannot be modulated to produce different magnetic fields. A transmit-receive 
coil can act as a transmitter to produce a RF field to focus the MRI signal, as well as 
receiver which can detect the RF signal produced by the MRI scan. For each animal, a 
rapid acquisition with relaxation enhancement (RARE) scan with a RARE factor of 4 was 
collected with the following weighting: repetition time 1.75 seconds (how many time 
each line of the image was scanned); echo time 17.5 ms (the duration between echo 
spins); field of view of 1.54cm (the region of interest analysed by scan frame); matrix 
size of 256*256*256 (how the field of view is divided into rows and columns).  A RARE 
factor of 4 means that the spin echo, which is the refocussing of the spin 
magnetisation by a pulse of RF, is detected a total of 4 times per line, column and 
frame of the images acquired. 3D images were acquired with a final resolution of 
60μm, which is determined as a function of the slice thickness, field of view, and 
matrix size. Therefore the in-plane resolution of an MRI image is a function of field of 
view/ matrix size. Total scan time was 16 hours and 48 minutes (scans were run 
overnight).  
Acquired MRI images were analysed in Analyze 10.0 (Biomedical Image Resource), 
where the total area of the brain, hippocampus and cerebellum were manually traced 
per slice of the image in order to reconstruct a 3D image in which the total volumes of 
these regions could be calculated. The percentage ratio of the hippocampus volume 
and cerebellum volume (mm3) to the total brain volume (mm3) was the calculated 
using the formula; hippocampus or cerebellar to brain volume (mm3) percentage ratio 
= (hippocampal or cerebellum volume (mm3) / total brain volume (mm3))*100. This 
hippocampus or cerebellar to brain volume (mm3) percentage ratio was then used to 
compare between the genotypes, to see if there was any statistical difference between 
the gross anatomy of the hippocampus and cerebellum. 
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2.10 Data Analysis.  
Statistical analysis was performed using R (The R Foundation for Statistical Computing). 
Where data was normally distributed, a Student’s t-test was applied, when only 
comparing 2 conditions, or a one way ANOVA was used to determine significance 
between 3 or more conditions. A Tukey’s HSD post-hoc test was deployed to compare 
significance between conditions. If the data was not normally distributed, either 
Mann-Whitney U tests were used to compare between 2 conditions or Kruskal-Wallis 
tests were used to compare between 3 or more conditions.  
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3.1 Introduction 
3.1.1 The anatomy of the hippocampus, its development and 
neurotrophic factor requirements 
The hippocampus is a major part of the limbic system and plays an important role in 
both short- and long-term memory, learning and spatial navigation. Damage to the 
hippocampus can result in anterograde amnesia: the inability to form new 
memories323. A number of neuropathological conditions, including Alzheimer’s disease 
and post-traumatic stress disorder, are primarily due to compromised hippocampal 
neuron function2 . In rodents, the hippocampus is a banana shaped forebrain structure 
with its dorsal aspect lying behind the septum. The hippocampus bends laterally and 
ventrally away from the septum, resulting in its ventral aspect lying in the temporal 
region of the rodent brain (figure 3.01). The hippocampi of the right and left cerebral 
hemispheres are connected by the hippocampal commissure that crosses the midline 
under the anterior corpus callosum. The rodent hippocampus is composed of 3 
regions, the CA1, CA2, and CA3 fields, that are a mixture of densely packed pyramidal 
neurons, interneurons and glial cells (Figure 3.02). The CA2 region is a small 
transitional region between the CA1 and CA3324. The hippocampal formation includes 
the hippocampus, dentate gyrus (DG) and the subiculum. Adjacent to the subiculum is 
the presubiculum, which connects, via the parasubiculum, to the entorhinal cortex 
(EC). 
The basic hippocampal circuit is a tri-synaptic loop involving the DG, CA3 and CA1 
regions2. The major input into the DG is from the layer II of the EC via performant 
pathway axons that make connections to the dendrites of DG granule cells. DG granule 
cells project axons (called mossy fibres) that innervate the dendrites of CA3 region 
pyramidal neurons. CA3 pyramidal neuron axons project to the dendrites of CA1 region 
pyramidal neurons and, in turn, CA1 pyramidal neurons extend axons out of the 
hippocampus, through the subiculum, and back into the EC. Despite the fact that they 
arise from a common population of precursor cells, pyramidal neurons of the different 
CA fields have distinctly different phenotypes from one another, with stark differences 
in their cyto-architecture, axonal projections and the incoming synaptic connections 
that they receive. The distinction between the neurons in these two CA fields arises 
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due to interactions between the neurons themselves and their local environment324-
326. 
  
Figure 3.01: Diagram showing the position of the left hippocampus of the rat. All forebrain 
structures are missing except those of the midline(from O’Keefe and Nadel, 1978327).  
 
Figure 3.02: Structure of the adult rat hippocampus. Camera lucida drawing through a 
coronal section of the adult rat hippocampus stained for Nissl substance. Sub, subiculum; DG, 
dentate gyrus, D; dorsal; L, lateral. Arrows indicate boundaries between major fields (from 
Grove and Tole, 1999324).  
During development, the hippocampal primordium arises from the dorso-medial 
telencephalon325, 327. The primordium comprises highly active proliferating cells with 
well characterised patterns of gene expression, which subsequently correspond with 
adult neuronal marker expression in the mature hippocampus324, 325. In the rat, 
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pyramidal neurons in each region of the hippocampus begin to differentiate and 
migrate to their respective positions in sequential, but overlapping, waves from 
embryonic day 15 (E15)328. In the mouse brain, CA3 pyramidal neurons are generated 
between E14 and E15 and CA1 neurons between E15-E16. Migration and maturation of 
these pyramidal neurons occurs from E15-E18.5329, 330. 
Pyramidal neurons have a single axon, multiple elaborate dendrites and a triangular 
soma (figure 3.03, stage 5). Mature hippocampal pyramidal neuron dendrites have 
numerous small processes called spines, which act to increase the dendritic surface 
area available for synaptic contact331. The axons of pyramidal neurons differ from 
dendrites in both morphology and function. Polyribosomes and mRNA are abundant in 
the somatodendritic compartment, but barely detectable in the axon332. Microtubule 
orientation within axons is uniform, with the plus ends distal to the neuron soma, 
whereas dendritic microtubules, when they are present, are orientated in both 
directions333, 334. The distribution of microtubule associated proteins is also different 
between the two process types, with tau found in the axons and MAP-2 in the 
somatodendritic compartment 335.  
 
Figure 3.03: The 5 stages of development of hippocampal neurons in vitro. Each stage 
corresponds to a number of days in culture(from Dotti et al., 1988336). 
The dendritic morphology of pyramidal neurons within the developing rodent 
hippocampus remains relatively simple until afferents begin forming synapses between 
P3 to P5. By P20 in the rat, pyramidal neuron dendrites have fully acquired their 
mature, complex and elaborate dendritic morphology337, 338. The development of 
hippocampal neurons follows 5 well-characterized stages in culture (Figure 3.03)336. 
Shortly after hippocampal neurons are plated, lamellipodia begin to form around the 
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cell bodies (Stage 1). After 12 hours in culture, the lamellipodia start to develop into 
minor processes (Stage 2). From 12-24 hours, neurons undergo initial polarization and 
by 1.5 days in vitro (DIVs) it is possible to distinguish the axon that has started to grow 
from one of the minor processes (Stage 3). By 4 DIVs, the remaining neuritic processes 
begin to develop into dendrites (Stage 4). At 7 DIVs, cultured hippocampal neurons 
display mature morphology and start to establish synaptic connections with their 
neighbouring neurons (Stage 5). The rate of axonal elongation is 5 to 10 times greater 
than the rate of dendritic growth.336. 
Although NGF mRNA expression within the CNS is highest in the cortex and 
hippocampus, a CNS specific conditional deletion of TrkA and NGF has revealed that, in 
contradiction to the neurotrophic factor hypothesis, basal forebrain cholinergic 
neurons that innervate the hippocampus do not require NGF for survival during 
development339, 340. NGF, however, is required for the development of the correct 
cholinergic circuitry of the hippocampus, and for the acquisition of a cholinergic 
phenotype by basal forebrain cholinergic neurons. In addition, cultured embryonic rat 
hippocampal pyramidal neurons can be rescued from glutamate or staurosporine 
induced apoptosis by the addition of NGF to cultures. The anti-apoptotic effects of NGF 
require both TrkA and p75NTR signalling341. NGF also promotes axon elongation in 
cultures of embryonic hippocampal neurons by a p75 dependent signalling pathway342. 
BDNF appears to promote the survival of developing hippocampal neurons by an 
autocrine mechanism. Hippocampal neuron cultures established from BDNF null 
mutant mouse embryos show reduced survival compared to wild type controls, and 
BDNF is required to support the survival of rat embryo hippocampal neurons in low 
density cultures, but not high density cultures343. BDNF has many other important 
roles in the developing hippocampus including, regulating dendrite number and 
complexity and promoting synapse formation and maturation344. BDNF is vital for 
synaptic plasticity, long term potentiation and long term depression in the postnatal 
rodent hippocampus, and is likely involved in memory acquisition345, 346. Interestingly, 
mice made to perform spatial memory tasks display a strong up-regulation of BDNF 
expression in the hippocampus347.  
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Members of the TNF and the transforming growth factor β (TGF-β) super-families have 
also been shown to play important roles in regulating the development of the 
hippocampus. For example TNFα, which is expressed by microglia and astrocytes in the 
adult brain following injury, infection or ischemia, is also expressed by neurons in the 
developing brain 348-350. TNFα can signal via either of two TNFR superfamily members, 
TNFRI or TNFRII351. TNFRI has an intracellular death domain and it has been shown to 
mediate TNFα induced apoptosis in cultures of E15 hippocampal cultures352. TNFα has 
also been shown to reduce process outgrowth and branching from cultured E16 mouse 
hippocampal neurons353. In contrast to TNFα, TGF-β has been shown to be neuro-
protective for hippocampal neurons354. For example, TGF-β protects cultured neonatal 
rat hippocampal neurons from staurosporine induced apoptosis by inhibiting the 
conversion of pro-caspase-3 to active caspase-3355.  
Some recent data from our lab has revealed that GDF-5 is required for the correct 
development of hippocampal neuron dendrites318. Hippocampal pyramidal neurons 
express GDF5 and its receptors, BMPR1B and BMPR2, and GDF5 greatly increases 
dendritic growth, but not axonal growth, from cultured E18 hippocampal neurons. 
GDF5 induced enhancement of dendritic growth from cultured pyramidal neurons is 
mediated by canonical Smad 1/5/8 signalling and Smad mediated upregulation of the 
transcription factor, HES5. The physiological relevance of these in vitro findings has 
been confirmed by the observation that the apical and basal dendritic arbors of CA1 
and CA3 pyramidal neurons are dramatically less elaborate in postnatal Gdf5bp/bp mice 
than they are in wild type control mice318. Moreover, preliminary data356 suggests that 
GDF5 deficiency results in a significantly smaller and morphologically abnormal 
hippocampus, raising the possibility that GDF5 may play a role in regulating some 
other aspect of hippocampal neuron development, such as: progenitor proliferation 
and/or differentiation, hippocampal neuron migration or hippocampal neuron survival.   
3.1.2 The anatomy of the cerebellum, its development and 
neurotrophic factor requirements  
The cerebellum plays an essential role in coordinating motor control and also appears 
to be involved in modulating non-motor functions, such as: attention, language and 
mood357. The cerebellum, which is located behind the pons, medulla and fourth 
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ventricle, is connected to the pons via three cerebellar peduncles (figure 3.04). The 
inferior and middle cerebellar peduncles are mainly afferents, whereas the superior 
cerebellar peduncle is composed mainly of efferent fibres4. The cerebellum has 
extensive connections with motor areas of the forebrain, midbrain, hindbrain and 
spinal cord, as well as connections with non-motor areas of the cerebrum, such as the 
limbic system and prefrontal cortex which are linked with emotional processing. The 
outside of the cerebellum comprises the highly folded cerebellar cortex. Beneath the 
cortex is the cerebellar white matter, a network of mostly myelinated axons that relay 
information to and from the cerebellum. Embedded within the white matter are three 
pairs of cerebellar nuclei that provide almost all of the efferent fibre output from the 
cerebellum2.  
 
Figure 3.04: Diagram showing the location of the cerebellum relative to other brain regions 
in the mouse brain (taken and adapted from Zhang and Chow, 2014358) 
The highly folded outer cortical layer of the cerebellum has major two transverse 
fissures, which divide the cerebellum into the anterior, posterior and flocculonodular 
lobes, and many shallow grooves, called folia. The folia and fissures increase the 
surface are of the cerebellum much like the gyri of the cerebral cortex increase its 
surface area. The folia and fissures run uninterrupted transversely across the midline 
of the cerebellum. However, the vermis, a depression along the midline of the 
cerebellum, divides the lobes into two hemispheres (figure 3.05). The vermis, and 
associated intermediate regions of each hemisphere are called the spinocerebellum 
and the lateral regions of each hemisphere are termed the cerebrocerebellum. The 
spinocerebellum regulates conscious and non-conscious (e.g. balance and posture) 
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body and limb movements and primarily receives afferent input from neurons of the 
medullary lateral cuneate nucleus that relay proprioceptive information carried by the 
spinocerebellar tracts. In addition, the spinocerebellum receives input from the 
auditory, visual and vestibular systems2. Efferents from spinocerebellar nuclei 
associated with the vermis project to vestibular and reticular motor nuclei that 
regulate the descending vestibulospinal and reticulospinal extra-pyramidal motor 
pathways, thereby regulating non-conscious activity of proximal limb and axial 
muscles, respectively. Vermis output is also to the cortex, via the thalamus, to 
coordinate corticospinal tract output to the lower motor neurons that innervate 
muscles of the axial and proximal limbs. Efferents from spinocerebellar nuclei 
associated with the intermediate region of the cerebral hemispheres innervate either 
the brain stem red nucleus or the cortex, via the thalamus, to coordinate conscious 
movement of distal limb muscles by neurons of the rubro-spinal and corticospinal 
tracts2.  
The cerebrocerebellum uses sensory information to plan motor movements and 
execute them with speed, precision and dexterity.  The cerebrocerebellum receives 
afferent input from motor and pre-motor cortices and sensory and sensory association 
cortices via the pontine nuclei2. Cerebellar nuclei associated with the 
cerebrocerebellum project efferents back to the motor and pre-motor cortices via the 
thalamus2. The flocculonodular lobe, or vestibulocerebellum, regulates balance and 
coordinates head and eye movements. The vestibulocerebellum receives direct 
vestibular input form the vestibular canals and indirect input from the vestibular 
nuclei. In addition, the vestibulocerebellum receives indirect visual input, via the 
pontine nuclei, from the thalamus, superior colliculi and visual cortex. Efferents from 
the cerebellar nuclei associated with the vestibulocerebellum project to the vestibular 
nuclei to coordinate output from the extra-pyramidal vestibulospinal motor pathway2. 
At the cellular level, the cerebellar cortex is a simple structure made up of three 
distinct layers that contain only five different types of neurons: stellate, basket, 
Purkinje, Golgi and granule cells359. Adjacent to the cerebellar white matter is the 
granule cell layer (GCL) that contains tightly packed small granule cells and a few larger 
Golgi cells. Above the GCL is the Purkinje cell layer (PCL) that contains a single layer of 
large Purkinje neurons that have extensive dendritic trees that extend into the 
Chapter 3                                               The role of GDF5 in the development of the hippocampus and cerebellum 
117 
 
outermost layer of the cerebellar cortex, the molecular layer (ML). Purkinje neurons 
are inhibitory, using 𝛾 aminobutyric acid (GABA) as their neurotransmitter, and project 
axons down through the underlying cerebellar white matter to synapse with neurons 
of the cerebellar nuclei359. The ML mainly contains axons of granule cells of the GCL 
that are termed parallel fibres and run perpendicular to the ascending fibres that 
provide afferent input to the cerebellar cortex. The ML also contains scattered stellate 
and basket cells.  
 
 
Figure 3.05: The different cell layers of the cerebellar cortex. Whilst the molecular layer (ML) 
contains some interneurons, it predominantly contains axons (parallel fibres) arising from cells 
of the granule cell layer (GL) and dendrites of Purkinje neurons within the Purkinje cell layer 
(PCL). Excitatory input to Purkinje neurons is either direct, from ascending fibres, or indirect 
from Mossy fibres. Beneath the GCL is the cerebellar white matter containing myelinated 
afferent and efferent fibres (adapted from Apps and Garwicz, 2005360). 
The activity of Purkinje neurons, that provide the only output from the cerebellar 
cortex, is regulated by two types of afferent excitatory inputs, mossy fibres and 
ascending fibres. In addition to providing excitatory input to Purkinje neurons, mossy 
fibres and ascending fibres have collateral branches that innervate the cerebellar 
nuclei. The activity of neurons within cerebellar nuclei is, therefore, determined by the 
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balance between the excitatory input from mossy and ascending fibres and the 
inhibitory input from Purkinje cells359. Mossy fibres originate from neurons within a 
number of brainstem nuclei and influence Purkinje neurons indirectly by synapsing 
with excitatory granule cells in the GCL. Granule cell axons project to the molecular 
layer where they bifurcate to form the parallel fibres that provide excitatory input to 
the dendrites of multiple Purkinje neurons. Ascending fibres originate from neurons 
within the inferior olivary nucleus of the medulla and make direct connections with 
Purkinje neuron soma and dendrites. In contrast to granule cell input, where individual 
Purkinje neurons receive input from multiple parallel fibres arising from multiple 
granule cells, Purkinje cells receive synaptic input from only one ascending fibre. In 
addition to excitatory input from ascending fibres and granule cells, Purkinje neurons 
receive inhibitory input from three interneurons: stellate and basket cells in the ML 
and Golgi cells in the GCL359. 
The development of cerebellum begins at around E8.5 in the mouse, with the 
cerebellar anlage arising from rhombomere 1 at the boundary between the hindbrain 
and midbrain361. At this age, rhombomere 1 is characterised by the fact that it does not 
express the midbrain specifying transcription factor, Otx2, or the hindbrain specifying 
transcription factor, Hoxa2, rather it expresses the transcription factor Gbx2 that is 
essential for cerebellum formation. There are two germinal zones from which cells of 
the cerebellum arise in a coordinated temporal sequence. The first of these is the 
ventricular zone, located along the dorsal surface of the fourth ventricle, which 
generates Ptf1a-positive progenitors that will become the GABAergic neurons of the 
cerebellum; Purkinje neurons, basket cells, Golgi cells, stellate cells, and inhibitory 
neurons of the cerebellar nuclei 359, 361, 362. Between E11-E13 Purkinje cells in the 
ventricular zone become postmitotic and migrate along radial glial cells to transiently 
form a multi layered tissue beneath the emerging external germinal layer (EGL). 
Around birth, Purkinje cells disperse from the multilayer structure to form a monolayer 
that becomes the mature Purkinje cell layer359. The other germinal zone is the rhombic 
lip, the most dorsal interface between neural and non-neural roof plate tissue, which 
generates Atoh1-positive progenitors that will give rise to glutamatergic granule cells 
and excitatory cerebellar nuclei neurons. Granule cell precursor migrate from the 
rhombic lip over the surface of the developing cerebellar anlage to form the EGL, 
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reaching it at around E13 in mice359. Granule cell precursors in the mouse EGL remain 
mitotically active until the second postnatal week with the peak of proliferation seen 
around P8. Shortly after birth, the first granule cell precursors differentiate in the deep 
EGL, exiting the cell cycle, growing processes and migrating from the medial to lateral 
region of the EGL (tangential migration). Following tangential migration, granule cells 
migrate radially along the processes of Bergmann glia cells, through the developing 
Purkinje cell layer, to form the granule cell layer. The phase of differentiation and 
migration is complete by P20, by which point the external granular layer has 
dispersed359. Progenitors of the inhibitory and excitatory neurons of the cerebellar 
nuclei migrate from the ventricular zone and rhombic lip, respectively, from E10 to E12 
to reach their correct positions. Ventricular zone cerebellar nuclei progenitors migrate 
radially to their final position, much like Purkinje cells. In contrast, rhombic lip 
excitatory cerebellar nuclei progenitors migrate over the surface of the developing 
cerebellum before radial migration to their correct position359, 361. 
There are multiple secreted factors which are important in the development of the 
cerebellum. FGF8, secreted by cells of Rhombomere 1, is required for correct midbrain 
and cerebellum development. In zebrafish the loss of FGF8 function causes a severe 
phenotype resulting in the loss of the cerebellum363. Double knockout FGF8 and FGF17 
mice show a complete absence of vermis lobe III364. In addition, FGF8neo mice, 
expressing a hypomorphic FGF protein, display a complete absence of the cerebellum 
at E18.5365. Moreover, Overexpression of FGF8 in chick, by in ovo electroporation of a 
cDNA construct encoding FGF8 at Hamburger-Hamilton stage 10, results in the loss of 
the midbrain and an enlarged cerebellum366, 367. Overexpression of FGF8 decreases the 
expression of the midbrain specifying transcription factor, Otx2, leading to the 
conclusion that FGF8 promotes cerebellum development by supressing the expression 
of Otx2 in rhombomere1, thereby preventing rhombomere 1 developing into midbrain 
tissue361, 366. BDNF appears to regulate the migration of post-mitotic granule cell 
precursor from the EGL to the granule cell layer362. There is a shallow BDNF gradient 
within the developing cerebellum, such that the expression of BDNF is 2-fold higher in 
the granule cell layer than the EGL during the time of active migration. In addition, 
BDNF promotes the secretion of BDNF from the leading edge of migrating granule 
cells, thereby amplifying the local BDNF gradient. Moreover, BDNF results in an 
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accumulation of the BDNF receptor, TrkB at the leading edge of migrating cells and 
BDNF null mutant post-mitotic granule cell precursors show migration deficits362. 
Smad2, an R-Smad associated with type 1 TGF-β/activin receptors, appears to be a 
negative regulator of axon growth from cultured P6 rat cerebellar granule cells368. 
Smad2 is basally phosphorylated and active in postnatal rat cerebellar granule cells 
and inhibition of Smad2 activity, by a number of different approaches, significantly 
increases axon growth from these cells in vitro368. Whilst the identity of the type 1 
receptor and TGF-β ligand that normally activate Smad2 in granule cells is not known, 
TGF-β2 has been shown to be expressed by rodent granule cells within the GCL and 
EGL and Purkinje neurons within the PCL369,370. The surface of the cerebellum is 
smooth during the earliest stages of its development; however, the grooves of the folia 
have begun to appear by E17 in the mouse and they become deeper as development 
proceeds359, 366. The folia are thought to form due to a combination of the anchorage 
of some neurons of the Purkinje cell layer to neurons of the cerebellar nuclei by their 
axons and the massive expansion of granule cells by progenitor cell proliferation. Shh is 
expressed by Purkinje cells, and initial in vitro and in vivo studies have revealed that 
Shh can promote the proliferation of cultured granule cell progenitors, and that 
injection of a blocking antibody against Shh into the developing cerebellum can inhibit 
granule cell progenitor proliferation. In addition, a conditional knockout of Shh 
expression in the cerebellum of mice has demonstrated a requirement for Shh for 
granule cell progenitor proliferation and the necessity of this proliferation for 
cerebellar foliation359.  
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3.1.3 Aims 
Previous work by a former lab member, Dr Catarina Osório356 has demonstrated that 
there is a marked decrease in the total area occupied by the hippocampus and the 
area of the CA fields between Gdf5bp/bp and Gdf5+/+ P10 mice. In contrast, there is not a 
difference in the area occupied by the whole cerebellar hemispheres between the 
genotypes. Whilst there is not a reduction in the density of cells within CA1 and CA3 
hippocampal regions in Gdf5bp/bp mice compared to Gdf5+/bp mice, there is a reduction 
in the total number of cells in the hippocampal CA regions of Gdf5bp/bp mice compared 
to Gdf5+/bp mice due to the reduced CA area of the former compared to the latter. 
Total hippocampal volume, calculated using the Cavalieri estimator371-374, also appears 
to be reduced in Gdf5bp/bp mice compared to Gdf5+/+ mice. The Cavalieri estimator is 
stereological method for the unbiased quantification of regional volumes. The volume 
of an object is estimated by summing the areas analysed in a slice and multiplying 
them by the thickness of the slices, therefore the Cavalieri estimator is likely to 
overestimate the volume if slices are thick relative to the size of the object being 
sliced. Random sections are taken from the cohort of experimental sections collected, 
based upon the fractionator principle. Under the paradigm being described, Dr 
Catarina Osório took every 5th section from the sliced hippocampus, equating to 
around 12 sections per experimental animal. A transparent acetate grid of equally 
spaced points was then superimposed over the sections being investigated an imaged 
using a Nikon phase contrast microscope, at 20x magnification. Boundaries of the 
areas being investigated had to be clearly defined and then points on the grid falling 
within those boundaries were counted using a cell counter. Those points outside the 
boundary were discarded. A tally of the points within the boundary was made and 
transferred into MSExcel. The Cavalieri estimator can then be applied:  
  
where t is the section cut thickness, k the correction factor, g the grid size and a’ the 
Projected area. This equation gives the estimated volume of the region being 
investigated, corrected for the over-projection based upon the thickness of the 
sections371-374.  
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In addition to a reduced volume as determined by the Cavalieri estimator, 3D 
reconstructions of the hippocampi, generated from measurements taken from serial 
sections of hippocampi from P10 Gdf5bp/bp,  Gdf5+/bp  and Gdf5+/+ mice, showed not only 
a reduction in hippocampal volume, but also a change in hippocampal morphology in 
the absence of functional GF5 expression. Hippocampi of postnatal Gdf5bp/bp mice 
appeared to lack the classical horn shape and to be narrower and more elongated than 
hippocampi of Gdf5+/+postnatal mice.  
The aims of this chapter were to further investigate the role that GDF5 plays in 
hippocampal development. Initially, the aim was to use an alternative method to 
histology to verify that a lack of functional GDF5 perturbs hippocampal development, 
reducing its volume and altering its morphology. The gross anatomical structure of the 
hippocampus and cerebellum was compared between Gdf5bp/bp, Gdf5+/bp and Gdf5+/+ 
mice using magnetic resonance imaging (MRI). In addition, because Gdf5bp/bp have 
shortened and malformed limbs/ digits and show reduced movement compared to 
wild type mice, it was hypothesised that they may display abnormalities of the 
cerebellum due to the likely reduction of cerebellar afferent activity after birth. 
Therefore, MRI was used to compare the gross anatomical structure of the cerebellum 
between Gdf5bp/bp, Gdf5+/bp and Gdf5+/+ mice.  
3.2 Results 
3.2.1 Comparison of anatomical MRI scans of adult mouse 
hippocampus and cerebellum  
In order to verify the results obtained by Dr Catarina Osório by using another method, 
the heads of 6 month old Gdf5bp/bp, Gdf5+/bp and Gdf5+/+ mice were scanned using MRI. 
6 month old mice were initially used to ensure that sufficient resolution of MRI scans 
was achieved. Whole heads were scanned and scan slices were manually examined, 
with the aid of  a mouse brain atlas375, to identify hippocampal and cerebellar 
structures and determine their area by tracing around them. Following this, traced 
scan slices were processed using Analyze 10.0 software to produce 3D images and to 
calculate the volumes of the hippocampi and cerebellums from each genotype. To 
correct for potential differences in hippocampal and cerebellar volumes due to 
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variations in total brain size as a result of size/weight variations between mice, 
hippocampal and cerebellar volumes were compared between mice and genotypes by 
determining the ratio of hippocampal/cerebellar volumes to the total brain volume.  
The hippocampi of adult Gdf5bp/bp, Gdf5+/bp and Gdf5+/+ mice do not appear to be 
morphologically distinct from one another (figure 3.06A). There also does not appear 
to be any difference in hippocampal volume between the three genotypes of mice 
(figure 3.06C). Although the hippocampal volume of Gdf5bp/bp mice appears to be 
greater than that of Gdf5+/+ mice, this increase in volume is not significant (p>0.05, 
one-way ANOVA).  There are also no differences between either the morphologies 
(figure 3.06B) or volumes (figure 3.06D) of cerebella from Gdf5bp/bp, Gdf5+/bp and 
Gdf5+/+ mice (p>0.05).   
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Figure 3.06: The loss of functional GDF5 does not lead to morphological abnormalities in 
adult hippocampus and cerebellum nor does it reduce their volume. (A) 3D models of the 
hippocampi of Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice obtained from MRI scans. (B) 3D models of 
the cerebellums of Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice obtained from MRI scans. (C) Bar chart 
showing the ratios of hippocampus volume to total brain volume in adult Gdf5+/+, Gdf5+/bp and 
Gdf5bp/bp mice.  (D) Bar chart showing the ratios of cerebellum volume to total brain volume in 
adult Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice. Data are expressed as a percentage of hippocampal 
(C) or cerebellar (D) volume in Gdf5+/+ mice. The data represent the mean ± s.e.m of data 
compiled from anatomical MRI of at least 5 animals of each genotype. Statistical analysis (one-
way ANOVA) shows no significant result (P value > 0.05).  
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3.2.2 Comparison of anatomical MRI scans of P10 mouse 
hippocampus and cerebellum  
The MRI images of the adult brains had a high background noise, and image quality 
between scan varied largely, but it was apparent that the MRI scanner had sufficient 
resolution (60µm) to successfully generate data on the 3D structure and volume of 
adult mouse hippocampus and cerebella. Since the MRI scanner was of sufficiently 
high resolution to get data from adult brains, MRI scans were repeated on brains from 
P10 Gdf5bp/bp, Gdf5+/bp and Gdf5+/+ mice.  Although MRI had shown that adult animals 
displayed no differences in the morphologies or volumes of their hippocampi in the 
absence of functional GDF5 expression, it is possible that the deficits in hippocampal 
volume and the morphological abnormalities previously observed in P10 mice 
Gdf5bp/bp356 have been compensated for by the adult. 
As with 6 month old mice, the hippocampi (figure 3.07A) and cerebella (figure 3.07B) 
of P10 Gdf5bp/bp mice are morphologically very similar to those of P10 Gdf5+/bp and 
Gdf5+/+ mice. Likewise, in contrast to the preliminary work conducted by Dr Catarina 
Osorio using histological techniques, hippocampal volume is not reduced in P10 
Gdf5bp/bp mice compared to P10 Gdf5+/bp and Gdf5+/+ mice when MRI is used to 
measure hippocampal volume (figure 3.07C). Although cerebellar volumes are slightly 
reduced in Gdf5bp/bp and Gdf5+/bp mice compared to Gdf5+/+ mice (figure 3.07D), these 
reductions are not statistically significant (p>0.05, one-way ANOVA). 
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Figure 3.07: The loss of functional GDF5 does not lead to morphological abnormalities in P10 
hippocampus and cerebellum nor does it reduce their volume. (A) 3D models of the 
hippocampi of P10 Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice obtained from MRI scans. (B) 3D models 
of the cerebellums of P10 Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice obtained from MRI scans. (C) Bar 
chart showing the ratios of hippocampal volume to total brain volume in P10 Gdf5+/+, Gdf5+/bp 
and Gdf5bp/bp mice.  (D) Bar chart showing the ratios of cerebellum volume to total brain 
volume in P10 Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice. Data are expressed as a percentage of 
hippocampal (C) or cerebellar (D) volume in Gdf5+/+ mice. The data represent the mean ± s.e.m 
of data compiled from anatomical MRI of at least 5 animals of each genotype. Statistical 
analysis (one-way ANOVA) shows no significant result (P value > 0.05).   
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3.3 Discussion 
The MRI study investigating potential anatomical differences in the hippocampi and 
cerebella of Gdf5bp/bp mice compared to Gdf5+/bp and Gdf5+/+ mice has not revealed any 
gross morphological differences between genotypes at either P10 or 6 months of age. 
Moreover, there are no differences in hippocampal or cerebellar volumes between the 
mouse genotypes at either of the ages investigated. The MRI study was based on data 
obtained from a histological analysis of serial frozen sections from P10 Gdf5bp/bp, 
Gdf5+/bp and Gdf5+/+ mice in which the volume of the hippocampus was calculated 
using the Cavalieri Estimator approach356. These preliminary data suggest that the loss 
of one functional Gdf5 allele does not significantly affect hippocampal volume, but P10 
Gdf5bp/bp mice show a near 50% reduction in hippocampal volume compared to wild 
type mice. Further analysis revealed that the area occupied by the CA regions of the 
hippocampus is reduced in GDF5 deficient mice compared to wild type mice, but the 
density of cells within the CA regions is the same in P10 mice of both genotypes. Cell 
density was established by counting the number of DAPI positive cells in a defined area 
of 2000µm2 in serial sections of hippocampi from both the Gdf5bp/bp and Gdf5+/+ mice. 
These previous observations fit well with the discovery that GDF5 and its receptors are 
expressed in developing hippocampal neurons and GDF5 regulates dendritic growth 
and elaboration from these neurons both in vitro and in vivo318. If the MRI study had 
confirmed the data from the previous histological study, it would have led to a detailed 
investigation into how the lack of GDF5 leads to a reduction in hippocampal volume. 
Such an investigation would have included looking into potential roles that GDF5 may 
play in: regulating the proliferation of hippocampal progenitors; modulating progenitor 
migration; promoting the differentiation of progenitors into post-mitotic neurons; 
enhancing the survival of post-mitotic neurons. Cerebellar morphology and cerebellar 
volume were determined from MRI scans, as it was hypothesised that the reduced 
mobility/activity of Gdf5bp/bp mice compared to wild type mice would be reflected by a 
reduced level of cerebellar afferent activity and this may translate into altered 
cerebellar development. This seems not to be the case, since MRI scans have failed to 
detect any differences between the cerebella of Gdf5bp/bp and Gdf5+/+ mice at P10 and 
adult ages. However, a lack of GDF5 expression may cause subtle perturbations in 
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cerebellum development compared to wild type mice that may be revealed by future 
immunohistochemical analysis. 
Histological preparations of brain tissue have previously been used to determine the 
gross size and volume of brain regions. By application of statistical techniques, it is 
possible to deduce the area, volume and even appearance of subcortical regions such 
as the hippocampus376. Specific methodologies, such as the Cavalieri Estimator 
(described in section 3.13, pg 105), aim to determine an accurate volume from serial 
sections of specific brain structures by making allowances for tissue shrinkage, due to 
poor sample preparation, and inaccurate estimation of tissue thickness350, 376. The 
advent of MRI imaging has presented another means to measure the volume of 
specific brain regions. Compared to histological methods, MRI produces 3D images 
and, because sample preparation does not destroy the tissue being investigated377, 
allowances do not need to be made for tissue shrinkage. Studies investigating the 
effects of ischemic stroke have long relied on the use of MRI imaging to investigate the 
effects of ischaemia on brain structure in experimental animals378. High resolution, in 
vivo MRI has been used to compare longitudinal changes in the volumes of specific 
brain structures in transgenic and wild type mice as they age379, 380. Of particular 
relevance to the current study, structural MRI has been successfully used to compare 
hippocampal areas and deduced hippocampal volumes between wild type mice and 
transgenic mice that over-express amyloid precursor protein from a platelet-derived 
growth factor promotor in a mouse model of Alzheimer’s disease381, thus 
demonstrating that MRI can be used to successfully measure hippocampal volumes in 
adult mice of 6 months of age.  
Whilst MRI has been successfully used to measure changes in the structure and 
volume of a number of brain regions in rodent models of disease, using the MRI 
images it was not possible to verify histological data suggesting that GDF5 deficiency 
results in morphologically abnormal hippocampi with a reduced volume. Therefore, 
the crucial question is, which of the two methodologies is the most sensitive, in terms 
of detecting small variations, and the most accurate, with regards to generating the 
smallest amount of error, for determining the shape and volume of different parts of 
the brain?  A previous study has suggested that histology and structural MRI deliver 
similar results when determining the volume of different cerebral compartments in 
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post mortem human brains372. The authors conducted this study to determine if non-
invasive techniques, such as MRI, were as efficient as classical techniques, such as fluid 
displacement and stereological analysis involving physical sectioning and applying the 
Cavalieri estimator, in calculating brain volume. A comparison of data obtained from 
each method only just failed to reach statistical significance, showing there were no 
significant variations between the MRI method and physical sectioning. However, only 
six post mortem brains were included in the study, suggesting that, had more brains 
been analysed, the data obtained from each of the methodologies may have been 
significantly different. Based upon a post hoc analysis of their data, the authors of this 
study concluded that certain specimens analysed by MRI had a large error of 
differentiation from their estimated volumes compared to the physical sectioning 
technique.  Interestingly, the authors of this study suggest that the finite resolution of 
MRI images, coupled with what is referred to as the intensity signal, may make it 
difficult for experimenters to accurately identify regions of interest within scan slices, 
even when a high resolution MRI scanner is used to examine the large human brain372. 
The MRI scanner used in this current study had a sufficient resolution (of 60µm) and, 
despite the mouse brains being analysed being very small, particularly at P10, MRI 
should have enabled even small differences in the volumes of the hippocampi and 
cerebella to be detected. However, it proved difficult to correctly identify the 
boundaries of the hippocampus and cerebella in some scan slices, possibly accounting 
for the inconsistency between the histology data obtained previously and the MRI data 
presented in this chapter. If time and resources were available, repeating the MRI 
analysis on P10 Gdf5bp/bp, Gdf5+/bp and Gdf5+/+ mouse brains, using a more up to date 
MRI scanner that would allow more scan protocols to be utilised to reduce the 
background noise of the acquired MRI images, may generate results similar to the 
initial histological analysis. In addition, new techniques are being developed that 
automatically measure brain compartments on MRI images, by referencing an 
anatomical atlas, and automatically correct for background noise on images, thereby 
producing more accurate data. Furthermore, repeating the histology study on larger 
numbers of P10 Gdf5bp/bp, Gdf5+/bp and Gdf5+/+ mouse brains would perhaps be the 
most straight forward way to investigate the effect of ablating GDF5 function in 
hippocampal development. If this did determine that the hippocampi of Gdf5bp/bp mice 
Chapter 3                                               The role of GDF5 in the development of the hippocampus and cerebellum 
130 
 
are smaller and morphologically abnormal compared to hippocampi from Gdf5+/+ mice, 
this would be an important finding that would open up a whole new project to 
determine the mechanisms that lead to the perturbation of hippocampal development 
in the absence of GDF5.  
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4. The functional role of GDF5 in vitro 
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4.1 Introduction 
Whilst NGF is not required for trophic support during the earliest stages of SCG 
development, other neurotrophic factors, such as artemin, HGF and NT-3, are required 
to promote the proliferation and survival of neuroblasts, neuronal differentiation and 
proximal axon growth15, 17, 60, 155. SCG neurons begin to require NGF for survival from 
about E1560, 155 as the axons of the earliest born neurons reach their peripheral target 
fields that express limited quantities of NGF 68, 382. Those SCG neurons that receive 
sufficient levels of target field-derived NGF survive and branch extensively within their 
targets, whereas those that obtain inadequate amounts of NGF undergo apoptosis15. 
NGF/TrkA retrograde signalling from target fields to neuronal soma has been shown to 
regulate gene expression within the soma that promotes survival and axon growth, 
whilst local signalling within the terminals of innervating neurons enhances axonal 
branching and arborisation 383-385. Recent data have revealed that whilst NGF is 
essential for correct target field innervation by developing SCG neurons, members of 
the TNFSF play roles in regulating NGF-promoted target field arborisation72, 153, 169, 170. 
TGF-β superfamily members have been shown to play important roles in the 
developing nervous system163, 282, 286, 310-312, 318, 386. For example, BMP2 has been shown 
to play an instructive role in the patterning of the neural tube and regulate whether 
NCCs differentiate into either parasympathetic or sympathetic neurons17. In addition, 
dorsal aorta expressed BMP4 and BMP7 both enhance adrenergic differentiation of 
migrating NCCs in vitro and in vivo, thereby directing the development of NCCs down 
the sympathetic lineage 282. BMP7 also causes growth of cortical dendrites in vitro, and 
increases the rate of synapse formation in hippocampal neurons cultures286. GDF5 is 
expressed throughout the nervous system, including the DRG, where it has been found 
to mediate the survival enhancing and process outgrowth promoting effects of NT-3 
and NGF on cultured chick DRG neurons310, 311. GDF5 has also been shown to exert 
trophic effects on developing ventral midbrain dopaminergic neurons387-390. In 
addition, GDF5 regulates developing hippocampal pyramidal neuron dendrite growth 
and elaboration, both in vitro and in vivo 318. In vitro, GDF5 promotes dendrite growth 
by activation of SMADs 1/5/8, and in vivo the apical and basal dendrites of 
hippocampal pyramidal neurons are stunted in Gdf5bp/bp mice compared to Gdf5+/+  
mice318. 
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4.1.1 Aims 
The aim of the experiments presented in this chapter was to investigate whether GDF5 
plays any trophic roles in the developing mouse SCG. To this end, the expression 
pattern of GDF5 receptors was investigated in the developing SCG. Having established 
that developing SCG neurons express both type 1 and type 2 GDF5 receptors, primary 
SCG cultures were set up from embryonic and postnatal mice and supplemented with 
either no factors, NGF, GDF5 or NGF plus GDF5 to determine whether GDF5 could 
promote neuronal survival or enhance neuritic process outgrowth and branching. 
Next, the observation that GDF5 can enhance process outgrowth and branching from 
cultured neonatal SCG neurons, lead to the use of microfluidic compartment cultures 
to determine whether GDF5 signals locally at axon terminals to promote growth. In 
addition, SCG cultures were also supplemented with GDF5 and different combinations 
of anti-GDF receptor blocking antibodies in an attempt to identify the receptor 
complex that GDF5 uses to mediate its growth enhancing effects. Finally, in vitro gene 
regulation experiments were conducted to determine whether GDF5 and/or NGF can 
regulate the expression of type 1 and type 2 GDF5 receptors.  
4.2 Expression of GDF5 receptors in the developing SCG  
GDF5 is potentially capable of signalling through receptor complexes consisting of the 
type 1 receptors, BMPR1A and BMPR1B and the type 2 receptors, BMPR2 and 
ACVR2A269. As a first step in investigating whether GDF5 has any trophic effects on 
developing SCG neurons, a RT-qPCR screen was conducted to determine the whether 
developing SCG neurons express BMPR1A, BMPR1B, BMPR2 and ACVR2A at the mRNA 
level. This approach was taken  to comply with the principles laid out in the three ‘R’s 
(replacement, reduction and refinement) which are explicit principles as laid out in 
ASPA (1986) and as amended to encompass EU Directive 2010/63/EU. The preliminary 
RT-qPCR screen enabled a narrower developmental window to be identified (maximal 
levels of expression of GDF5 receptor mRNAs) where GDF5 may affect the survival of 
and/or process outgrowth from cultured SCG neurons, thereby reducing the number 
of pregnant mice and neonatal pups that needed to be sacrificed to initially establish 
whether GDF5 has any neurotrophic effects on developing SCG neurons.  
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The RT-qPCR screen was carried out on RNA from SCG ranging from E16 through to 
P10, covering a period where NGF is required to prevent the developmental 
programmed cell death of SCG neurons and to promote target field innervation and 
arborisation of their axons.  Bmpr1a and Acvr2a mRNAs are both detectable from E16 
and show a similar developmental pattern of expression. Their expression levels, 
relative to a geometric mean of the reference mRNAs Gapdh, Sdha and Hprt1, increase 
from E16 to reach a peak at P0, before falling approximately 50% between P0 and P10 
(figure 4.01A). Whilst the increase in the levels of Acvr2a or Bmpr1a mRNAs between 
E16 and P0 is not statistically significant, (p>0.05, Student’s t-test), the decrease in 
mRNA expression levels of both receptors between P0 and P10 is statistically 
significant (p<0.001 and p<0.05, for Acvr2a and Bmpr1a, respectively (students t-test)). 
Gapdh, Sdha and Hprt1 were chosen as reference mRNAs because they are genes 
involved in basal metabolism and therefore should be expressed at relatively constant 
levels throughout development and under different culture conditions. Three 
reference genes were used to reduce the impact that minor developmental regulation 
of any one of the reference gene would have on the accuracy of GDF5 receptor mRNAs 
expression patterns. Bmpr1b and Bmpr2 mRNAs are also detectable in the SCG 
throughout the developmental period analysed and show a similar pattern of 
expression (figure 4.01B) to each other. Both mRNAs are expressed at their highest 
levels at E16 and the expression levels of both mRNAs fall gradually from E16 as 
development proceeds. In the case of Bmpr1b mRNA, there is a statistically significant 
60% reduction in expression levels between E16 and P10 (p<0.05, Student’s t-test). In 
the case of BmpR2 mRNA, expression levels drop a statistically significant 45% 
between E16 and P5 (p<0.05, Student’s t-test), before increasing by a statistically 
significant 20% between P5 and P10 (p<0.05, Student’s t-test) (figure 4.01B).  
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Figure 4.01: Relative level of expression of GDF5 receptor mRNAs in the developing SCG from 
E16 to P10. (A) Expression profiles for Bmpr1a and Acvr2a mRNAs and (B) Bmpr1b and Bmpr2 
mRNAs in the developing SCG relative to the geometric mean of the reference mRNAs; Gapdh, 
Hprt1 and Sdha. The data shown represents the mean ± s.e.m. of data compiled from 4 
separate pairs of ganglia at each developmental age. * = P< 0.05,  *** = P< 0.001, and ns. = not 
significant, statistical comparisons conducted using Student’s t-test. 
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Immunocytochemistry was used to ensure that the expression of Bmpr1a, Bmpr1b, 
Acvr2a and Bmpr2 mRNAs in the developing SCG corresponded to the expression of 
receptor proteins within SCG neurons. P0 SCG neuronal cultures were established and 
cultured for 24 hours, in the presence of 1ng/ml NGF, before being fixed and stained 
with appropriate antibodies against each GDF5 receptor and an antibody against GDF5 
itself (figures 4.03, 4.04, 4.05). Fixed cultures were co-stained with an antibody against 
β-III tubulin, enabling correct identification of neurons and their processes. DAPI was 
also used as a nuclear marker to identify neuronal and non-neuronal cell soma. Control 
stainings, omitting primary antibodies, were carried out to rule out non-specific 
binding of secondary antibodies. Control staining images are presented in figure 4.02. 
 
Figure 4.02: Control immunocytochemistry images omitting primary antibodies. Neurons 
were cultured for 18 hours in the presence of 0.1ng/ml NGF and the fixed and stained without 
primary antibody incubation. Addition of chick Alexa Fluor 488 (green), rabbit Alexa Fluor 594 
(red), DAPI (blue). 
 
Figure 4.03: Expression of GDF5 in P0 SCG neurons. Neurons were cultured for 24 hours in the 
presence of 1ng/ml NGF before being fixed and stained. Expression of GDF5 (green), β-III 
tubulin (red), DAPI (blue) and a merge of all three images are shown. Scale bar represents 
20µm. 
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Anti-GDF5 staining showed that the protein is expressed primarily in the soma of P0 
SCG neurons; however it also appears to be expressed at low levels in the processes of 
neurons, particularly the proximal processes (figure 4.03).  
 
Figure 4.04: Expression of type 1 BMP receptors in P0 SCG neurons. Neurons were cultured 
for 24 hours in the presence of 1ng/ml NGF before being fixed and stained. (A) Expression of 
BMPR1A (green), β-III tubulin (red), DAPI (blue) and a merge of all three images are shown. (B) 
Expression of BMPR1B (green), β-III tubulin (red), DAPI (blue) and a merge of all three images 
are shown.  Scale bar represents 20µm. 
The expression of Bmpr1a and Bmpr1b mRNAs at P0 in the developing SCG also 
appears to correspond to their expression in P0 SCG neurons at the protein level 
(figure 4.04). Figure 4.04A reveals that BMPR1A is very strongly expressed in both the 
soma and processes of P0 SCG neurons. However, BMPR1B (figure 4.04B) appears to 
be expressed primarily in the soma of P0 SCG neurons, with only faint staining in 
processes. The DAPI panel of figure 4.04A shows a non-neuronal cell that is clearly not 
stained for BMPR1A or β-III tubulin. No β-III tubulin positive cells (neurons) were found 
that did not express either BMPR1A or BMPR1B, suggesting that all P0 SCG neurons 
express both type 1 GDF5 receptors panel. 
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Figure 4.05: Expression of type 2 BMP receptors in P0 SCG neurons. Neurons were cultured 
for 24 hours in the presence of 1ng/ml NGF. (A) Expression of ACVR2A (green), β-III tubulin 
(red), DAPI (blue) and a merge all three images are shown. (B) Expression of BMPR2 (green), β-
III tubulin (red), DAPI (blue) and a merge of all three images are shown.  Scale bar represents 
20µm. 
Both of the two type 2 receptors, BMPR2 and ACVR2A, are also expressed in P0 SCG 
neurons at the protein level (figure 4.05). ACVR2A (figure 4.05A) and BMPR2 (figure 
4.05B) are both expressed in the soma and processes of P0 SCG neurons, although 
ACVR2A appears to be expressed at higher levels in processes than BMPR2. The 
expression of BMPR1A, BMPR1B, BMPR2 and ACVR2A in cultured P0 SCG neurons 
verifies that the mRNA detected by RT-qPCR is translated into the corresponding 
proteins and suggests that GDF5 may play some role in the development of SCG 
neurons. 
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4.3 Effects of recombinant GDF5 on sympathetic SCG 
neuronal cultures 
To test the physiological relevance of the expression of GDF5 and its receptors, further 
experiments were initially designed to determine whether GDF5 could promote 
neurite outgrowth and branching from cultured SCG neurons. Recombinant GDF5 
ligand was added to low density SCG cultures established from E18, P0, P1 and P2 mice 
and cultures were incubated for 18 hours in the presence of 50 μM Boc-D-FMK caspase 
inhibitors to prevent neuron death in the absence of NGF. Control cultures at each age 
contained only caspase inhibitors. An initial concentration of 10ng/ml of GDF5 ligand 
was added to cultures based on data from previously published literature examining 
the effects of recombinant GDF5 on cultured neurons310, 311, 386. After the 18 hour 
culture period, cultures were stained with calcein-AM and imaged using a fluorescence 
microscope. The extent of process outgrowth in the presence and absence of 10ng/ml 
GDF5 was quantified from images using a modified Sholl analysis program running on 
MATLAB, as described in chapter 2. In brief, the data from MATLAB can be exported to 
Excel and used to plot the number of intersections that processes make with virtual 
concentric rings, centred on the neuron soma, at increasing distances from the cell 
soma. The larger the area underneath the Sholl plot, the more complex and robust 
process outgrowth is. The exported MATLAB data in Excel can also be used to calculate 
mean total process length for each experimental culture condition as well as mean 
number of branch points.  
At E18, 10ng/ml GDF5 does not enhance neurite outgrowth from cultured SCG 
neurons compared to control cultures, as seen by the overlapping Sholl plots for 
control and GDF5 supplemented culture conditions at this age (figure 4.06A). However, 
GDF5 increases the extent of process outgrowth compared to control cultures at P0 
and P1, as demonstrated by the increased area under the Sholl plots for GDF5 
supplemented cultures compared to control cultures (figure 4.06A). Analysis of mean 
total neurite length and mean number of branch points (data not shown) shows that 
the increase in the length and branching of processes induced by 10ng/ml GDF5 is 
statistically significant at both P0 and P1 (p<0.001 for both length and branching at 
both ages, Student’s t-test). The process growth promoting effects of exogenous GDF5 
have disappeared by P2 (figure 4.06A). Having established that GDF5 can enhance the 
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extent of process outgrowth from P0 SCG neurons, additional experiments were 
carried out to determine whether 10ng/ml GDF5 could also enhance the extent of NGF 
promoted process outgrowth at this age. Representative images of P0 SCG neurons 
cultured for 18 hours in the presence of caspase inhibitors alone or with caspase 
inhibitors plus either 1ng/ml NGF, 10ng/ml GDF5 or 1ng/ml NGF plus 10ng/ml GDF5 
are shown in figure 4.06B. The images show that GDF5 can both promote process 
growth on its own and enhance NGF promoted process outgrowth. A Sholl plot 
comparing NGF supplemented and NGF plus GDF5 supplemented cultures clearly 
shows that GDF5 enhances NGF promoted process outgrowth at P0 (figure 4.06C). An 
analysis of mean total neurite length and mean number of branch points (data not 
shown) reveals that the addition of 10ng/ml GDF5 to cultures containing 1ng/ml NGF 
significantly increases the length and number of branch points of the processes of 
cultured P0 SCG neurons (p<0.01 for both length and branching, Student’s t-test).  
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Figure 4.06: GDF5 promotes neurite outgrowth from cultured P0 and P1 SCG neurons. (A) 
Sholl plots derived from the analysis of process outgrowth from E18, P0, P1 and P2 SCG 
neurons cultured for 18 hours with either caspase inhibitors alone (no factors) or caspase 
inhibitors plus 10ng/ml GDF5. (B) Representative images of P0 SCG neurons cultured for 18 
hours with either caspase inhibitors alone or with caspase inhibitors plus either 1ng/ml NGF, 
10ng/ml GDF5 or 1ng/ml NGF plus 10ng/ml GDF5. (C) Sholl analysis of arbors of P0 SCG 
neurons cultured for 18 hours with either 1 ng/ml NGF alone or with 1ng/ml NGF plus 10ng/ml 
GDF5. Sholl plots represent data from the analysis of at least 60 neurons from each of 3 
separate experiments, * = P< 0.01 and *** = P< 0.001, statistical comparisons conducted using 
Student’s t-test for both length and branching. 
Having determined that GDF5 enhances process outgrowth from P0 SCG neurons both 
in the presence and absence of NGF, a dose response analysis was carried out to 
identify the optimal growth promoting concentration of GDF5. Cultures of P0 SCG 
neurons were supplemented with 50μM Boc-D-FMK caspase inhibitors and incubated 
for 18 hours with either no additional factors, 1ng/ml GDF5, 10ng/ml GDF5 or 
100ng/ml GDF5. Following calcein-AM staining and fluorescence imaging, the extent of 
process outgrowth was analysed by Sholl analysis on MATLAB and data exported to 
Excel was used to determine mean total neurite length and mean number of branch 
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points for each condition. The experiment was repeated 3 times, with at least 60 
individual neurons analysed for each culture condition for each repeat. A statistical 
comparison between conditions was performed using a one way ANOVA in the 
statistical package, R.   
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Figure 4.07: GDF5 promotes process elongation and branching from cultured P0 SCG neurons 
in a dose dependent manner. P0 SCG neurons were cultured for 18 hours with 50μM Boc-D-
FMK caspase inhibitor (CasX) either alone or with 1ng/ml GDF5, 10ng/ml GDF5 or 100ng/ml 
GDF5. (A) Mean number of branch points for each culture condition normalised to CasX 
control. (B) Mean total neurite length under each culture condition (μm) (C) Sholl profiles of 
neurons cultured under each condition. All Graphs are mean ± s.e.m. n=3 experiments with at 
least 60 neurons imaged for each condition for each experiment. ***=p<0.001, **=p<0.01, 
comparison with CasX, Tukey’s HSD test. 
In the absence of NGF, GDF5 increased mean total process length (figure 4.07B) and 
mean number of branch points (figure 4.07A) of cultured P0 SCG neurons in a dose 
dependent manner, with the maximally effective dose of GDF5 being 100ng/ml. The 
dose dependent increase of process outgrowth and complexity induced by GDF5 is 
clearly reflected in the Sholl plot in figure 4.07C. The increase in the number of branch 
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points promoted by GDF5 was not significant at 1ng/ml GDF5, but was significant at 
10ng/ml and 100ng/ml GDF5 (p<0.01 and p<0.001, respectively, Tukey’s HSD test). The 
increase in mean process length induced by GDF5 was highly significant at all three 
concentrations of GDF5 tested (p<0.001, Tukey’s HSD test) and, whilst maximal 
increase in process length was seen at 100ng/ml GDF5, the increase in length between 
10ng/ml GDF5 and 100ng/ml GDF5 was minimal (figure 4.07B). Interestingly, P0 SCG 
neurons cultured without the addition of neurotrophic factors and those cultured with 
10ng/ml GDF5 did not grow as large in this set of experiments as those in the previous 
experiments represented in figure 4.06. In figure 4.06A, neurons in control cultures 
made an average of around 2.5 intersections with the virtual concentric rings of the 
Sholl analysis programme at a distance of 150µm from the neuron soma and those 
cultured with 10ng/ml GDF5 made an average of 5 intersections. In figure 4.07C the 
average number of intersections at 150µm from the cell soma is only approximately 
0.5 for neurons in control cultures and 1.5 for neurons cultured with 10ng/ml GDF5. 
This inconsistency is inherent with primary cell culture techniques and could plausibly 
be explained by variations between the biological activity of different batches of GDF5 
supplied by the manufacturer and batch to batch variation in the quality of cell culture 
reagents, such as laminin and F14, especially as the latter were prepared from stocks 
and aliquoted by different members of the lab on a rota basis. Despite the reduced 
efficacy of GDF5 in the experiments represented in figure 4.07 compared to those in 
figure 4.06, 10ng/ml GDF5 still significantly increases the mean neurite length (figure  
4.07B) and mean number of branch points (figure 4.07A), compared to control cultures 
in the experiments represented by figure 4.07.    
By P0, SCG neurons have extended their processes to innervate their peripheral target 
fields and are beginning to ramify. At this age, neurons are dependent on target field-
derived NGF for their survival and those that receive inadequate trophic support begin 
to undergo apoptosis. The ability of GDF5 to enhance neurite outgrowth in vitro, both 
independently and in association with NGF, raises the possibility that GDF5 can also 
independently promote the survival of P0 SCG neurons or enhance NGF promoted 
survival. To address this question, cultures of P0 SCG neurons were established in the 
absence of caspase inhibitors and supplemented with varying concentrations of NGF, 
ranging from 0.01ng/ml NGF to 10ng/ml NGF, either with or without 100ng/ml GDF5. 
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The concentration of 100ng/ml of GDF5 was chosen based upon the results of dose 
response carried out previously and shown in figure 4.07, whereby 100ng/ml GDF5 
caused the maximal outgrowth of axons from P0 SCG neurons. Control cultures 
contained either no factors or 100ng/ml GDF5 without NGF. Neuron counts were 
performed at 4 hours to assess the initial number of neurons in each culture and 
repeated after 24 and 48 hours of culture. The number of neurons surviving in each 
culture condition after 24 and 48 hours was expressed as a percentage of the number 
of neurons in the initial 4 hour count. 
 
Figure 4.08: GDF5 modulates the NGF promoted survival of cultured P0 SCG neurons. (A) NGF 
dose response with and without 100ng/ml GDF5 showing the percentage of P0 SCG neurons 
surviving after 24 hours of culture. (B) NGF dose response with and without 100ng/ml GDF5 
showing the percentage of P0 SCG neurons surviving after 48 hours of culture. Percentage 
survival in no factor control and 100ng/ml GDF5 control are also shown after 24 hours (A) and 
48 hours (B) of culture. Data represents mean survival  ± s.e.m, from 3 individual experiemnts 
with each experiment containing 4 individual dishes for each condition. ***=p<0.001, 
**=p<0.01, *=p<0.05 comparison at each NGF concentration between survival in cultures 
containing NGF alone and cultures containing  NGF plus 100ng/ml GDF5; Tukey’s HSD test. 
NGF clearly promotes the survival of cultured P0 SCG neurons in a dose dependent 
manner after both 24 (figure 4.08A) and 48 hours (figure 4.08B) of culture, with 
maximal survival seen at 1 ng/ml NGF.  100ng/ml of GDF5 did not increase survival at 
either time point compared to no factors control cultures, neither did 0.01ng/ml NGF 
on its own. Interestingly, the addition of 100ng/ml of GDF5 to cultures supplemented 
with 0.01ng/ml NGF did significantly increase the survival of P0 SCG neurons compared 
to no factor control cultures at both 24 hours (figure 4.08A) and 48 hours (figure 
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4.08B) (p<0.01 and p<0.001, respectively, Tukey’s HSD test). GDF5 was also able to 
significantly increase the survival of P0 SCG neurons in culture supplemented with 
0.1ng/ml NGF, compared to cultures containing 0.1ng/ml NGF alone, at 24 hours 
(p<0.01, Tukey’s HSD test), but not 48 hours. Curiously, 100ng/ml GDF5 reduced the 
survival of neurons cultured with either 1ng/ml NGF or 10ng/ml NGF at both 24 hours 
(figure 4.08A) and 48 hours (figure 4.08B).  At 24 hours, the reduction of survival by 
100ng/ml GDF5 was statistically significant in cultures containing both 1ng/ml NGF and 
10ng/ml NGF (p<0.001 and p<0.05, respectively, Tukey’s HSD test). However, after 48 
hours of culture, the reduction in survival induced by GDF5 was only statistically 
significant in cultures containing 1ng/ml NGF (p<0.05, Tukey’s HSD test). These results 
suggest that, although GDF5 is unable to promote the survival of P0 SCG neurons on its 
own, it may enhance the survival promoting effects of low concentration of NGF on 
neonatal SCG neurons, whilst inhibiting the ability of high concentrations of NGF to 
promote their survival. If this is the case in vivo, GDF5 may potentially modulate the 
survival of developing SCG neurons depending on the available NGF concentration. The 
amount of NGF synthesised by target fields varies between individual target fields 
(chapter 5 of this thesis). Within individual target fields, the level of NGF synthesised 
also varies depending on developmental stage (see chapter 5 of this thesis and also 
Davies, A.M, 200960). Thus, GDF5 may regulate the survival of developing SCG neurons 
at different developmental stages depending on the target fields their axons project 
to.   
Collectively, the data presented above demonstrate that GDF5 is able to both promote 
process outgrowth from cultured neonatal SCG neurons on its own and enhance NGF 
promoted process growth. In addition, GDF5 appears to modulate the NGF promoted 
survival of PO SCG neurons in vitro. NGF exerts most of its trophic effects as a target 
field derived factor that binds to receptors on axon terminals and retrogradely signals 
to regulate gene transcription in the nucleus103, 106, 384. To assess whether GDF5 could 
potentially be a target field derived factor that is capable of retrograde signalling, 
compartmentalised culture experiments using microfluidic chambers were performed 
with P0 SCG neurons. As described in chapter 2, microfluidic chambers allow the fluid 
microenvironment that surrounds the neuron soma and neuronal processes to be 
manipulated individually, thereby allowing a trophic factor to be added to either the 
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neuron soma or the neuron processes individually. A schematic demonstrating the 
design of microfluidic chambers is shown in figure 2.02. Compartment cultures in 
microfluidic chambers could not be established in the absence of NGF, as P0 SCG 
neurons will not extend processes that are long enough to project from the soma 
compartment of the microfluidic chamber through the micro-channel barrier and into 
the process (axon) compartment without NGF. For this reason, 1 ng/ml NGF was added 
to the culture media in both the soma and axon compartments. Control cultures were 
not supplemented with additional trophic factors in either the soma or axon 
compartment; whereas half of the chambers had 100ng/ml GDF5 added to the axon 
compartment. After 24 hours, microfluidic chamber cultures were stained by adding 
calcein-AM to the axon compartment and imaged.   
GDF5 added to the axon compartment clearly increased the length and complexity of 
P0 SCG neuron processes in the axon compartment compared to control cultures 
(figure 4.09A and C). Quantification of mean process length revealed that the 
processes of P0 SCG neurons cultured in microfluidic chambers that were 
supplemented with 100ng/ml GDF5 in the axon compartment were 70% longer than 
the processes of P0 SCG neurons cultured in control microfluidic chambers (figure 
4.09B), an increase that was statistically significant (p<0.001, Student’s t-test). These 
data demonstrate that GDF5 can act locally on axons to enhance NGF promoted 
process growth, suggesting that target field-derived GDF5 may enhance target field 
innervation and arborisation by SCG neurons in vivo. Whilst local intracellular signalling 
at process terminals may mediate the growth promoting effects of GDF5, by activating 
local protein synthesis in the growth cones of developing SCG neurons, these data 
raise the possibility that GDF5 may be capable of signalling retrogradely to exert its 
growth enhancing effects. Further work will be needed to determine which of these 
signalling modalities is important in mediating the trophic effects of GDF5 on P0 SCG 
neurons. 
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Figure 4.09: GDF5 acts locally at process terminals to promote process outgrowth. (A) and (C) 
Representative images of P0 SCG neurons cultured in microfluidic chambers for 24 h with 1 
ng/ml NGF in both compartments (A) and NGF in both compartments plus 100 ng/ml GDF5 in 
the axon compartment (C). Scale bar = 300μm. (B) Mean axon length data from 3 separate 
experiments, measured using a modified line intercept method, with each experiment 
containing 3 individual microfluidic chamber cultures for each condition. *** = P< 0.001, 
statistical comparison with NGF alone, Student’s t-test). 
4.4 Blocking type 1 and type 2 receptors for GDF5 can 
inhibit GDF5 promoted outgrowth 
GDF5 is potentially capable of signalling through the type 1 receptors, BMPR1A and 
BMPR1B and the type 2 receptors BMPR2 and ACVR2A269 and all four receptors are 
expressed in the developing SCG (figures 4.01 to 4.05). In an attempt to identify the 
receptors that GDF5 acts through to enhance process outgrowth and branching from 
cultured P0 SCG neurons, a series of in vitro experiments were carried out using 
antibodies that are capable of blocking the function of type 1 and type 2 receptors. 
Validated blocking antibodies were available for BMPR1A, BMPR1B and ACVR2A 
receptors, but, none were commercially available for BMPR2. The effects of each 
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available blocking antibody on the extent of GDF5-promoted process outgrowth and 
branching was tested in P0 SCG cultures containing both NGF and GDF5 together or 
GDF5 alone. Prior to initiating this series of experiments, isotype control antibodies 
(one for each of the receptor blocking antibodies) were tested in culture to ensure that 
they did not modulate process outgrowth and branching from P0 SCG neurons 
cultured with either GDF5 alone or NGF plus GDF5. These control experiments were 
carried out to ensure that any effects of receptor blocking antibodies on the extent of 
NGF or GDF5-promoted process outgrowth and branching was not due to non-specific 
effects of blocking antibody non-variable regions on neurons. The effects of the 
isotype control antibodies on P0 SCG neuron survival were not tested, as subsequent 
cultures to investigate whether receptor blocking antibodies interfered with GDF5-
promoted growth and branching were to be supplemented with caspase inhibitors to 
prevent neuronal death.  
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Figure 4.10: Isotype control experiment verification. P0 SCG neurons were cultured for 18hrs 
with 50µM Boc-D-FMK caspase inhibitors either without the addition of other factors (CasX), 
with 100 ng/ml GDF5 alone (GDF5) or 0.1ng/ml NGF alone (NGF), 100 ng/ml GDF5 plus 0.1 
ng/ml NGF (GDF5 + NGF), with 100 ng/ml GDF5 plus 2 µg/ml of iso-BMPR1A, iso-BMPR1B and 
iso-ACVR2A (Isotype controls) or with 100 ng/ml GDF5 plus 0.1 ng/ml NGF and 2 µg/ml of iso-
BMPR1A, iso-BMPR1B and iso-ACVR2A (Isotype controls + NGF). (A) Mean number of branch 
points as a percentage of the GDF5 + NGF control cultures for isotype controls + NGF. (B) Mean 
total process length as a percentage of GDF5 + NGF control cultures for isotype controls + NGF. 
(C) Mean number of branch points as a percentage of the GDF5  cultures for isotype controls 
and (D) Mean total process length as a percentage of GDF5 cultures for isotype controls. All 
Graphs represent means ± s.e.m. n=3 separate experiments with at least 60 neurons analysed 
for each condition from each experiment. ***=p<0.001, **=p<0.01, relative to GDF5 + NGF 
control, Tukey’s HSD test. 
The results of these control experiments confirmed that isotype control antibodies do 
not interfere with GDF5 promoted-process growth or branching either in the presence 
or absence of NGF (figure 4.10). There are no significant differences in the length and 
degree of branching of the processes of P0 SCG neurons cultured in medium 
containing either 100ng/ml GDF5 or 100ng/ml GDF5 plus 0.1ng/ml NGF when isotype 
control antibodies are added to the cultures (p=0.273 and p=0.14, for both axon 
branching and length respectively in cultures containing GDF5 alone and p=0.242 and 
p=0.387, for both axon branching and length respectively with NGF, Tukey’s HSD test). 
GDF5 was also able to significantly increase both length and branching in the absence 
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of NGF compared to no factor controls (p<0.001 for both, Tukey’s HSD). The effect of 
GDF5 on axon length when used in combination with NGF was also significant (p<0.01, 
Tukey’s HSD); however, GDF5 did not have a significant effect on axon branching over 
that of NGF (p=0.09, Tukey’s HSD). In these experiments, 0.1ng/ml of NGF was used as 
opposed to the 1ng/ml of NGF used previously (figure 4.06) because it was thought 
GDF5s effects would be more noticeable at a sub-saturating dose of NGF based upon 
previous dose response data shown in figure 4.08. 
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Figure 4.11: Blocking GDF5 receptor function in the presence of NGF inhibits GDF5 promoted 
process elongation, but not branching, from cultured P0 SCG neurons. P0 SCG neurons were 
cultured for 18hrs with 50µM Boc-D-FMK caspase inhibitors either without the addition of 
other factors (CasX) or with either: 0.1ng/ml NGF (NGF); 0.1ng/ml NGF plus 100ng/ml GDF5 
(GDF5 + NGF); 0.1ng/ml NGF plus 100ng/ml GDF5 together with 2μg/ml of either anti-BMPR1A 
antibody (anti-BMPR1A), anti-BMPR1B antibody (anti-BMPR1B) or anti-ACVR2A antibody (anti-
ACVR2A). (A) Mean number of branch points as a percentage of the GDF5 + NGF control 
cultures. (B) Mean total process length as a percentage of GDF5 + NGF control cultures (C) 
Sholl profiles of neurons cultured under the various conditions. All Graphs represent means ± 
s.e.m. n=5 separate experiments with at least 60 neurons analysed for each condition from 
each experiment. ***=p<0.001, **=p<0.01, *=p<0.05 relative to GDF5 + NGF control, Tukey’s 
HSD test. 
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Initial experiments were conducted using cultures of P0 SCG neurons supplemented 
with a combination of 100ng/ml GDF5 plus 0.1ng/ml NGF together with 2µg/ml of 
either BMPR1A, BMPR1B or AVCR2A blocking antibodies. This concentration of 2µg/ml 
was used on the recommendation of the manufacturers. All cultures contained 50μM 
Boc-D-FMK caspase inhibitors. Control conditions, containing no blocking antibodies 
were: caspase inhibitors only, 0.1ng/ml NGF alone and 0.1ng/ml NGF plus 100ng/ml 
GDF5. Neurons were cultured for 18 hours prior to staining with calcein-AM and 
imaging with a fluorescence microscope. A modified Sholl analysis was then performed 
and differences in the extent of process elongation and branching between culture 
conditions were analysed using a one way ANOVA in the statistical package R. Sholl 
profiles were also plotted for each of the culture conditions. NGF was used at 0.1ng/ml 
because this was found to be a sub-saturating concentration in terms of promoting 
process outgrowth and it was assumed that the application of 100ng/ml GDF5 would 
have the maximal effect in enhancing process outgrowth at this concentration. 
100ng/ml GDF5 significantly enhanced both NGF promoted branching (figure 4.11A) 
and process elongation (figure 4.11B) compared to NGF alone (p<0.05 for mean 
number of branch points and p<0.001 for mean total process length, Tukey’s HSD test). 
None of the receptor blocking antibodies decreased the mean number of branch 
points compared to the NGF plus GDF5 control condition (figure 4.11A). However, all 
of the receptor blocking antibodies significantly reduced mean total process length 
compared to the NGF plus GDF5 condition (figure 4.11B) (p<0.001, 0.01 and 0.05 for 
anti-BMPR1A, anti-BMPR1B and anti ACVR2A, respectively, Tukey’s HSD test). The 
antibody with the greatest effect on GDF5 promoted axon elongation was anti-
BMPR1A and the antibody with the least effect on GDF5 promoted axon elongation 
was anti-ACVR2A. The reduction of mean total process length compared to NGF plus 
GDF5 controls that is induced by the addition of blocking antibodies is seen in the Sholl 
profiles as a reduction in the number of intersections at a distance greater than 360μm 
from the cell soma for antibody containing cultures compared to NGF plus GDF5 
cultures (figure 4.11C). The fact that all three blocking antibodies tested were able to 
reduce the ability of GDF5 to enhance NGF promoted axon elongation to some extent, 
suggests a certain degree of redundancy in GDF5/GDF5 receptor signalling in 
developing SCG neurons. What is also apparent in figure 4.11C is that the Sholl profile 
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of P0 SCG neurons cultured with 0.1ng/ml of NGF is very similar to that of P0 SCG 
neurons cultured with 1ng/ml NGF in a previous experiment represented by figure 
4.06C. Moreover the Sholl profile of neurons cultured with 0.1ng/ml NGF plus 
100ng/ml GDF5 in figure 4.11C is very similar to the profile of neurons cultured with 
1ng/ml NGF plus 10ng/ml GDF5 in figure 4.06C. These observations reiterate the point 
made above about the inherent variability between primary cultures that are carried 
out at different periods of time.  As alluded to above, these differences over time may 
be due to batch to batch variations in the potency of purchased neurotrophic factors 
and/or tissue culture reagents, and/or variation in the accuracy of the preparation and 
aliquoting of cell culture reagents by different lab members.  
From previous experiments, it appeared that GDF5 was more effective in enhancing 
process outgrowth and branching in the absence of NGF (figure 4.06 and 4.07). It was, 
therefore, reasoned that the ability of receptor blocking antibodies to interrupt GDF5 
signalling and inhibit GDF5 promoted process elongation and branching may be more 
clearly seen in P0 SCG cultures established in the absence of NGF, thereby facilitating 
the identification of the predominant receptor combination that mediates GDF5 
promoted process outgrowth.  To this end, P0 SCG neuronal cultures were established 
containing 50μM Boc-D-FMK caspase inhibitors and either no additional factors, 
100ng/ml GDF5 or 100ng/ml GDF5 plus 2μg/ml of either anti-BMPR1A, anti-BMPR1B 
or anti-ACVR2A.  
GDF5 at a concentration of 100ng/ml significantly enhanced neurite branching (figure 
4.12A) and the total length of processes (figure 4.12B) compared to caspase inhibitor 
controls (p<0.001 for both branching and length, Tukey’s HSD test). Once again, as in 
figure 4.07C, the extent of process outgrowth in control cultures and cultures 
supplemented with 100ng/ml GDF5 seen in figure 4.12C was considerably less than 
that in control cultures and GDF5 supplemented cultures in figure 4.06A. The 
experiments represented by the data in figures 4.06A, 4.07C and 4.12C were 
performed many months apart and, as mentioned previously, batch to batch variations 
in the quality and potency of GDF5 and/or cell culture reagents may account for the 
discrepancy between experiments performed at different time periods. The addition of 
an anti-BMPR1A blocking antibody to cultures containing GDF5 significantly reduced 
the extent of GDF5 promoted process elongation and branching (p<0.001 in both 
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cases). In fact, inhibiting the binding of GDF5 to BMPR1A totally prevented GDF5 from 
increasing the length and degree of branching of PO SCG neuron processes over that 
seen in control cultures (figure 4.12 A and B). Adding either anti-BMPR1B or anti-
ACVR2A antibodies did not have a significant impact on the number of branch points 
compared to cultures containing GDF5 alone (figure 4.12A). However, both antibodies 
significantly reduced the efficacy of GDF5 in enhancing process elongation (p<0.05 for 
both antibodies), although not as effectively as anti-BMPR1A antibodies. The reduction 
of GDF5 promoted growth due to the addition of GDF5 receptor blocking antibodies to 
cultures is seen in the Sholl profiles as a reduction in the number of intersections at a 
distance greater than 30μm from the cell soma for antibody containing cultures 
compared to cultures containing only GDF5 (figure 4.12C). 
Taken together, the data presented in figures 4.11 and 4.12 suggest that BMPR1A is 
the primary type 1 receptor through which GDF5 signals to promote process 
outgrowth from P0 SCG neurons, at least in vitro. Whilst blocking binding of GDF5 to 
ACVR2A did cause a reduction in GDF5 promoted process outgrowth, the magnitude of 
the growth inhibition caused by anti-ACVR2A was relatively small and no comparison 
with the effects of blocking BMPR2 signalling on GDF5 promoted process outgrowth 
could be made due to lack of availability of an appropriate blocking antibody. 
Therefore, further research is needed to identify the type 2 receptor that GDF5 utilises 
to enhance process outgrowth from neonatal SCG neurons. Interestingly, it became 
apparent during the course of these experiments that GDF5 in the absence of NGF 
promotes both axon branching and length consistently (figures 4.10 C and D and 4.12 A 
and B). Whilst GDF5 is able to enhance NGF promoted axon elongation consistently 
(figures 4.10B and 4.11B), GDF5 does not promote branching consistently in the 
presence of NGF (figures, 4.10 A and 4.11 A).  
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Figure 4.12: Blocking GDF5 receptors inhibits GDF5 promoted process elongation and 
branching from cultured P0 SCG neurons.  P0 SCG neurons were cultured for 18hrs with 50µM 
Boc-D-FMK caspase inhibitors either without the addition of other factors (CasX), with 
100ng/ml GDF5 alone (GDF5) or 100ng/ml GDF5 together with 2μg/ml of either anti-BMPR1A 
antibody (anti-BMPR1A), anti-BMPR1B antibody (anti-BMPR1B) or anti-ACVR2A antibody (anti-
ACVR2A). (A) Mean number of branch points as a percentage of the GDF5 control cultures. (B) 
Mean total process length as a percentage of GDF5 control cultures (C) Sholl profiles of 
neurons cultured under the various conditions. All Graphs represent means ± s.e.m. n=6 
separate experiments with at least 60 neurons analysed for each condition from each 
experiment. ***=p<0.001, **=p<0.01, *=p<0.05 relative to GDF5 control, Tukey’s HSD test. 
GDF5 has previously been shown to act locally on processes to promote process 
elongation and branching (figure 4.09) and, whilst all the receptors have been shown 
to be expressed by P0 SCG neurons, BMPR1A and ACVR2A are expressed most strongly 
on processes (figures 4.04 and 4.05). For this reason, it was decided to use microfluidic 
compartment cultures to investigate the efficacy of GDF5 receptor blocking antibodies 
in inhibiting the growth promoting effects of GDF5 when GDF5 and blocking antibodies 
are only applied to processes. All microfluidic chamber cultures were set up with 
media supplemented with 1ng/ml of NGF and 50μM Boc-D-FMK caspase inhibitors in 
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both the soma and axon compartment. 1ng/ml NGF was used to ensure that SCG 
neuron processes grew robustly enough to cross the microfluidic barrier into the axon 
compartment. Control cultures, containing 100ng/ml of GDF5 in the axon 
compartment, were also established. In experimental cultures, function blocking 
antibodies against either BMPR1A, BMPR1B or ACVR2A were added at a concentration 
of 2μg/ml to the axon compartment of microfluidic chambers together with 100ng/ml 
of GDF5. The cultures were incubated for 24 hours, stained with calcein-AM and 
imaged using a fluorescence microscope. The extent of neuronal process outgrowth in 
each microfluidic chamber was measured according to the methods presented in 
chapter 2. Due to time constraints, this experiment was only repeated once. 
In contrast to the previous microfluidic chamber experiments (figure 4.09), the 
addition of 100ng/ml GDF5 to the axon compartment did not promote significant 
process growth compared to NGF only control cultures (figure 4.13, p=0.327, Tukey’s 
HSD test). Once again, the most likely cause of these experiment to experiment 
inconsistencies in the efficacy of GDF5 is batch to batch variations in the potency of 
GDF5 and/or the quality of tissue culture reagents. The data in figure 4.13; however, 
still suggest that blocking the binding of GDF5 to BMPR1A and ACVR2A receptors 
expressed on processes dramatically reduces GDF5 promoted process outgrowth . In 
contrast, the addition of anti-BMPR1B antibodies to the axonal compartment had little 
effect on the extent of GDF5 promoted process outgrowth. The reduction in GDF5 
promoted process outgrowth effected by anti-BMPR1A anti-ACVR2A blocking 
antibodies is statistically significant (p<0.01 compared to GDF5 only in the case of anti-
BMPR1A and p<0.001 compared to GDF5 only in the case of anti-ACVR2A, Tukey’s HSD 
test). This data suggests that a receptor complex containing BMPR1A and ACVR2A 
mediates GDF5 promoted process outgrowth in vitro when GDF5 is applied only to 
processes.  
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Figure 4.13: Preventing GDF5 from binding to BMPR1A and ACVR2A receptors located on 
processes inhibits local GDF5 promoted process outgrowth. (A-E) Representative images 
showing the extent of process outgrowth under the various experimental conditions. All 
conditions contain 1ng/ml NGF in both the axon and soma compartments. The axon 
compartment of microfluidic chambers is on the left of each image and the soma 
compartment is on the right. (A) no additional factors in the axon compartment (control). (B) 
100ng/ml GDF5 in the axon compartment. (C) 100ng/ml GDF5 + 2μg/ml anti-ACVR2A in the 
axon compartment and (D) 100ng/ml GDF5 + 2μg/ml anti-BMPR1A in the axon compartment. 
(E) 100ng/ml GDF5 + 2μg/ml anti-BMPR1B in the axon compartment. (F) Graph displaying 
average total process length for each condition. Graph represents mean ± s.e.m from 3 
separate cultures from one experiment. ***=p<0.001, **=p<0.01 comparison to GDF5 in axon 
compartment, Tukey’s HSD test). 
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4.5 Regulation of GDF5 receptor expression in vitro 
NGF promotes the survival, target field innervation and maturation of developing SCG 
neurons by regulating gene expression269, 391, 392. Since the peak expression of type 1 
and type 2 GDF5 receptors in the developing SCG corresponds to the period where the 
axons of SCG neurons are gaining access to target field-derived NGF, it is not 
inconceivable that NGF regulates the expression of GDF5 receptors, thereby 
modulating the responsiveness of SCG neurons to GDF5. Moreover, because some 
neurotrophic factors regulate the expression of their own receptors in developing 
peripheral neurons18, 393 and GDF5 appears to act locally on the axons of sympathetic 
neurons (figure 4.11), it is possible that target field-derived GDF5 may regulate the 
expression of its own receptors in the developing SCG.  
To determine whether GDF5 is able to regulate the expression of its own receptors, P0 
SCG neurons were cultured for 48 hours in the presence of 1ng/ml NGF, 50μM Boc-D-
FMK caspase inhibitor and a varying concentration of GDF5 ranging from 1ng/ml to 
100ng/ml. After 48 hours in culture, neurons were lysed to release RNA and total RNA 
was purified from the lysate. RT-qPCR was used to determine the levels of Bmpr1a, 
Bmpr1b, Acvr2a and Bmpr2 mRNAs in each purified total RNA sample relative to the 
geometric mean of the reference mRNAs, Gapdh, Sdha and Hprt1.  
The expression of Bmpr1a and Bmpr1b mRNAs appear to be regulated in a reciprocal 
way by GDF5, in a dose dependent manner (figure 4.14). In the case of Bmpr1a, GDF5 
increases mRNA expression (figure 4.14A). Whilst this increase in Bmpr1a mRNA 
expression is not significant compared to NGF alone when 1ng/ml of GDF5 is added to 
cultures (p>0.05, Tukey’s HSD), the addition of 10ng/ml and 100ng/ml of GDF5 does 
produce statistically significant increases in Bmpr1a mRNA expression compared to 
cultures containing NGF alone (p<0.001, for 10ng/ml and 100ng/ml GDF5, Tukey’s 
HSD) (figure 4.14A). 1, 10 and 100 ng/ml GDF5 significantly decreases the expression of 
Bmpr1b mRNA compared to cultures containing just NGF (p<0.001, for all three 
concentrations of GDF5, Tukey’s HSD) (figure 4.14C). The net result of GDF5 type 1 
receptor gene regulation by GDF5 is a dose dependent increase in the ratio of Bmpr1a 
mRNA to Bmpr1b by GDF5 (figure 4.15). The ratio of Bmpr1a mRNA to Bmpr1b 
increases more than 10-fold between cultures containing no GDF5 and cultures 
Chapter 4                                                                                                                           The functional role of GDF5 in vitro 
158 
 
supplemented with 100ng/ml GDF5. In contrast to type 1 receptors, GDF5 has no 
effect on the expression levels of Bmpr2 mRNA compared to NGF control cultures 
(p>0.05, for all concentrations tested, Tukey’s HSD) (figure 4.14D). Although GDF5 
modestly promotes the expression of Acvr2a mRNA compared to control cultures, the 
increase in expression with GDF5 is not statistically significant at any of the 
concentrations of GDF5 used (p>0.05, for all concentrations tested, Tukey’s HSD) 
(figure 4.14B). 
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Figure 4.14: GDF5 reciprocally regulates the expression of its type 1 receptor mRNAs in a 
dose dependent manner. P0 SCG cultures were cultured for 48 hours in media containing 
1ng/ml NGF and 50μM Boc-D-FMK caspase inhibitors together with either no GDF5 or with 1, 
10 or 100ng/ml GDF5. Receptor mRNA expression levels were determined using RT-qPCR. 
Graphs show the relative mRNA expression of( A) Bmpr1a (B) Acvr2a (C) Bmpr1b (D) Bmpr2 
mRNAs. Each value represents mean +/- s.e.m. of 4 individual RNA samples from each of three 
different culture experiments. Graph represents mean ± s.e.m from 3 separate cultures from 
one experiment. ***=p<0.001, ns.=p>0.05, Tukey’s HSD test). 
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Figure 4.15: Ratio of expression of Bmpr1a to Bmpr1b mRNA. Values calculated from the data 
presented in figure 4.12 
To determine whether NGF was able to regulate the expression of GDF5 receptor 
mRNAs cultures were established containing caspase inhibitors and varying 
concentrations of NGF from 0.01ng/ml to 10ng/ml, either in the absence or presence 
of 100ng/ml GDF5. After 48 hours of culture, neurons were lysed and total RNA was 
purified from the lysate. RT-qPCR was used to determine the levels of Bmpr1a, 
Bmpr1b, Acvr2a and Bmpr2 mRNAs in each purified total RNA sample relative to the 
geometric mean of the reference mRNAs, Gapdh, Sdha and Hprt1. 
Like GDF5, NGF also regulates the levels of Bmpr1a and Bmpr1b mRNAs in a reciprocal 
fashion (figure 4.16). Whereas GDF5 increases the expression of Bmpr1a mRNA (figure 
4.14A), concentrations of NGF above 0.1ng/ml significantly decrease the expression of 
this mRNA (p<0.05, Tukey’s HSD). The addition of 100ng/ml GDF5 cannot reverse NGF-
induced down regulation of Bmpr1a mRNA expression. NGF concentrations above 
0.1ng/ml significantly increase the expression of Bmpr1b mRNA compared to control 
cultures (p<0.001, Tukey’s HSD) (figure 4.16C), whereas GDF5 decreases the expression 
of this mRNA in a dose dependent manner (figure 4.14C). Indeed, 100ng/ml GDF5 can 
completely prevent the up-regulation of Bmpr1b mRNA expression by concentrations 
of NGF above 0.1ng/ml (p<0.001, Tukey’s HSD) (figure 4.16C). Like GDF5, NGF does not 
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appear to regulate the expression of Bmpr2 mRNA in culture (p>0.05 for all NGF 
concentrations, ANOVA) (figure 4.16D). Although NGF appears to modestly increase 
the expression of Acvr2a mRNA in a dose dependent manner, the increase in Acvr2a 
mRNA expression compared to control cultures is not significant at any of the NGF 
concentrations tested (p>0.05 for all NGF concentrations, ANOVA) (figure 4.16B). 
Taken together, the data in figures 4.14 to 4.16 suggest that, should the expression of 
GDF5 receptors be regulated in the same manner in vivo as in vitro, the levels of type 1 
GDF5 receptors expressed by developing SCG neurons, and hence neuronal 
responsiveness to GDF5, may be tightly regulated by the local relative concentrations 
of NGF and GDF5 within target fields.  
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Figure 4.16: NGF regulates the expression of GDF5 receptor mRNAs. P0 SCG cultures cultured 
for 48 hours in media containing 50μM Boc-D-FMK caspase inhibitors and either no NGF or 
with 0.01, 0.1, 1 or 10ng/ml NGF. A second set of cultures contained the same concentrations 
of caspase inhibitors and NGF, but with the addition of 100ng/ml GDF5. Receptor mRNA 
expression levels were determined using RT-qPCR. Graphs show the relative mRNA expression 
of (A) Bmpr1a (B) Acvr2a (C) Bmpr1b (D) Bmpr2 mRNAs. Each value represents mean +/- s.e.m. 
of 4 individual RNA samples from each of three 3 different culture experiments. *= p<0.05, 
***= P<0.001 compared to 0.1 ng/ml NGF (Tukey’s HSD test). ***= p<0.001 the addition of 
GDF5 compared to cultures containing NGF alone (Tukey’s HSD test) 
4.6 Discussion 
The data presented in the chapter reveal novel effects of GDF5 on developing 
sympathetic neurons of the mouse SCG in vitro. Bmpr1a, Bmpr1b, Bmpr2 and Acvr2a 
mRNAs, encoding type 1 and type 2 GDF5 receptors269, are expressed in the SCG 
throughout late embryonic and early postnatal development, with peak levels of 
expression observed around birth. Immunocytochemistry has demonstrated that all 
four putative GDF5 receptors are expressed at the protein level within the soma and 
processes of P0 SCG neurons. GDF5 is able to act in a dose dependent manner to 
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increase the extent of process elongation and branching from cultured SCG neurons 
over a narrow developmental window that encompasses P0 and P1. In addition, GDF5 
significantly enhances NGF promoted process elongation from neonatal SCG neurons, 
although it does not consistently enhance process branching in the presence of NGF.  
An intriguing feature of many of the experiments presented in this chapter is that 
whilst GDF5 consistently increases process elongation and branching by a similar 
degree compared to control cultures in the absence of NGF, the numerical values 
representing the mean number of intersections of processes in control cultures and 
cultures supplemented with GDF5 at different distances from the neuron soma, and 
hence the degree of process outgrowth, varies markedly between experiments carried 
out at different times over an extended time frame. As alluded to before, this is 
probably partly due to variations in the potency of GDF5 between different batches 
received from the manufacturer. In addition, tissue culture reagents, such as laminin, 
poly-ornithine, trypsin and F14 are prepared from stocks and aliquoted in working 
concentrations/amounts by lab members on a rota basis, whereby individual lab 
members are responsible for a task for a certain period of time before it is taken over 
by another lab member. It is likely that some lab members are less diligent/accurate 
than others when preparing and aliquoting reagents, leading to variations in the 
quality of some reagents over time. In particular, F14 powder is custom made for the 
research group (JRH Biosciences) and a new batch is received from the manufacturer 
every 9 months or so. In addition to the inherent variability in preparation of the 
working F14 stock solutions from the dry powder by different lab members, it is likely 
the exact composition and quality of the F14 powder from JRH Biosciences varies from 
batch to batch. Indeed, in the past, the research group have received batches of F14 
that are so poor that neurons fail to survive in culture for more than 24 hours and the 
F14 batch has needed to be discarded. Despite the inconsistencies in the absolute 
amount of process outgrowth and branching rising from P0 SCG neurons cultured in 
different experiments over a long time frame, the fact remains that the relative 
increase in the extent of process elongation and branching induced by the addition of 
GDF5 is consistent between experiments.  
The observation that application of GDF5 to the axon compartment of P0 SCG neurons 
cultured in microfluidic compartmentalised chambers increases NGF promoted process 
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outgrowth raises the possibility that GDF5 may be a target derived neurotrophic factor 
for these neurons in vivo. The data presented here are not the first demonstration that 
GDF5 has trophic effects on neurons. For example, GDF5 has been characterised as a 
potential neurotrophic factor for embryonic chicken DRG sensory neurons310, 311In 
cultures of developing mouse hippocampal pyramidal neurons, GDF5 causes growth 
and elaboration of dendritic processes, but, in contrast to the data presented in this 
chapter, GDF5 does not promote the growth of hippocampal neuron axons318. The 
effects of GDF5 on the elaboration of hippocampal neuron dendritic processes is 
reflected by the fact that CA1 and CA3 pyramidal neurons of postnatal Gdf5bp/bp mice 
have dramatically smaller dendritic arbors than those of age matched Gdf5+/+ mice318. 
In addition to its neurotrophic effects on developing chicken DRG and mouse 
hippocampal neurons, GDF5 also promotes the survival of cultured rat embryonic 
ventral midbrain neurons. GDF5 also protects such cells from N-methylpyridinium ion 
(MPP+) and free radical toxicity and promotes an increase in the length of their 
processes, the number of process branch points and neuron soma size387-389. In vivo, 
intracerebral injection of GDF5 into adult rats protects ventral midbrain dopaminergic 
neurons against the neurotoxic effects of 6-OHDA in a rat model of Parkinson’s 
disease390.  
As a result of GDF5 binding to the type 1 receptor, BMPR1B, with higher affinity than it 
does to the type 1 receptor, BMPR1A, it has been largely assumed that the biological 
effects of GDF5 are mediated by a receptor complex comprising BMPR1B in 
combination with either BMPR2 or ACVR2A269.  However, the data presented in this 
chapter suggest that, in the case of P0 SCG neurons, GDF5 may promote process 
elongation and branching by activating a receptor complex containing the BMPR1A 
receptor. Whilst neutralising the activity of either BMPR1A or BMPR1B with blocking 
antibodies reduces the efficacy of GDF5 in promoting process elongation and 
branching, thereby suggesting a certain level of redundancy in GDF5 type 1 receptor 
usage, anti-BMPR1A antibodies appear to be more effective than anti-BMPR1B 
antibodies in inhibiting the growth promoting effects of GDF5. A caveat to this 
interpretation is that it is not clear how specific the blocking antibodies are to their 
target receptors, i.e. whether there is any cross reactivity of each antibody to other 
neuronal plasma membrane proteins, and what the relative binding affinity of each 
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antibody is to its target receptor. These questions need to be addressed by western 
blotting and/or immuno-precipitation experiments to be able to draw the conclusion 
that anti-BMPR1A antibodies are more effective than anti-BMPR1B antibodies in 
preventing GDF5-promoted process outgrowth from cultured P0 SCG neurons. Given 
the potential limitations of blocking antibodies as a tool, the best approach to 
determining which type 1 receptor is responsible for mediating the process elongation 
and branching effects of GDF5 on cultured SCG neurons is to use additional 
methodologies to confirm and extend the data obtained with blocking antibodies. Such 
alternative methodologies include; using siRNAs and/or shRNAs to knockdown 
endogenous expression of each receptor in turn, overexpressing functional and 
dominant-negative BMPR1A and/or BMPR1B receptors in cultured P0SCG neurons. 
 Interestingly, GDF5 promotes the expression of Bmpr1a mRNA in cultured SCG 
neurons, but strongly down-regulates the expression of Bmpr1b mRNA in the same 
neurons. The upregulation of Bmpr1a mRNA expression and the downregulation of 
Bmpr1b mRNA expression by GDF5 could be interpreted as indicating that BMPR1A is 
the preferred receptor for GDF5 as it upregulates its expression. However, another 
interpretation that is equally as likely is that GDF5 downregulates the expression of its 
preferred receptor, BMPR1B, in a negative feedback loop to regulate responsiveness to 
GDF5. Therefore the reciprocal regulation of Bmpr1a and Bmpr1b mRNAs by GDF5 in 
culture sheds no light on the identity of the type 1 receptor that mediates the process 
out growth enhancing effects of GDF5 on P0 SCG neurons. 
 The identity of the type 2 receptor that mediates the growth promoting effects of 
GDF5 is unclear at present. Blocking binding of GDF5 to ACVR2A reduces the efficacy of 
GDF5 in promoting process outgrowth from cultured P0 SCG neurons, especially when 
anti-ACVR2A blocking antibodies are applied to the axon compartment of microfluidic 
chambers. The lack of availability of a verified BMPR2 blocking antibody, however, has 
prevented an investigation into whether redundancy in type 2 receptors also exists for 
mediating the effects of GDF5 on developing SCG neurons, as it does for type 1 
receptors. The fact that GDF5 does not significantly regulate the expression of either 
type 2 receptor mRNA in cultures of P0 SCG neurons also provides no clues to the 
preferred type 2 receptor for GDF5 in SCG neurons. Further investigation is clearly 
required to identify the type 2 receptor that GDF5 uses to mediate its trophic effects 
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on neonatal SCG neurons. Again, one useful methodological approach to clarifying the 
identity of the type 2 receptor would be to use either siRNAs or shRNAs to knockdown 
the expression of each type 2 receptor in cultured SCG neurons and observe how this 
interferes with the ability of GDF5 to promote process elongation and branching from 
these neurons. This approach would also further clarify the identity of the type 1 
receptor that GDF5 utilises to exert its trophic effects on SCG neurons.  
In addition to enhancing the elongation and branching of cultured neonatal SCG 
neuron processes, GDF5 also modulates the NGF promoted survival of cultured P0 SCG 
neurons; it does not affect survival in the absence of NGF. GDF5 enhances the survival 
of cultured P0 SCG neurons at low concentrations of NGF, whereas it reduces the 
efficacy of concentrations of NGF above 0.1ng/ml in promoting neuron survival. This 
somewhat confusing and contradictory finding could be potentially explained by the 
differential regulation of GDF5 type 1 receptors by NGF. Dose response experiments 
with NGF have shown that concentrations of NGF above 0.1ng/ml greatly reduce the 
expression of Bmpr1a mRNA, whilst at the same time significantly increasing the 
expression of Bmpr1b mRNA. If the changes in mRNA levels are reflected at the protein 
level, the ratio of BMPR1B receptors compared to BMPR1A receptors will increase by 
more than 60-fold between P0 SCG neurons cultured in media containing 0.1ng/ml 
NGF and neurons cultured in media containing 1ng/ml NGF. It is feasible that GDF5 
promotes the survival of P0 SCG neurons by signalling through a receptor complex 
containing BMPR1A, whereas it interferes with NGF-promoted survival when it signals 
though a receptor complex containing BMPR1B. The hypothesis is highly speculative 
and therefore requires much additional research to verify; such as using a combination 
of blocking antibodies (after having investigated their specificity and efficacy by 
western blotting) and siRNAs/shRNAs to determine whether blocking GDF5 binding to 
either BMPR1A or BMPR1B alters the way that GDF5 modulates NGF promoted SCG 
neuron survival in culture  Moreover, it is necessary to establish with western blotting 
whether NGF regulates the expression of type 1 receptors at the protein level in the 
same way as it does at the mRNA level. In support of the above hypothesis, a recent 
publication has shown that NGF regulates the responsiveness of developing SCG 
neurons to the novel neurotrophic factor, CD40L by regulating the expression of CD40L 
and its receptor, CD4072. An alternative explanation for the differential effects of 
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100ng/ml GDF5 on NGF promoted survival at different concentrations of NGF could 
potentially be that GDF5 interferes with the efficacy of NGF/TrkA and/or NGF/p75NTR 
interactions. This could potentially be addressed by immunoprecipitation experiments 
using antibodies against NGF, TrkA and p75 to quantify the number of NGF/TrkA and 
NGF/p75 complexes that form when PO SCG neurons are cultured with different 
amounts of NGF either in the presence or absence of 100ng/ml GDF5. 
To further complicate matters, GDF5 regulates the expression of its type 1 receptors in 
a reciprocal manner to NGF, with GDF5 promoting the expression of Bmpr1a mRNA 
and inhibiting the expression of Bmpr1b mRNA. Assuming that the regulation of GDF5 
type 1 receptors in vivo reflects the situation in vitro, the levels of each type 1 receptor 
that individual neurons express in vivo, and hence their survival and/or process 
outgrowth response to target field-derived GDF5, may be determined by the precise 
concentrations of NGF and GDF5 that they are exposed to within the local 
microenvironment of their target fields.  
Whilst the data obtained from microfluidic compartmentalised cultures suggest target 
field-derived GDF5 may regulate the innervation and arborisation of developing SCG 
neurons, more research is needed to validate this. In particular, there appears to a 
large variation between experiments in the efficacy of GDF5 in enhancing NGF 
promoted process outgrowth when it added to the axon compartment of microfluidic 
devices (figures 4.09 and 4.13). Further experiments with microfluidic devices are 
clearly needed to clarify the degree to which distally applied GDF5 can promote 
process elongation. In addition, the expression of GDF5 within the targets of SCG 
neurons needs to be demonstrated to provide further evidence that GDF is acting as a 
target field-derived neurotrophic factor for developing SCG neurons. In support of a 
target field-derived mode of action for GDF5, data presented in chapter 5 show that 
Gdf5 mRNA is expressed robustly in all SCG target fields at all ages analysed. Another 
unanswered question is whether local signalling mechanisms are used to enhance 
process outgrowth from SCG neurons when GDF5 is applied to process terminals, or 
whether retrograde signalling and transcriptional modulation is required for GDF5 to 
promote process outgrowth. In the case of NGF, the application of NGF to processes 
can promote their growth and branching through two mechanisms. The first is by local 
signalling, involving the activation of PLCγ and the subsequent mobilisation of 
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intracellular calcium stores and activation of PKC. The second is through a signalling 
endosome mediated retrograde signalling mechanism that results in alterations in 
transcriptional activity within the nucleus74. GDF5 principally exerts its biological 
effects by the activation of receptor SMADs 1,5,8 and their nuclear translocation, 
together with coSMAD4, to the nucleus where they modulate gene transcription394. A 
convenient way to demonstrate whether retrograde SMAD signalling mediates the 
process growth promoting effects of GDF5 when GDF5 is applied to the terminals of 
processes would be to culture P0 SCG neurons in microfluidic chambers. GDF5 can 
then be applied to the axon compartment. After a brief incubation, the neurons can 
then be fixed and stained with an antibody against phosphorylated SMADs 1,5,8. 
Enhanced nuclear phospho-SMAD staining after peripheral application of GDF5 would 
clearly indicate retrograde GDF5/GDF5 receptor signalling.   
Immunocytochemistry not only demonstrated that P0 SCG neurons express the type 1 
GDF5 receptors, BMPR1A and BMPR1B, and the type 2 receptors, ACVR2A and BMPR2, 
but also revealed that SCG neurons themselves express GDF5. The expression of GDF5 
and its receptors within developing SCG neurons raises the possibility that an autocrine 
GDF5 signalling loop exists that may exert trophic effects on SCG neurons in the 
absence of exogenous GDF5. The existence of a potential autocrine signalling loop 
needs to be tested in future culture experiments by determining whether blocking 
GDF5 activity with an anti-GDF5 blocking antibody modulates NGF promoted survival 
and/or NGF promoted process outgrowth and branching. An alternative approach 
would be to block any putative autocrine GDF5 signalling loop using the secreted BMP 
antagonist, Noggin, a protein that binds to BMPs and interferes with their interactions 
with BMP receptors309. A third, and perhaps more direct, approach to investigating the 
potential existence of an autocrine GDF5 signalling loop would be to compare how P0 
SCG neurons from Gdf5bp/bp and Gdf5+/+ neonates respond to NGF in culture. A series of 
NGF dose responses, investigating both survival and the extent of process outgrowth 
and branching, with cultures established in parallel from Gdf5bp/bp and Gdf5+/+ embryos 
and postnatal pups at several ages would comprehensively test whether a GDF5 
autocrine signalling loop operates to modulate NGF promoted survival and process 
outgrowth in developing SCG neurons in vitro. Given that Noggin can regulate the 
efficacy of GDF5/GDF5 receptor signalling, and the effects of GDF5 on cultured SCG 
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neurons are temporally limited to a very narrow postnatal developmental window, it 
will be important in future experiments to determine whether Noggin is expressed in 
developing SCG neurons, at both the mRNA and protein level. A detailed analysis of 
the temporal pattern of Noggin expression in the developing SCG may help to explain 
why the effects of GDF5 on SCG neurons are restricted to such a short developmental 
window.  If Noggin is expressed in developing SCG neurons, it would be informative to 
ascertain whether its expression is regulated in culture by either NGF and/or GDF5.  
In conclusion, the data presented in the chapter demonstrate that GDF5 is able to 
function as a neurotrophic factor for developing sympathetic neurons in vitro during a 
specific, narrow postnatal period. The next chapter will attempt to determine the 
physiological relevance of these in vitro findings by analysing the innervation of SCG 
neuron target fields by SCG neurons in wild type mice and transgenic mice that lack 
expression of either functional GDF5 or BMPR1B.  
   
Chapter 5 
 
 
 
 
 
 
 
 
 
5. The role of GDF5 in sympathetic 
target field innervation in vivo 
 
 
 
 
 
 
 
 
 
Chapter 5                                     The role of GDF5 in sympathetic target field innervation in vivo 
170 
 
5.1 Introduction 
Neurons of the rodent SCG innervate a number of defined target fields in the head. For 
example, SCG neurons provide sympathetic innervation to the submandibular salivary 
glands (SMG), pineal glands, oral and nasal mucosa and iris15, 60, 395. SCG neurons also 
provide sympathetic innervation to a number of tissues in the neck and thorax. The 
smooth muscles of the trachea receive extensive innervation by neurons of the SCG 
and also some sympathetic innervation by neurons of the more caudally situated 
stellate ganglion60, 164, 396-398. Whilst the heart receives substantial sympathetic 
innervation, this is primarily from the stellate ganglion in rodents. However, a small 
percentage of the sympathetic fibres that innervate the heart arise from the SCG and 
mid-thoracic paravertebral ganglia 164, 399. Initial target field innervation by mouse SCG 
neurons occurs in the late embryonic and perinatal period and between P0 and P10 
innervating fibres branch and ramify extensively within their target fields, a process 
termed target field arborisation 60, 164. In addition to its crucial role in supporting the 
survival of developing sympathetic neurons during the period of developmental 
neuronal death, target field-derived NGF is also required for successful target field 
innervation and arborisation by sympathetic neurons. Although NGF appears to be the 
main driver of target field innervation for the majority of developing SCG neurons, 
reflected by the complete lack of innervation of some targets, like the SMG, in the 
absence of NGF, the innervation of some targets, like the trachea, are significantly less 
affected by a lack of NGF 60, 164. This heterogeneous requirement for NGF in 
establishing correct target field innervation indicates that other neurotrophic factors 
must play a role in promoting the innervation of some SCG target fields. Indeed, a 
number of novel neurotrophic factors have recently been identified that modulate 
NGF promoted process outgrowth and branching from developing SCG neurons in 
culture and are required for normal innervation of certain SCG neuron target fields in 
vivo. These novel neurotrophic factors include; TNFα153 GITR169, RANKL170 and CD40L72. 
The data presented in chapter 4 have revealed that GDF5 promotes the elongation and 
branching of the processes of cultured neonatal SCG neurons by acting locally on the 
terminals of extending processes, suggesting that it may be a novel target field-derived 
neurotrophic factor that modulates the extent of target field innervation and 
arborisation in vivo. Interestingly, GDF5 can promote process outgrowth on its own 
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and also enhance NGF promoted process outgrowth. In addition, GDF5 appears to 
modulate NGF promoted survival of cultured neonatal SCG neurons. The available in 
vitro evidence raises the possibility that GDF5 exerts its neurotrophic effects by 
signalling through a receptor complex that includes the type 1 receptor BMPR1A, 
rather than its normal signalling partner, BMPR1B.  
This chapter aims to test the physiological relevance of the in vitro findings in chapter 4 
by analysing the innervation of several SCG target fields by TH-positive sympathetic 
neurons in postnatal Gdf5+/+ (wild type), Gdf5+/bp (heterozygote) and Gdf5bp/bp mice. In 
addition, the identity of the type 1 receptor that mediates the trophic effects of GDF5 
on developing SCG neurons will be investigated by examining sympathetic target field 
innervation in postnatal Bmpr1b+/+, Bmpr1b-/+ and Bmpr1b-/- mice. Unfortunately, due 
to the embryonic lethality, at E9.5, of a homozygous deletion in the Bmpr1a gene the 
role of BMPR1A in mediating the neurotrophic effects of GDF5 on developing SCG 
neurons could not be directly tested by comparing target field innervation between 
Bmpr1a+/+, Bmpr1a+/- and Bmpr1a-/- mice. However, target field innervation was 
analysed in adult heterozygote Bmpr1a mutant mice.   
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5.2 Comparison between sympathetic target field 
innervation in P10  Gdf5+ /+ ,  Gdf5+ /b p  and Gdf5b p /b p  mice 
To determine whether the ability of GDF5 to enhance the elongation and branching of 
the processes of cultured postnatal SCG neuron has any relevance to SCG neuron 
target field innervation in vivo, tyrosine hydroxylase (TH) immunofluorescence was 
used to identify sympathetic fibres and quantify innervation density in sections of SCG 
target fields dissected from P10 Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice. The SCG target 
fields analysed by immunohistochemistry were iris and SMG, since they receive dense 
innervation from the SCG and were practically the easiest tissues to section and stain. 
P10 mice were chosen for analysis, because this time point is after the window where 
GDF5 has a process outgrowth promoting affect in vitro and by P10 sympathetic 
arborisation within the iris and SMG is complete60. 
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Figure 5.01: GDF5 does not appear to be required for correct innervation of the SMG by SCG 
neurons in vivo. Bar chart showing density of TH-positive innervation in sections of SMGs that 
have been dissected from P10 Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice. Data represent means +/- 
s.e.m of 10 animals per genotype.  Values are normalised to the innervation density of TH-
positive fibres in the SMG sections from Gdf5+/+ mice. One-way ANOVA shows that the values 
for innervation density between the different mouse genotypes are not significantly different 
(p=0.905).  
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Whilst there are no significant differences in the density of sympathetic innervation 
between sections of SMGs dissected from P10 Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice 
(figure 5.01, p=0.905; one-way ANOVA), the extremely high variance in data between 
different animals of the same genotype, as indicated by the high s.e.m. values and 
coefficient of variation values of 45%, 60% and 79% for Gdf5+/+, Gdf5+/bp and Gdf5bp/bp 
mice, respectively, means that it is difficult to conclude whether GDF5 plays a role in 
modulating the innervation of the iris in vivo. Moreover, because of the large variation 
in SMG innervation density within animals of the same genotype, no representative 
images of TH-positive innervation have been included in figure 5.01. In marked 
contrast, a loss of functional GDF5 has dramatic dose dependent effects on the 
sympathetic innervation of the iris (figure 5.02). The representative images of iris 
sections from each genotype clearly show a reduction in TH-positive staining between 
sections from Gdf5+/+ and Gdf5+/bp mice (figure 5.02A). In iris sections from Gdf5bp/bp 
mice, TH-positive fibres are greatly depleted compared to iris sections from Gdf5+/+ 
and Gdf5+/bp mice. Image analysis and quantification of TH-positive innervation density 
of irides for each genotype reveals a 50% reduction in innervation density between 
Gdf5+/+ and Gdf5+/bp mice and an almost 80% reduction in the density of innervation 
between Gdf5+/+ and Gdf5bp/bp mice (figure 5.02B). These reductions in the density of 
sympathetic innervation in GDF5 mutant mice compared to Gdf5+/+ mice are highly 
statistically significant (p<0.001 for Gdf5+/bp and Gdf5bp/bp mice; Tukey’s HSD test).  
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Figure 5.02: GDF5 is essential for correct innervation of the iris by SCG neurons in vivo. (A) 
Representative images of sections of iris dissected from P10 Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice 
that have been stained with an antibody against TH. Scale bar 100μm. (B) Bar chart showing 
density of TH-positive innervation in sections of irides that have been dissected from P10 
Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice. Data represent means +/- s.e.m of 10 animals per 
genotype. Values are normalised to the innervation density of TH-positive fibres in the iris 
sections from Gdf5+/+ mice.  ***=p<0.001 comparison to Gdf5+/+ mice; Tukey’s HSD test.  
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Figure 5.03: Control images of immunohistochemistry TH quantification experiment. Sections 
of iris and SMG were incubated without primary anti-TH (rabbit) antibody but with secondary 
rabbit Alex Fluor 488 antibody. A) Section of iris without primary antibody incubation but 
stained with secondary, (B) an example image of anti-TH stained iris, (C) section of SMG 
without primary antibody incubation but stained with secondary and (D) an example image of 
anti-TH stained SMG. 
Control staining images (no primary antibody) for the TH quantification of target field 
innervation are shown in figure 5.03. To ascertain the relationship between 
sympathetic fibres in the iris and GDF5 expression, sections of Gdf5+/+ irides were 
double stained for TH and GDF5. As seen in figure 5.04, the stroma of the iris expresses 
GDF5 and TH-positive fibres innervate the stroma. Control staining images (no primary 
antibodies) for the double staining of the iris with GDF5 and TH are shown in figure 
5.05. 
 
 
Figure 5.04: Representative sections of the iris of a P10 Gdf5+/+ mouse double stained for 
GDF5 and TH.  Arrow indicates stroma. Post, posterior aspect of the iris. Scale bars = 100m.  
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Figure 5.05: Control images of immunohistochemistry double staining experiment. Sections of 
iris were incubated without primary antibodies but with secondary antibodies. A) Rabbit Alexa 
Fluor 488 (green), (B) sheep Alexa Fluor 594 (red) (C) merge image and (D) an example merged 
image of double stained iris with anti-GDF5 and anti-TH primary antibody incubation. 
To further investigate the role that GDF5 plays in sympathetic target field innervation 
in vivo, whole-mount TH-staining was used to analyse the sympathetic innervation of 
the pineal gland, heart and trachea in P10 Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice. In 
rodents, the heart receives most of its sympathetic innervation from the stellate 
ganglion, but receives a small number of sympathetic fibres from neurons within the 
SCG and paravertebral sympathetic ganglia 164, 399. The pineal gland and trachea are 
predominantly innervated by sympathetic neurons within the SCG. The whole-mount 
staining technique allows a 3D examination of target field innervation to be conducted, 
thereby revealing the spatial organisation of innervation. A modified line-intercept 
method was used to analyse whole mount images, as described in detail in see section 
2.8, allowing a semi-quantitative assessment of the density of sympathetic innervation 
within the three target fields examined for each genotype of mouse.  
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Figure 5.06: GDF5 plays a role in regulating sympathetic innervation of the heart in vivo. (A) 
Representative images of TH-stained whole mount preparations of hearts from P10 Gdf5+/+, 
Gdf5+/bp and Gdf5bp/bp mice. Scale bars, 100µm. (B) Relative density of TH positive fibres 
innervating the left ventricle of the hearts of P10 Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice. Data 
represent mean ± s.e.m. Values are normalised to the mean innervation density of TH-positive 
fibres in the left ventricles of hearts from Gdf5+/+ mice. n= 5 animals for each genotype. 
*=p<0.05 compared to Gdf5+/+ hearts, Tukey’s HSD test.  
It appears that correct sympathetic innervation of the heart is partially dependent on 
GDF5 expression, since Gdf5bp/bp and Gdf5+/bp mice have a small, but significant, 
reduction in the density of sympathetic fibres innervating the left ventricle of their 
hearts compared to Gdf5+/+ mice (p<0.05 for both Gdf5bp/bp and Gdf5+/bp mice; Tukey’s 
HSD test) (figure 5.06). Where the atrioventricular node and bundle of His enter the 
left ventricle were used as anatomical landmarks to ensure that the analysis of images 
between genotypes was consistent. This data provides evidence that GDF5 also plays a 
role in modulating target field innervation by neurons that reside in sympathetic 
ganglia other than the SCG, in this case the stellate ganglion.  
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Figure 5.07: GDF5 is not required for successful innervation of the pineal gland by developing 
SCG neurons in vivo. Representative images of TH-stained whole-mount preparations of pineal 
glands from P10 Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice. Scale bars, 100µm. (B) Relative density of 
TH positive fibres innervating the pineal glands of P10 Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice. 
Data represent mean ± s.e.m. Values are normalised to the mean innervation density of TH-
positive fibres in the pineal glands from Gdf5+/+ mice. n= 5 animals for each genotype. One-way 
ANOVA shows that differences in the innervation density of the pineal glands between the 
three genotype of mice are not significant (p=0.981). 
In contrast to the heart where the data shows a significant difference between 
genotypes, there are no significant differences in the extent of sympathetic 
innervation between pineal glands from P10 Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice 
(p=0.981, one-way ANOVA) (figure 5.07).  It should be noted that the background 
strain of these mice (C57/B6) have a deficient pineal gland that does not produce 
melatonin.  The major axonal bundle entering the pineal gland was used as an 
anatomical landmark to ensure that the analysis of sympathetic innervation density 
within pineal glands was consistent between animals of each genotype.  
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Figure 5.08: GDF5 plays a role in regulating sympathetic innervation of the trachea by 
developing SCG neurons in vivo. Representative images of TH-stained whole-mount 
preparations of trachea from P10 Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice. Scale bars, 100µm. (B) 
Relative density of TH positive fibres innervating the trachea of P10 Gdf5+/+, Gdf5+/bp and 
Gdf5bp/bp mice. Data represent mean ± s.e.m. Values are normalised to the mean innervation 
density of TH-positive fibres in the trachea from Gdf5+/+ mice. n= 5 animals for each genotype. 
*=p<0.05, **= p<0.01 compared to Gdf5+/+ trachea, Tukey’s HSD test.  
The trachea of  P10 Gdf5bp/bp and Gdf5+/bp mice show significantly reduced innervation 
by SCG neurons compared to the P10 Gdf5+/+ mice (p<0.01 and p<0.05, respectively) 
(figure 5.08). The major lateral axon bundle of the trachea was used as an anatomical 
landmark to ensure that the analysis of trachea innervation was consistent between 
genotypes. Taken together, immunohistochemical and whole-mount analysis of 
sympathetic target field innervation in P10 Gdf5+/+, Gdf5+/bp and Gdf5bp/bp has revealed 
that GDF5 is required for complete innervation of some sympathetic targets, but not 
others, raising the possibility that GDF5 plays a tissue-selective role in establishing 
correct patterns of sympathetic innervation in developing mice. However, the high 
degree of variance in some of the data, especially SMG innervation data suggests that 
this interpretation of the data should be made with caution.  
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5.2 Comparison between SCG target field innervation in 
P10  Bmpr1b+/ + ,  Bmpr1b -/+and Bmpr1b - /- mice. 
The in vitro findings presented in chapter 4 of this thesis raise the possibility that the 
trophic effects of GDF5 are mediated by a signalling complex that includes the type 1 
GDF5 receptor, BMPR1A, rather than the usual GDF5 type 1 receptor, BMPR1B. The 
most direct way to test this hypothesis would be to examine the innervation of 
sympathetic target fields in Bmpr1a-/- mice to determine whether the deficits in 
innervation due to the loss of GDF5 expression were mirrored in mice lacking BMPR1A.  
However, since Bmpr1a-/- mice are embryonic lethal275, TH-positive innervation was 
analysed by immunohistochemistry on sections of the SMG and iris dissected from P10 
Bmpr1b+/+, Bmpr1b-/+ and Bmpr1b-/- mice in an attempt to verify whether BMPR1A 
mediates the trophic effects of GDF5 on developing SCG neurons by a process of 
elimination.  
There were no deficits in the sympathetic innervation of SMGs dissected from P10 
Bmpr1b-/+ and Bmpr1b-/- mice compared to SMGs dissected from Bmpr1b+/+mice (figure 
5.09). In contrast to the dramatic reduction in iris innervation seen in GDF5 deficient 
mice compared to wild type mice, the irides of P10 Bmpr1b-/+ and Bmpr1b-/- mice are 
innervated to a similar extent as the irides of P10 Bmpr1b+/+ mice (figure 5.10). Whilst 
there does appear to be a small reduction in the density of sympathetic fibres that 
innervate the irides of Bmpr1b-/- mice compared to the irides of Bmpr1b+/+ mice, this 
reduction is not significant  (p= 0.707; one-way ANOVA) (figure 5.010B) due to the high 
degree of variance seen in data for each genotype (as indicated by the large s.e.m.). 
Although these data suggests that GDF5 does not mediate its trophic effects on 
developing sympathetic neurons of the SCG by signalling through a receptor complex 
incorporating BMPR1B, other interpretations of the data are possible, as discussed 
below. It should be noted the relatively small sample size (n=5, per genotype) could 
explain why no significant difference in the level of innervation was seen between the 
three genotypes of mice with data exhibiting such a high degree of variance.  
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Figure 5.09: The loss of functional BMPR1B expression does not affect sympathetic 
innervation of the SMG in vivo. (A) Representative images of sections of SMGs dissected from 
P10 Bmpr1b+/+, Bmpr1b-/+ and Bmpr1b-/- mice that have been stained with an antibody against 
TH. Scale bar 200μm. (B) Bar chart showing density of TH-positive innervation in sections of 
SMGs that have been dissected from P10 Bmpr1b+/+, Bmpr1b-/+ and Bmpr1b-/- mice. Data 
represent means +/- s.e.m of 5 animals per genotype. Values are normalised to the innervation 
density of TH-positive fibres in the SMG sections from Bmpr1b+/+ mice. One-way ANOVA shows 
that the values for innervation density between the different mouse genotypes are not 
significantly different (p=0.932).  
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Figure 5.10: The loss of functional BMPR1B expression does not appear to affect sympathetic 
innervation of the iris in vivo. (A) Representative images of sections of irides dissected from 
P10 Bmpr1b+/+, Bmpr1b-/+ and Bmpr1b-/- mice that have been stained with an antibody against 
TH. Scale bar 200μm. (B) Bar chart showing density of TH-positive innervation in sections of 
irides that have been dissected from P10 Bmpr1b+/+, Bmpr1b-/+ and Bmpr1b-/- mice. Data 
represent means +/- s.e.m of 5 animals per genotype.  Values are normalised to the 
innervation density of TH-positive fibres in the iris sections from Bmpr1b+/+ mice. One-way 
ANOVA shows that the values for innervation density between the different mouse genotypes 
are not significantly different (p=0.707).  
5.4 Sympathetic target field innervation in Bmpr1a+/+  and 
Bmpr1a+ / - adult mice 
Whilst the Bmpr1a-/- mice are embryonic lethal 275, a Bmpr1aloxP/loxP transgenic mouse 
line has been generated400-402. By crossing Bmpr1aloxP/loxP mice with the appropriate 
cre-recombinase driver strain, it is possible to delete Bmpr1a expression in specific 
tissues/cell types. It was not possible to import Bmpr1aloxP/loxP mice and establish a 
breeding colony in our laboratory. SMG and iris tissue from adult Bmpr1a+/+ and 
Bmpr1a-/+ heterozygous deleted mice was kindly provided by Jack Kessler and Chian-Yu 
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Peng of Northwestern University, Illinois, USA.  It was not possible to acquire SMG and 
iris tissue from P10 Bmpr1aloxP/loxP, Bmpr1aloxP/- and Bmpr1a-/- mice (as a result of 
crossing conditional Bmpr1a mice with Nestin-CreERT2 transgenic mice) because of 
problems breeding the mice. Immunohistochemistry of the adult tissues with a TH 
antibody revealed that there is no difference in the density of sympathetic innervation 
in the SMG of adult Bmpr1a+/+ mice compared to the SMG of adult Bmpr1a-/+ mice 
(figure 5.11); however, these data are from a very small sample size of n=3 for 
Bmpr1a+/+ and n= 4 for Bmpr1a-/+, so this interpretation of the data should be treated 
with caution  
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Figure 5.11: The deletion of one BMPR1A allele does not affect the sympathetic innervation 
of the SMG in adult mice. (A) Representative images of sections of SMGs dissected from adult 
Bmpr1a+/+ and Bmpr1a-/+ mice that have been stained with an antibody against TH. Scale bar 
200μm. (B) Bar chart showing density of TH-positive innervation in sections of SMGs that have 
been dissected from adult Bmpr1a+/+ and Bmpr1a-/+ mice. Data represent means +/- s.e.m, n=3 
for Bmpr1a+/+ mice and n=4 for Bmpr1a-/+ mice.  Values are normalised to the innervation 
density of TH-positive fibres in the SMG sections from Bmpr1a+/+ mice. Mann-Whitney test 
shows that the values for innervation density between the two mouse genotypes are not 
significantly different (p=0.288).  
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Figure 5.12: The deletion of one BMPR1A allele does not significantly affect the sympathetic 
innervation of the iris in adult mice. (A) Representative images of sections of irides dissected 
from adult Bmpr1a+/+ and Bmpr1-/+- mice that have been stained with an antibody against TH. 
Scale bar 200μm. (B) Bar chart showing density of TH-positive innervation in sections of irides 
that have been dissected from adult Bmpr1a+/+ and Bmpr1a-/+ mice. Data represent means +/- 
s.e.m, n=3 for Bmpr1a+/+ mice and n=4 for Bmpr1a-/+ mice.  Values are normalised to the 
innervation density of TH-positive fibres in the iris sections from Bmpr1a+/+ mice. Mann-
Whitney test shows that the values for innervation density between the two mouse genotypes 
are not significantly different (p=0.191).  
The in vivo analyses of TH-positive target field innervation by SCG neurons in P10 
Gdf5bp/bp mice suggested that only certain target fields of these mice have a reduction 
in sympathetic innervation compared to P10 Gdf5+/+ mice. The target organ most 
affected by a loss of functional GDF5 is the iris (figure 5.02). Interestingly, the iris does 
not show a significant innervation deficit in P10 Bmpr1b-/- mice compared to P10 wild 
type mice (figure 5.10), although, as mentioned above, this could be a result of the 
small sample size and a high level of variance in innervation density between 
individuals of each genotype. Figure 5.12 shows the quantitative analysis of 
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immunofluorescence in the irides of adult Bmpr1a+/+ mice compared to adult Bmpr1a-
/+ mice. Although there is a 40% reduction in the density of sympathetic innervation in 
the irides of Bmpr1a-/+ mice compared to Bmpr1a+/+ mice, this reduction is not 
statistically significant (p=0.1913, Mann-Whitney U test). Because of the small sample 
size (n=3 for Bmpr1a+/+ mice and n=4 for Bmpr1a-/+ mice) and the high degree of 
variance in innervation density between individuals of the same genotype, it is not 
possible to make any firm conclusions as to whether BMPR1A is the type 1 receptor 
that mediates the GDF5 promoted innervation of the iris. Analysis of the TH-positive 
innervation of the irides of a sufficient number of P10 Bmpr1aloxP/loxP, Bmpr1aloxP/- and 
Bmpr1a-/- mice in the future may determine what role Bmpr1a plays in mediating 
GDF5-promoted innervation of the iris in developing mice.  
5.5 Temporal expression of Gdf5 mRNA in SCG neuron 
target fields of postnatal CD1 mice 
The in vitro data presented in chapter 4 suggest that GDF5 could be a target field-
derived neurotrophic factor that promotes target field innervation by developing 
mouse SCG neurons. An in vivo analysis of target field innervation in GDF5 mutant 
mice has raised the possibility that GDF5 is required to establish the appropriate 
innervation of some sympathetic neuron target fields, but not others. Given that 
developing sympathetic neurons express GDF5 (figure 5.04), it is necessary to verify 
that sympathetic neuron target fields express GDF5 during development, at similar or 
higher levels than are expressed in sympathetic neurons, to provide further evidence 
that GDF5 promotes the innervation of certain sympathetic neuron target fields in vivo 
by acting as a target field-derived neurotrophic factor. Moreover, a quantitative 
analysis of GDF5 expression in developing sympathetic target fields may provide data 
that helps explain why certain target fields show a deficit in sympathetic innervation in 
GDF5 mutant mice whereas other target fields are unaffected, especially if the analysis 
of GDF5 expression is coupled with a quantitative analysis of NGF expression in the 
same target fields. RT-qPCR was used to provide quantitative data for the levels of 
Gdf5 and Ngf mRNAs expressed within SCG neurons and sympathetic neuron target 
fields dissected from P0, P5, P10 and adult CD1 mice.  
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Somewhat surprisingly, Ngf mRNA is expressed by postnatal SCG neurons, albeit at low 
levels compared to most of the sympathetic target fields analysed (figure 5.13A). In the 
early postnatal period the highest levels of Ngf mRNA are found in the iris and pineal 
gland, with expression levels in both of these targets decreasing from P0 to P10, 
although this decrease in expression between P0 and P10 is not significant in the iris 
(p>0.05, Tukey’s HSD), it is in the pineal gland (p<0.001, Tukey’s HSD). The expression 
of Ngf mRNA decreases further in the iris and pineal gland between P10 and the adult, 
although this decrease is not significant for either target (p>0.05, Tukey’s HSD). The 
total decrease in the levels of Ngf mRNA between P0 and adult is significant for both 
the iris and pineal gland (p<0.001, for both, Tukey’s HSD).  Whilst, the SMG expresses 
low levels of Ngf mRNA at P0, there is a three-fold increase in expression between P0 
and P10 (P<0.01, Tukey’s HSD) and a dramatic 150-fold increase in the expression of 
Ngf mRNA between P10 and adult (p<0.001, Tukey’s HSD). In fact, the levels of Ngf 
mRNA expressed within the adult SMG are so high that the data cannot be plotted on 
the same graph as the SCG and target field data (figure 5.13A). The postnatal and adult 
heart expresses very low levels of Ngf mRNA that is of a similar magnitude to Ngf 
mRNA expression within the SCG.  
Gdf5 mRNA is expressed in the SCG and all the sympathetic target fields examined 
(figure 5.13B). By far, the highest levels of Gdf5 mRNA are expressed in the postnatal 
and adult SMG, with a highly significant four-fold increase in levels between P0 and a 
peak of expression at P10 (p<0.001, Tukey’s HSD) followed by a 30% decline in 
expression between P10 and adult that is also statistically significant (p<0.01, Tukey’s 
HSD). At P10, Gdf5 mRNA is expressed at 30-, 200- and 2000-fold higher levels than it is 
in P10 pineal gland, iris and heart, respectively. The very high level of Gdf5 mRNA 
expressed within the SMG is surprising, given that no changes were observed in the 
sympathetic innervation of the SMG in P10 Gdf5bp/bp mice compared to wild type mice. 
The second highest levels of Gdf5 mRNA are expressed in the pineal gland, an SCG 
target that also does not show defective innervation in P10 Gdf5bp/bp mice and is 
coincidentally known to be melatonin deficient in C57/B6 mice. The lowest levels of 
target field Gdf5 mRNA are found in the iris and heart (figure 5.13C), both of which 
show statistically significant innervation deficits in Gdf5bp/bp mice. There are large 
reductions in the levels of Gdf5 mRNA expressed within the SCG, iris, pineal gland and 
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heart between neonatal and adult ages. These reductions in GDF5 mRNA levels 
between neonatal and adult ages are statistically significant in the case of the SCG, iris 
and pineal gland (p<0.01, 0.001 and 0.01, respectively, Tukey’s HSD test), but not the 
heart (p>0.05, Tukey’s HSD) 
Since NGF is the main driver of sympathetic target field innervation and arborisation in 
the developing mouse60, the ratio of Gdf5 mRNA relative to Ngf mRNA was calculated 
from the individual Gdf5 and Ngf mRNA expression data for the SCG and each 
sympathetic target field in a bid to make sense of the somewhat surprising Gdf5 mRNA 
expression data displayed in figure 5.14. The highest level of Gdf5 mRNA expression 
relative to Ngf mRNA expression was observed in the SMG during the postnatal period 
(figure 5.14A) and the lowest ratio of Gdf5 mRNA expression relative to Ngf mRNA 
expression was observed in the postnatal iris (figure 5.14B).  
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Figure 5.13: Quantitative analysis of Gdf5 and Ngf mRNA expression levels in SCG and 
selected sympathetic target fields. (A) Ngf mRNA expression in postnatal and adult SCG and 
sympathetic target fields. (B) Gdf5 mRNA expression in postnatal and adult SCG and 
sympathetic target fields. (C) Gdf5 mRNA expression with SMG data removed. Expression of 
Ngf and Gdf5 mRNAs are relative to a geometric mean of the reference mRNAs; Gapdh, Sdha 
and Hprt1. Data represents means ± s.e.m. from 4 separate RNA samples from each 
developmental-age.
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Figure 5.14: Ratio of Gdf5 mRNA levels relative to Ngf mRNA levels in SCG and selected 
sympathetic target fields. (A) Ratio of Gdf5 mRNA levels relative to Ngf mRNA levels in 
postnatal and adult SCG and target fields. (B) Ratio of Gdf5 mRNA expression relative to Ngf 
mRNA expression with SMG data removed. Values are mean +/- s.e.m. and are calculated from 
data presented in figure 5.11.  
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5.6 Discussion 
The data presented in this chapter demonstrate that the GDF5 promoted 
enhancement of process outgrowth and branching from cultured neonatal SCG 
neurons that was identified and characterised in the previous chapter is physiologically 
relevant in vivo. The loss of either one or two functional Gdf5 alleles leads to a deficit 
in sympathetic innervation in some SCG neuron target fields, such as the iris, but not 
others. Although this raises the possibility that GDF5 plays a tissue-selective role in 
establishing functional sympathetic innervation in vivo, significant further investigation 
is required to verify if this is the case and, if it is, to determine the mechanism that 
underlies any target field-specific requirement for GDF5 to promote functional 
innervation. The SCG target field showing the largest innervation deficit in postnatal 
Gdf5bp/bp mice is the iris. A complete lack of functional GDF5 expression results in an 
almost 80% reduction in the density of sympathetic innervation in the iris of Gdf5bp/bp 
mice compared to wild type mice, whereas the loss of one functional Gdf5 allele 
results in a 50% deficit in innervation in Gdf5+/bp mice compared to wild type mice. The 
reduction in the density of sympathetic innervation in the irides of Gdf5+/bp mice 
suggest that the levels of GDF5 expressed in either the SCG (autocrine-derived GDF5) 
or iris (target field-derived GDF5) are limiting with respect to the enhancement of 
process outgrowth and branching from SCG neurons innervating the iris. Another SCG 
neuron target field that displays an innervation deficit in GDF5 mutant mice compared 
to wild type mice is the trachea. In the case of the trachea, the innervation deficit 
observed in the complete absence of functional GDF5 expression is only 20% and not 
greater than the deficit observed in Gdf5+/bp mice that lack one functional GDF5 allele. 
In contrast to the iris and trachea, the sympathetic innervation of the SMG and pineal 
glands dissected from Gdf5+/bp and Gdf5bp/bp mice is not distinguishable from that seen 
in wild type mice. However, in the case of the SMG, the high degree of variance 
observed in the density of sympathetic innervation between postnatal mice of the 
same genotype, prevents any conclusion being drawn as to whether GDF5 is needed 
for functional innervation of this target. Clearly, more SMGs need to be analysed from 
GDF5+/+, GDF5+/bp and GDF5bp/bp mice, perhaps using a better tissue preparation 
method, such as iDISCO403, and/or an alternative quantification method, to establish 
whether GDF5+/bp and GDF5bp/bp mice show a deficit in SMG innervation compared to 
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wild type mice. In addition to SCG neuron target fields, the sympathetic innervation of 
the heart, a target of stellate ganglion neurons 404, was analysed in GDF5 mutant mice 
and shown to be reduced by approximately 20% compared to wild type mice, thereby 
potentially demonstrating that GDF5 is a not just a neurotrophic factor for sympathetic 
neurons of the developing SCG.  
In many respects, a potential heterogeneous requirement for GDF5 to promote 
optimal target field innervation resembles that of NGF164. Whilst NGF is absolutely 
required for sympathetic innervation of the SMG, the heart is partially innervated in 
the absence of NGF and sympathetic innervation of the trachea is not affected by the 
loss of NGF. The data presented in this chapter suggest that GDF5 may be one 
neurotrophic factor that promotes sympathetic innervation of the heart and trachea in 
the absence of NGF. The innervation of the pineal gland and iris have not been 
analysed in the absence of NGF164. Therefore, it is not clear whether pineal gland 
innervation is absolutely dependent on NGF, which would be in agreement with the 
observation that the pineal gland is innervated normally in Gdf5bp/bp mice, or whether 
GDF5 promotes the innervation of the iris on its own or enhances NGF-promoted 
innervation.  
Data presented in chapter 4 suggested that GDF5 exerts its growth promoting effects 
on cultured neonatal SCG neurons by activating a receptor complex containing the 
type 1 GDF5 receptor, BMPR1A. Analysis of SCG target field innervation in postnatal 
Bmpr1b+/+, Bmpr1b-/+ and Bmpr1b-/- mice and adult Bmpr1a+/+ and Bmpr1a-/+ mice has 
failed to clarify the identity of the type 1 receptor that mediates GDF5 promoted 
target field innervation in vivo. The loss of functional BMPR1B does not reduce the 
innervation of the SMG compared to wild type mice, although, as with the analysis of 
SMG innervation in GDF5 mutant mice, the high degree of variance in innervation 
density within animals of the same genotype prevents a definitive conclusion on the 
role that BMPR1B plays in mediating the innervation of the SMG being made. The 
within genotype variance in innervation density is relatively small for the analysis of 
SMG innervation in adult Bmpr1a+/+and Bmpr1a+/- mice and indicates that the loss of 
one functional Bmpr1a allele does not compromise the innervation of the SMG 
compared to wild type mice. In contrast to Gdf5+/bp mice, the loss of one BMPR1B 
allele does not significantly alter the density of sympathetic innervation within the P10 
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iris compared to the irides of Bmpr1b+/+mice . Moreover, Bmpr1b-/- mice only show a 
small deficit in sympathetic innervation of the iris compared to Bmpr1b+/+mice, a 
reduction that is not statistically significant. However, in contrast to the analysis of iris 
innervation in Gdf5+/+, Gdf5+/bp and Gdf5bp/bp mice, there is a high degree of variance in 
innervation density within individual genotypes in the analysis of iris innervation in 
BMPR1B mutant mice, that is possibly due to a small sample number of 5 per 
genotype.  Therefore, it is not possible to conclude that BMPR1B is not required to 
mediate GDF5-promoted innervation of the iris in vivo without repeating the analysis 
of iris innervation in a greater number of P10 wild type and BMPR1B transgenic mice. 
Despite this, the data does at least suggest that GDF5 does not signal through BMPR1B 
in vivo to promote target field innervation, raising the possibility that either another 
type 1 receptor is used by GDF5 to promote the innervation of the iris in vivo, or that 
there is functional redundancy in the type 1 receptors that GDF5 can signal though in 
vivo. The analysis of iris innervation in adult Bmpr1a+/+and Bmpr1a+/- does not shed 
any light on whether BMPR1A mediates the GDF5-promoted innervation of the iris in 
vivo. Although iris innervation density is reduced in Bmpr1a+/- mice compared to 
Bmpr1a+/+ mice, once again the high degree of variation in the data for each genotype 
prevents any conclusions being drawn. To clarify whether BMPR1A mediates the 
growth promoting effects of GDF5 in vivo, it will be necessary to breed and obtain 
sufficient numbers of irides from P10 Bmpr1aloxP/loxP, Bmpr1aloxP/- and Bmpr1a-/- mice 
and analyse their TH-positive innervation. If Bmpr1a-/- and Bmpr1aloxp/-  irides show 
significant deficits in sympathetic innervation compared to irides from Bmpr1aloxP/loxP 
mice, reflecting the phenotype of Gdf5+/bp and Gdf5bp/bp mice, this would be the first 
indication that BMPR1A potentially mediates the biological effects of GDF5 in vivo. 
However, if further analysis of irides from P10 BMPR1A conditional null mutant mice 
reveals that a loss of functional BMPR1A does not significantly reduce the innervation 
of the SMG compared to control mice, this could provide evidence that there is a 
functional redundancy between GDF5 type 1 receptors in the developing SCG.  
TH immunofluorescence was used to quantify the density of sympathetic innervation 
within SMGs and irides from; Gdf5+/+, Gdf5+/bp, Gdf5bp/bp, Bmpr1b+/+, Bmpr1b-/+, 
Bmpr1b-/- , Bmpr1a+/+ and Bmpr1a+/- mice. This method of quantification is based upon 
the fact that TH, the rate limiting enzyme in catecholamine synthesis, is expressed 
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within sympathetic fibres and thus quantification of TH is assumed to be a direct 
measure of sympathetic fibre innervation. Whilst this is an accepted and widely used 
protocol to analyse sympathetic innervation density72, 153, 164, 169, it is only appropriate 
to compare target field innervation between wild type mice and null mutant mice in 
situations where the null mutation of a particular gene does not alter either the 
expression level of TH or its ability to be transported to axon terminals. For example, 
using this approach to quantify sympathetic innervation in GDF5, BMPR1A and 
BMPR1B mutant mice would not accurately reflect the role of each of these proteins in 
modulating sympathetic target field innervation if GDF5, either signalling though 
BMPR1A or BMPR1B, was able to regulate the expression of TH. TH expression in 
developing mouse SCG neurons has been shown to be promoted in vitro and in vivo by 
NT-3 signalling through TrkA391, raising the possibility that GDF5 could also regulate TH 
expression. To rule out this possibility, RT-qPCR and western blotting should be used to 
quantify the expression of TH within SCG dissected from P10 Gdf5+/+ and Gdf5bp/bp 
mice. Since GDF5 appears to modulate NGF promoted survival of cultured neonatal 
SCG neurons, a more likely possibility is that the innervation data from Gdf5+/+ and 
Gdf5bp/bp mice could reflect a loss of neurons innervating the iris and trachea in the 
absence of functional GDF5 expression. To address this possibility it will be necessary 
to use a stereology based approach on TH-stained sections of SCG dissected from P10 
Gdf5+/+ and Gdf5bp/bp mice to accurately determine the number of neurons in the SCG 
of each genotype.  
The analysis of GDF5 expression within different sympathetic target fields during the 
postnatal period did not help to explain why the iris exhibits such a large deficit in 
innervation in the absence of functional GDF5 expression compared to other target 
fields examined in Gdf5bp/bp mice. At the transcript level, the highest amounts of Gdf5 
mRNA are expressed in the SMG, a target field in which it was not possible to make 
any conclusions as to whether GDF5 plays a role in modulating its innervation by 
sympathetic neurons, due to the high degree of variance in innervation data from 
Gdf5bp/bp, Gdf5+/bp and wild type mice. The second highest levels Gdf5 mRNA are 
expressed in the pineal gland, a target that does not show an innervation deficit in 
Gdf5bp/bp mice. The fact that the iris expresses only moderate levels of Gdf5 mRNA, at a 
similar level to that seen within the SCG, and the heart barely expresses Gdf5 mRNA 
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leads to the conclusion that the levels of Gdf5 mRNA expressed within target fields do 
not appear to show a positive correlation with a requirement for GDF5 to establish 
correct target field innervation. It could be hypothesised that GDF5 may be necessary 
for the correct innervation of sympathetic target fields expressing low levels of NGF. 
However, there are no obvious correlations between the levels of Ngf mRNA 
expressed within sympathetic target fields and the innervation deficits observed in 
Gdf5bp/bp mice. In fact, if the ratios of Gdf5 mRNA relative to Ngf mRNA are calculated 
for the different target fields, the target field with the highest level of Gdf5 mRNA 
expression compared to Ngf mRNA expression is the SMG and the target field with the 
lowest level of Gdf5 mRNA relative to Ngf mRNA is the iris.  
The apparent lack of correlation between the levels of GDF5 expressed within target 
fields and the requirement for GDF5 to establish correct target field innervation in vivo 
could theoretically be explained in a number of ways. The simplest explanation is that 
the expression levels of Gdf5 mRNA do not reflect the expression levels of mature 
GDF5 protein in all target fields. Like other members of the TGF-β ligand superfamily, 
GDF5 is initially transcribed and translated as a precursor (pro-) protein that is 
processed within the cell by proteases, before being secreted as a mature protein 
homodimer191-193. RT-qPCR quantifies levels of the mRNA encoding the precursor and 
precursor mRNA levels may not correlate to mature protein levels in all target fields. 
For example, the different cell types that synthesise GDF5 within different target fields 
may translate Gdf5 precursor mRNA into pro-GDF5 with different efficiencies. 
Different cell types may also cleave pro-GDF5 into mature GDF5 with different 
efficiencies and dimerization of monomers into functional disulphide linked 
homodimers may occur at different rates in different target fields. In addition, the 
longevity of functional GDF5 homodimers within target fields may depend on the 
specific combination and expression levels of extracellular proteases within each 
target field.  Clearly, if a correlation is to be established between the levels of GDF5 
expressed within different sympathetic target fields and a requirement for GDF5 to 
promote correct target field innervation in vivo, the levels of mature GDF5 
homodimers within each target field need to semi-quantitatively assessed by western 
blotting. If the levels of GDF5 homodimers expressed within targets show a positive 
correlation with the severity of the innervation deficits observed in Gdf5bp/bp mice, this 
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would provide strong evidence that GDF5 is a target field-derived neurotrophic factor 
for a subpopulation of developing sympathetic neurons. 
If the expression levels of GDF5 homodimers in different target fields mirror the 
expression levels of Gdf5 mRNA, this could suggest that GDF5 does not act as a target 
field-derived neurotrophic factor to promote target field innervation by a 
subpopulation of developing sympathetic neurons. Since Gdf5 mRNA is expressed at 
relatively high levels in postnatal SCG, and GDF5 protein is expressed within cultured 
P0 SCG neurons, it is possible that neuron-derived GDF5 acts in an autocrine manner in 
vivo to enhance the elongation and branching of the neurons that synthesise it. A 
precedent for autocrine signalling by neurotrophic factors within the developing SCG 
has previously been established72, 169, 172. Because only certain SCG target fields show 
an innervation deficit in mice lacking functional GDF5, only a subpopulation of SCG 
neurons should express GDF5 in vivo if an autocrine GDF5 signalling loop is operating 
in the developing SCG. An Immunohistochemical analysis of GDF5 expression within 
the neonatal SCG should be conducted to confirm whether this is the case. The most 
stringent way to test the hypothesis that autocrine GDF5 signalling is required for 
successful target field innervation by some developing SCG neurons would be to 
eliminate GDF5 expression selectively in the peripheral nervous system and determine 
whether any deficits in sympathetic target field innervation match those seen in 
Gdf5bp/bp mice. However, whilst appropriate Cre-driver strains that express cre-
recombinase selectively in the peripheral nervous system exist405, a conditional GDF5 
knockout mouse line has not yet been generated. 
As alluded to in the discussion of chapter 4, the biological activities of BMPs are 
regulated by secreted BMP antagonists, such as Noggin, Chordin and Follistatin, which 
bind to BMPs to prevent them from engaging with their receptors406-408. BMP 
antagonists play vital roles in coordinating the dorsal-ventral patterning of the neural 
tube406-410 and regulating skeletogenesis 411, 412.  Noggin has been shown to antagonise 
the activity of GDF5 as well as many BMP family members389, 413. This raises the 
possibility that the levels of GDF5 expressed within sympathetic target fields may not 
be the sole determinant of the responsiveness of innervating sympathetic neurons to 
GDF5. Although the SMG expresses the highest levels of GDF5 amongst SCG target 
fields, GDF5 may not normally promote the innervation of the SMG by SCG neurons in 
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vivo due to a high level of Noggin expression within the SMG. If this is the case, then it 
would not be surprising that the SMG is innervated normally in P10 Gdf5bp/bp mice. 
Conversely, low level Noggin expression within the developing iris may allow the 
relatively low levels of GDF5 expressed within the iris to promote innervation by 
sympathetic fibres in vivo, thereby explaining why P10 Gdf5bp/bp mice display such a 
dramatic innervation deficit compared to wild type mice. This hypothesis could easily 
be tested by using RT-qPCR to quantify the expression of Noggin mRNA, and Western 
blotting to determine the expression of Noggin protein, in SCG target fields.  
In conclusion, the results in the chapter show that GDF5 is required to promote the 
correct sympathetic innervation of the iris and also, to a lesser extent, the heart and 
the trachea, in the developing mouse in vivo. It has not been possible to reach a 
conclusion on the role that GDF5 plays in modulating sympathetic innervation of the 
SMG. Whilst the type 1 receptor that mediates the neurotrophic actions of GDF5 is still 
unclear, the available evidence suggests that it is not BMPR1B. BMPR1A is a candidate 
for the type 1 receptor that mediates the biological effects of GDF5 on developing SCG 
neurons. However, significant further research is needed to establish the identity of 
the type 1 receptor is that is required for sympathetic neuron development. Since the 
levels of GDF5 expressed within sympathetic target fields in the postnatal period does 
not predict whether GDF5 is necessary for establishing correct target field innervation 
in vivo, more research is needed to determine why certain sympathetic neuron target 
fields display a large innervation deficit in the absence of GDF5, whereas others show 
either only a small innervation deficit or no detectable change in the density of 
innervation. Moreover, further investigation is needed to clarify whether GDF5 is 
acting in an autocrine or target-derived mode to promote the innervation of some 
sympathetic target fields. Despite the many open questions, the data presented in this 
chapter extends our understanding of the developmental mechanisms that lead to the 
formation of a functional sympathetic nervous system 
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6.1 Discussion 
The overall aim of this body of work was to characterise potential novel roles for GDF5 
in the developing hippocampus and sympathetic nervous system. Whilst it was not 
possible to reproduce preliminary data suggesting that GDF5 regulates the 
morphological development of the hippocampus356, GDF5 has been shown to be a 
neurotrophic factor for perinatal sympathetic neurons of the SCG in vitro and a 
subpopulation of developing sympathetic neurons in vivo. GDF5 modulates NGF 
promoted survival of cultured P0 SCG neurons. In addition, GDF5 enhances NGF 
promoted process outgrowth from cultured P0 SCG neurons and promotes process 
outgrowth, in a dose dependent manner, from cultured P0 and P1 SCG neurons in the 
absence of NGF. Moreover, GDF5 regulates the expression of type 1 BMP receptor 
mRNAs, Bmpr1a and Bmpr1b, in a reciprocal manner. A particularly striking finding is 
that P10 Gdf5bp/bp mice, which do not express functional GDF5, show a large deficit in 
the sympathetic innervation of the iris, and a more modest, although statistically 
significant, deficit in the innervation of the trachea and heart compared to wild type 
mice. Due to the high degree of variance in innervation data from the SMG, it was not 
possible to determine whether GDF5 plays a role in establishing the correct 
innervation of this SCG target field. Innervation of the pineal gland by SCG neurons is 
not affected by the lack of functional GDF5. The reasons why the sympathetic 
innervation of certain target fields appears to be more dependent on GDF5 than the 
sympathetic innervation of other target fields is not clear. There does not appear to be 
a direct correlation between the expression levels of GDF5 within target fields and the 
extent of the innervation deficit in Gdf5bp/bp mice. Likewise, there does not appear to 
be a correlation between the levels of NGF expressed by target fields and target field 
innervation deficits in the absence of functional GDF5. Clearly more research is needed 
to address why some sympathetic target fields show large innervation deficits in the 
absence of GDF5, others show modest innervation deficits and others appear to be 
innervated normally.  
The available in vitro evidence suggests that GDF5 exerts its growth promoting effects 
on developing SCG neurons by activating a receptor complex that comprises the type 1 
receptor, BMPR1A, together with either of the type 2 receptors, ACVR2A or BMPR2. If 
this is verified by further research, especially in vivo, this is an important and novel 
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observation, since the available literature strongly suggests that BMPR1B is the 
preferred type 1 receptor for GDF5269, 414. Recently, the intracellular signalling 
mechanism that GDF5 uses to promote process outgrowth from cultured neonatal SCG 
neurons has been identified as canonical Smad signalling involving Smads 1/5/8 
(personal communication, Gerard O’Keeffe, University College Cork). Canonical Smad 
1/5/8 signalling also mediates GDF5 induced elaboration of dendrites from cultured 
mouse hippocampal pyramidal neurons and GDF5 promoted outgrowth of processes 
from cultured embryonic rat midbrain dopaminergic neurons318, 390, 414. 
The physiological relevance of GDF5s modulation of NGF promoted survival in cultures 
of neonatal SCG neurons is not clear, especially as GDF5 cannot promote neuron 
survival on its own. To determine whether this is merely a culture artefact or whether 
this has consequences in vivo, detailed analysis of neuron numbers needs to be 
performed on SCG from P10 Gdf5bp/bp and Gdf5+/+ mice. Another open question is 
whether GDF5 acts as a target field-derived neurotrophic factor to promote the 
innervation of certain sympathetic target fields. Whilst the data from microfluidic 
device cultures and target field expression of GDF5 suggest that GDF5 is a target field 
derived tropic factor, Gdf5 mRNA levels within the developing SCG are of a similar 
magnitude to those within target fields that show an innervation deficit in Gdf5bp/bp 
mice. This observation raises the possibility that an autocrine GDF5 signalling loop 
operates to promote the innervation of selective sympathetic target fields. If this were 
the case, then it might be expected that GDF5 would only be expressed in the subset 
of SCG neurons that innervate target fields showing deficient sympathetic innervation 
in Gdf5bp/bp mice. Clearly, this is something that needs to be examined in the future, 
together with an investigation into whether retrograde signalling of GDF5 and/or 
GDF5/GDF5 receptor signalling complexes occurs in developing SCG neurons.   
Whilst several questions remain to be addressed to fully characterise the mechanisms 
behind GDF5’s ability to promote the innervation of sympathetic target fields like the 
iris, the data in chapter 4 and 5 add to a growing body of evidence that GDF5 has a 
number of important roles in the development and maintenance of the nervous 
system. In the developing PNS, GDF5 has been shown to enhance NGF and NT-3 
promoted survival of cultured E8 chick DRG neurons, in addition to enhancing NGF and 
cell adhesion molecule promoted process outgrowth from cultured E9 chick DRG 
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neurons310, 311. In the developing CNS, GDF5 promotes the growth and elaboration of 
mouse hippocampal pyramidal neuron dendrites in vitro and in vivo 318, and promotes 
the survival of rat embryonic midbrain neurons in culture390, 415. GDF5 is also 
neuroprotective for adult rat midbrain dopaminergic neurons in a number of trauma 
paradigms415, 416. 
To date, multiple trophic factors have been shown to modulate process outgrowth and 
branching from developing SCG neurons during a narrow postnatal developmental 
window without being able to promote neuron survival. The early postnatal period is a 
time when sympathetic neurons are ramifying and branching extensively within their 
target fields in vivo. These multiple trophic factors do not appear to have redundant 
functions with GDF5, rather they operate by different mechanisms and have distinct 
effects on sympathetic target field innervation in vivo. For example, target field-
derived TNFR1 can reverse signal through TNFα expressed at axon terminals to 
promote growth and branching of axons through a developmental window that 
extends from P0 to P5153. Unlike GDF5, postnatal Tnfr1-/- and Tnfα- /- mice show 
substantial innervation deficits in all target fields examined, rather than innervation 
deficits in some target fields, but normal innervation in others. TNFR1 expression in 
restricted to the soma of developing SCG neurons153, and the addition of TNFα to 
cultures of late embryonic and neonatal SCG neurons that are supplemented with NGF 
reduces the extent of process outgrowth and branching by conventional forward 
signalling171, 417. The physiological relevance of TNFα forward signalling in the 
developing sympathetic nervous system is at present unclear. TNF superfamily 
member, RANKL, signalling through its receptor, RANK, also negatively regulates NGF 
promoted process outgrowth and branching from postnatal SCG neurons in culture170. 
RANK/RANKL signalling operates to reduce process outgrowth and branching from 
cultured SCG neurons over an extended postnatal period that covers P0 to the latest 
age investigated, P10. The physiological relevance of RANK/RANKL signalling has not 
been tested, as RANK null mutant mice are embryonic lethal170. 
Signalling between two other TNF superfamily members and their receptors, 
CD40/CD40L72 and GITR/GITRL169 also enhances process outgrowth and branching 
from cultured SCG neurons during a narrow postnatal developmental window. 
However, in contrast to GDF5, which most likely acts as a target field-derived trophic 
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factor, CD40/CD40L and GITR/GITRL signalling promote process outgrowth and 
branching by an autocrine mechanism. In addition, CD40/CD40L signalling is reverse 
signalling72. Whilst GDF5 can promote process outgrowth and branching from cultured 
neonatal SCG neurons in the absence of NGF, CD40/CD40L and GITR/GITRL are unable 
to act on their own and can only enhance NGF-promoted process outgrowth. In vivo, 
the lack of functional GITR results in a deficiency in sympathetic innervation in all 
target fields investigated169. Like Gdf5bp/bp mice, postnatal Cd40-/-mice show regional 
deficits in sympathetic innervation72. Since NGF is a strong negative regulator of CD40 
and CD40L expression, CD40/CD40L only enhances NGF-promoted process outgrowth 
at low concentrations of NGF in vitro. Consequently, only sympathetic target fields 
expressing low levels of NGF, like thymus and peri-orbital tissue, show innervation 
deficits in Cd40-/- mice72.  
HGF418 and Wnt5a419 are two other factors that enhance sympathetic axon growth by 
an autocrine mechanism during the stage of development when sympathetic axons are 
ramifying in their final targets. While this activity has only been reported for HGF in 
vitro, the importance of Wnt5a has been demonstrated in vivo in mice containing a 
sympathetic nervous system specific conditional deletion of Wnt5a.  In these mice, 
sympathetic fibres reach their final targets, but display greatly reduced growth and 
terminal arborization in multiple target tissues, contrasting with the regional 
innervation deficit observed in Gdf5-/- mice.   
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6.2 Conclusion 
This thesis presents a body of work which attempts to further characterise the 
functions of GDF5 in the developing nervous system. Although GDF5 has previously 
been shown to regulate dendritic growth and branching from developing hippocampal 
pyramidal neurons in vitro and in vivo, structural MRI has failed to identify 
morphological and/or volume differences between wild type mice and mice that do 
not express functional GDF5 at both P10 and adult ages.  GDF5 has been identified as 
another factor that promotes process outgrowth and branching from cultured SCG 
neurons during a narrow developmental window and is required for correct target 
field innervation in vivo. In contrast to the other trophic factors that have been shown 
to play a role in regulating sympathetic target field innervation, GDF5 can act 
independently of NGF. In addition, GDF5 modulates NGF promoted survival of cultured 
neonatal SCG neurons, although the physiological relevance of this finding remains to 
be determined. In vivo, GDF5 is required for the correct innervation of several 
sympathetic target fields, such as the iris, heart and trachea. The molecular 
mechanisms underlying GDF5s role in regulating sympathetic target field innervation 
require further investigation. The data in this thesis helps clarify the roles of GDF5 in 
the developing nervous system and adds to our understanding of the processes that 
regulate the development of postganglionic sympathetic neurons. 
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Appendix I:  BMPR1B (Alk6) mice genotyping 
Primers Sequence 
Alk6-I 5’- TGG TGA GTG GTT ACA ACA AGA TCA GCA -3’ 
Alk6-E 5’- CTC GGC CCA AGA TCC TAC GTT G -3’ 
Neo-Al2 5’- GAA AGA ACC AGC TGG GGC TCG AG -3’ 
Table i: List of primers and sequences. 
Genotype band Band size (bp) 
WT 363 
KO 304 
Table ii: Estimated band size. 
Step# Temp OC Time Note 
1 95 2 min  
2 95 30 s  
3 63 30 s  
4 72 50 s Repeat steps 2-4 for 40 cycles 
5 72 3 min  
Table iii: PCR program. 
Reaction Components Volume(μl) 10X Reaction 5xReaction 
Buffer 2.5 25 12.5 
DNTPs 100Mm 0.25 2.5 1.25 
Alk6-I 1 10 5 
Alk6-E 0.5 5 2.5 
Neo-Al2 0.5 5 2.5 
H2O 18 180 90 
DNA 2   
Taq 0.25 2.5 1.25 
Table iv: PCR reaction (Paq5000 Hotstart DNA Polymerase, Agilent Technologies) or PFU. 
Reaction mix: 2μl of DNA + 23μl of PCR mix.  
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